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Abstract 
With many occupations involving the use of chemicals considered hazardous to health, 
the use of biological monitoring to monitor and control exposure to chemicals may 
help to reduce the risk of ill health. However, this is not always possible for all 
elemental workplace exposures. 
The work in this PhD thesis outlines the improvement of existing methodologies and, 
the development of novel speciation methodologies, including single particle analysis. 
It furthers biological monitoring research of elements that are of a carcinogenic 
occupational concern, i.e. inorganic arsenic, hexavalent chromium and respirable 
crystalline silica (RCS). Current biological monitoring methods are either no longer 
deemed fit for purpose (arsenic), not ideal (chromium) or are not available (RCS). The 
limitations of occupational exposure assessment of hexavalent chromium and RCS are 
linked to the unsuitability of biological matrices for biological monitoring purposes. 
Therefore, the work in this thesis also evaluates exhaled breath condensate (EBC) for 
its potential as a new biological matrix for biological monitoring of chromium and RCS.  
The analytical technique used for arsenic speciation, chromium speciation and single 
particle analysis of RCS was inductively couple plasma – mass spectrometry (ICP-MS). 
Separation was achieved for the chromium and arsenic methodologies by hyphenating 
the ICP-MS with a micro liquid chromatography (µLC) system coupled to an anion 
exchange column. 
For arsenic speciation, a novel and robust 6-minute method was established. 
Additionally, a background levels study was conducted to establish an unexposed 
background reference range for five species of arsenic, to improve interpretation of 
biological monitoring results. Unexpected arsenic peaks in routine biological 
monitoring samples were also investigated, with one of which being determined as 
thio-DMA. 
For chromium speciation, a novel method to simultaneously separate and detect both 
hexavalent and trivalent species in EBC was developed, incorporating a storage 
stability study of both species of chromium in EBC. This was followed by a feasibility 
study, which determined that both species of chromium can be detected and 
ŵeasuƌed iŶ ͚ƌeal͛ EBC saŵples aŶd that oĐĐupatioŶallǇ eǆposed ǁoƌkeƌs shoǁed 
significantly higher levels of both chromium species in EBC samples compared to an 
unexposed control group. 
For RCS, the potential of utilising EBC to both detect and measure occupational 
exposure to RCS, employing the new and challenging analytical technique of single 
particle ICP-MS, was studied. The work demonstrated that individual particles of silica 
can be detected and counted in an EBC sample, with occupationally exposed workers 
showing significantly more RCS particles than an unexposed control group.   
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Chapter 1. 
Introduction 
2 
This PhD thesis outlines the improvement of existing methodologies and the 
development of new speciation methodologies centred around the analytical 
technique, inductively coupled plasma mass spectrometry (ICP-MS), when 
investigating occupational exposure to toxic elements. The main elements and their 
species investigated are: arsenic, chromium and silicon. Each of these elements is 
challenging both analytically and from a biological monitoring approach because they 
exhibit different compounds and oxidation states of varying toxicity. In each method 
described the overall concept is for workplace exposure to be determined in a 
biological sample. 
Arsenic speciation is the focus of Chapters 2 and 3. Chapter 2 summarises an optimised 
arsenic speciation method that is fast, reliable and robust for the analysis of routine 
biological samples using a novel µLC system coupled to an ICP-MS. Currently arsenic 
speciation results determined in a urine sample are difficult to interpret, as there are 
no guidance values for any of the individual species of arsenic. Neither are there 
defined levels of arsenic species in various foodstuffs nor how this affects arsenic 
species excreted in urine after ingestion. Chapter 2 focuses on the production of a 
background reference unexposed range for five species of arsenic in urine samples to 
aid interpretation of results from occupationally exposed individuals. The study also 
aims to provide a better understanding of dietary exposures and the types of food 
sources that may result in elevated urinary arsenic species. Arsenic speciation is an 
ever-evolving subject in terms of analytical and toxicological aspects. Therefore, 
Chapter 3 highlights the incidences of unexpected arsenic peaks in occupational 
routine urine samples and non-routine samples from hospital patients. The study 
outlines an investigation to identify these unexpected arsenic species and highlights 
the difficulties and limitations in this challenging area of arsenic speciation.  
Chapters 4 and 5 focus on chromium speciation. Hexavalent chromium is of 
occupational concern because it is a carcinogen. Current biological monitoring of 
occupational exposure to hexavalent chromium is in the form of a urinary total 
chromium measurement, making it impossible to distinguish and quantify the essential 
trivalent form from the hazardous hexavalent species of chromium. Although 
3 
occupational exposure results from three routes or pathways, inhalation is the primary 
route of exposure in many chromium industries and occupations. Exhaled breath 
condensate (EBC) is a relatively  under investigated biological matrix that represents 
occupational and environmental contaminants inhaled into the lungs, making it a 
potential biological matrix to assess occupational exposure. Chapter 4 demonstrates 
the first publication of the development of a method to simultaneously detect and 
measure both trivalent and hexavalent chromium in EBC samples using the a novel µLC 
system. In addition, a storage stability study of both species of chromium is presented. 
Chapter 5 is a feasibility study, incorporating this newly developed method, to 
determine if both species of chromium can be detected and ŵeasuƌed iŶ ͚ƌeal͛ EBC 
samples from workers occupationally exposed to hexavalent chromium by inhalation 
and a control group.  
Chapter 6 outlines the potential of utilising EBC to both detect and measure 
occupational exposure to respirable crystalline silica, employing the new and 
challenging analytical technique of single particle ICP-MS. Exposure to respirable 
crystalline silica is associated with lung diseases including emphysema, COPD, lung 
cancer and the terminal and irreversible condition known as silicosis. However, 
biological monitoring is currently unavailable for occupational assessment and so 
Chapter 6 highlights the potential of remedying this limitation.      
1.1 Biological Monitoring 
According to the Health and Safety at Work summary statistics 2016 provided by the 
Health & Safety Executive (HSE) for Great Britain, during the 2015/2016 financial year 
1.3 million workers were reported to be suffering from a work related illness.
1
 There 
are also an estimated 13000 annual deaths linked to past chemical or dust workplace 
exposure. It is believed that 36% of current annual deaths are related to asbestos-
related cancer, 33% are related to chronic obstructive pulmonary disease (COPD), 21% 
are related to other respiratory cancers and 10% to non-respiratory cancer.
1
 One 
objective of HSE is to reduce work-related death, injury and ill health.
2
 The Health & 
“afetǇ LaďoƌatoƌǇ ;H“LͿ is H“E͛s laďoƌatoƌǇ aŶd is oŶe of the ǁoƌld͛s leadiŶg pƌoǀideƌs 
4 
 
of health and safety solutions to industry, government and professional bodies, with 
the main focus of work on understanding and reducing health and safety risks.
3
  
Potential hazards are present in all workplaces. One way HSL can help HSE to reduce 
work-related death, injury and ill health is by helping employers to protect employees 
by: monitoring and assessing exposure; testing and checking protective clothing and 
equipment; evaluating workplace equipment or personnel problems; and developing 
solutions to workplace problems.
4
 These deliverables are supported by an extensive 
scientific range of expertise. One area of workplace risk is occupational exposure to 
chemical substances and one practical approach to protecting employees and reducing 
workplace exposure is through biological monitoring. 
1.1.1 What is Biological Monitoring? 
Biological monitoring or biomonitoring can be defined as the assessment of systemic 
exposure to a chemical by the measurement of that chemical or its breakdown 
products (known as metabolites) in exposed individuals.
5
 There are three routes of 
exposure: inhalation; ingestion (usually by hand to mouth contamination); and dermal 
absorption through the skin.
5
 Biological monitoring measurements will reflect the 
total/combined uptake of a chemical by an individual through any of these exposure 
pathways or a combination of all three, from workplace, environmental and/or dietary 
exposures.
5
  Biological monitoring measurements are primarily undertaken in either a 
urine or whole blood sample, but can also be performed in other biological matrices 
such as breath, serum, plasma, hair, nail or other tissue samples.
5,6
 
1.1.2 The Role of Biological Monitoring 
Biological monitoring is a measurement of exposure, not ill health. The use of 
biological monitoring in an occupational setting to monitor and control exposure to 
chemicals can subsequently help to reduce the risk of ill health. If long-term control 
was accomplished then it is feasible that a reduction in ill health would be achieved. 
5 
Many occupations can involve the use of chemicals considered hazardous to health. 
The Control of Substances Hazardous to Health Regulations
7
 (COSHH) state that it is 
important that exposure to chemicals classified as carcinogens, mutagens and 
sensitisers be reduced to as low as is reasonably practicable (ALARP). In order to 
demonstrate that ALARP is in place, the workplace must be able to show evidence of 
their efforts to implement this viewpoint. Whilst this is a recommendation and 
biological monitoring is not compulsory (with the exception of lead exposure),
8
 it is 
one approach through measurement that can be used for assessing, reducing and 
controlling workplace exposure.  
Biological monitoring offers an actual personal exposure measurement, differing from 
eŶǀiƌoŶŵeŶtal ŵoŶitoƌiŶg, ǁhiĐh ŵeasuƌe aŶ iŶdiǀidual͛s poteŶtial eǆposuƌe, foƌ 
example by measuring a chemical in workplace air. The benefits of biological 
monitoring mean it can assess overall exposures (from three different routes) and 
provide an insight into the efficacy of personal protective equipment (PPE) or 
respiratory protective equipment (RPE), engineering controls and human factors. 
Badham and Taylor first mentioned a form of biological monitoring in 1927 for lead in 
urine of exposed workers to help diagnose lead induced industrial disease.
6
 Since then, 
biological monitoring has been extensively used in numerous types of industries to 
help monitor workplace exposure to a wide range of chemical hazards, for example 
pesticides, solvents, isocyanates, metals and metalloids.  
1.1.3 The Difference between Biological Monitoring, Biological Effect 
Monitoring and Biomarkers 
Over recent decades, terms such as ͚biomarkers of eǆposuƌe͛ and ͚biological effect 
monitoring͛ have been introduced to the scope of biological monitoring. Whilst 
biological monitoring is the measurement of the uptake of a chemical, biological effect 
monitoring relates to the measurement and assessment of biological effects as a result 
of the uptake. This usually involves the actual measurement of the biochemical effect. 
A biomarker of exposure is an indicator signalling a measure of exposure and a 
6 
biomarker of effect is an indicator signalling a change to a biological function or a 
recognised possible health impairment or disease. For example, when monitoring 
exposure to inorganic lead (a chemical widely used by industries and occupations such 
as battery manufacture, lead paint production and use, foundries, roofing and glazing), 
the biological monitoring would be the quantitative determination of lead in a whole 
blood sample. The biological effect monitoring would be the measurement of zinc 
protoporphyrin (ZPP), because exposure to inorganic lead causes the inhibition of 
ferrocheletase, an enzyme that converts protoporphyrin into haem using the iron ion 
in red blood cells.
9
 This biochemical effect results in a zinc ion instead of a ferrous ion 
binding to protoporphyrin creating ZPP. This is a delayed action seen up to 2 months 
after the lead exposure.
9
 The measurement of ZPP in whole blood as a biomarker of 
effect can assist screening for lead exposure. 
1.1.4 Biological Mechanism and Factors Affecting Exposure Assessment 
As previously stated, any biological sample, fluid or tissue could be considered suitable 
for biological monitoring. However, blood and urine are the two biological samples 
most often used.
6
 This is especially true in Great Britain, as a non-invasive biological 
monitoring approach is favoured,
10
 meaning the majority of biological monitoring is 
based on urine samples. This approach also makes it easier for non-medically trained 
staff within workplaces to collect and send samples through the post. However, it is 
crucial to understand the pathways of uptake and excretion of a chemical, because 
sometimes a blood sample will be required when urine sampling is not considered 
appropriate. It is also important to understand dose, distribution, possible 
accumulation and metabolism of chemical substance after single or multiple exposures 
to fully evaluate and interpret biological monitoring results. In addition, individual 
behaviour and characteristics also have to be considered when evaluating results from 
different employees exposed to the same exposure. For example, the difference in 
speed and depth of breathing whilst performing workplace activities between 
individuals due to manual tasks or working in heat, the physiology and body mass of 
individuals in addition to age and gender will all influence uptake, metabolism and 
7 
 
excretion. Furthermore, often being a smoker will increase the risk of hand to mouth 
contamination over non-smokers.  
1.1.4.1 Kinetics – Dose, Half-Life, Distribution and Elimination 
After exposure to a chemical, the amount that is taken in by inhalation, absorption or 
ingestion is called the dose, whilst the total concentration of that chemical found in 
the body, whether it be from the dose, accumulative doses or the background level 
concentration of a chemical found in a population, is termed the body burden. A 
biological half-life relates to the time required for the chemical substance in a 
biological system to reduce to half of its original value.
11
 The half-life can vary 
considerably depending on the chemical substance and also differs depending on the 
biological matrix, for example in blood, urine or organs.
12
  Compounds such as 
isocyanates can have a very short half-life of only 2 hours.
13
 As shown in Table 1, 
elements tend not to have such short half-lives but can still vary greatly, for example 
cobalt has a half-life of 2-3 days
9
 whereas lead can be as long as 4 weeks.
14
 Biphasic or 
triphasic half-lives are known to exist, where an element has an initial rapid 
elimination followed by a second or third slower elimination.  
Table 1 The biological half-lifes of common occupational elements in 
urine(unless stated otherwise) 
Element Half Life Ref 
Antimony 
10 – 95 hours 
20 – 40 days 
9
 
Arsenic  
(Varied, depending on species) 
Inorganic arsenic –  
20 hours  
300 hours 
15
 
Beryllium Not fully understood 
9
 
Cadmium in urine –  
critical level from 
accumulation in liver & kidney 
Up to 30 years (liver & kidney)  14 
8 
Element Half Life Ref 
Cadmium (blood) 100 days 
14
Chromium 
7 hours 
15 – 30 days 
3 – 5 years 
16,17
Cobalt 2 – 3 days 9
Lead (inorganic) 3 – 4 weeks (blood) 14
Mercury 1 – 3 months 18
Mercury (blood) 
Elemental & inorganic 
Methyl mercury 
1-3 days
1 – 3 week 
50 days 
18
Nickel 17 – 53 hours 14
Platinum 
50 hours 
24 days 
9
Selenium 
1 day 
8 – 20 days 
65 – 116 days 
9
Silicon (Silica) 
Ingested – < 24 hours 
Inhaled - unknown 
19
Thallium 15 – 30 days 9
Titanium Not fully understood 
20
Vanadium 15 – 40 hours 9
As shown in Figure 1 no matter the route of exposure, the blood is responsible for the 
circulation of the dose of the chemical substance around the body to the organs 
including the liver (the liver is the site of most elemental biotransformation, such as 
the methylation of arsenic) and ultimately excretion via the kidneys in urine. As the 
blood circulates the chemical around the body, the term critical organ relates to those 
9 
organs where the first signs of an adverse effect can be detected.
12
 This adverse effect 
within the human body is also known as the critical effect.
12
 
Figure 1 Distribution and excretion pathways of an element in the human 
body after exposure by absorption, inhalation or ingestion. 
1.1.4.2 Kidney Function 
The dose of a chemical substance eliminated in a urine sample is heavily influenced by 
kidney function and the degree of dilution.
12
 The kidneys are constantly producing 
urine by a complex system of filtration, reabsorption and elimination. From the blood 
flowing through the renal glomeruli, the glomeruli filter out water, salts, amino acids, 
sugars and small proteins into the renal tubules.
6,12
 Much of this filtrate known as 
primary urine is needed by the body, resulting in more than 99% being reabsorbed.
12
 
The remaining water and other unwanted substances that have not been reabsorbed 
10 
are eliminated from the body as urine. Some chemical substances such as cadmium 
and mercury are bound to small proteins causing them to be reabsorbed in the renal 
tubules instead of being eliminated in the urine.
6
 This reabsorption causes 
accumulation within the renal tubules. The elimination of cadmium in urine can be 
used as a biomarker of the critical organ.
6
 Renal dysfunction affecting glomerular 
filtration capacity (GFC) is a consequence of the critical concentration of cadmium, 
resulting in the excretion of cadmium in the urine. Furthermore, a biomarker of effect 
would be the measurement of retinol binding protein in a urine sample,
9
 with 
iŶĐƌeased pƌoteiŶ iŶ the uƌiŶe ƌesultiŶg iŶ the kidŶeǇ͛s iŶaďilitǇ to ƌeaďsoƌď it iŶ the 
renal tubules being a suitable form of biological effect monitoring to assess cadmium 
exposure. 
1.1.4.3 Urinary Adjustment 
In a clinical setting 24 hour urine collections are normal practice.
21
 However, the only 
practical workplace approach to biological monitoring means spot urine collections 
either during or at the end of the working shift. This can result in a wide range of 
dilution from one spot urine collection to the next and amongst different individuals 
experiencing similar workplace chemical exposures. The analyte of interest measured 
in urine samples will be significantly affected by the urine concentration or dilution 
depending on the fluid balance of the individual.
21
 There are several approaches to this 
problem all involving a measurement of adjustment, however the two most common 
are creatinine correction and specific gravity.
6
 Specific gravity or relative density of 
urine corrects for difference in urine density i.e. changes in urine flow.
6
 Adjustment is 
calculated by specific gravity increment in relation to a reference density of either 
1.018 or 1.024.
6
 The second and most common method of dilution adjustment,
21
 and 
the one favoured by HSL, is creatinine correction. Creatinine is related to muscle mass, 
as it is a metabolite of creatine (an important muscle energy store).
21
 The elimination 
of creatinine is entirely through glomerular filtration, with the production and 
excretion remaining relatively constant within an individual, increasing from childhood 
into adulthood, with a slow decline after the age of 65 years.
21
 Creatinine corrected 
11 
 
results are expressed as moles of analyte per mole of creatinine or less often as grams 
of analyte per grams of creatinine.
6
 However, both methods have their limitations. 
When a urine sample is extremely dilute or concentrated, the correction is likely to not 
be as accurate as with a urine sample of equal fluid balance. At HSL, a urine sample 
with a creatinine concentration of less than 3 mmol/L or greater than 30 mmol/L is 
flagged as a possible unreliable result. Similar limitations can be used for specific 
gravity, when relative density of a urine sample falls outside the range of 1.010 – 
1.030.
6
 Because creatinine is dependent on muscle mass, women tend to have lower 
levels of creatinine than men, resulting in a different creatinine corrected estimate of 
dose in women than in men.
6
 However, from a biological monitoring approach most 
guidance values and reference ranges are expressed as either uncorrected 
concentrations or creatinine adjusted values.
21
 In addition, the biological monitoring of 
workplace exposure will eliminate the variation of creatinine production and the 
inaccuracies in creatinine adjustment observed in urine samples from children and 
those over 65 years of age. 
1.1.5 Guidance Values 
The correct interpretation of biological monitoring results is crucial in maintaining the 
effectiveness of its use in exposure assessment. The main method of interpreting 
results is to compare them to background reference ranges and guidance values. 
Different countries and organisations have different kinds of guidance values and the 
teƌŵ ͚ďiologiĐal ŵoŶitoƌiŶg guidaŶĐe ǀalue͛ ;BMGVͿ is aŶ uŵďƌella teƌŵ to eŶĐoŵpass 
them all. Workplace guidance values have been produced by the American Conference 
of Governmental Industrial Hygienists (ACGIH),
22
 the German Science Foundation 
(DFG)
23
 and HSE
24
 in Great Britain. The different guidance values have different origins 
and can become confusing if not fully understood. Guidance values can be divided into 
health based and non-health based. Health based guidance values include the 
American produced Biological Exposure Indices (BEI), the German produced Biological 
Tolerance values (Biologische Arbeitsstoff-ToleƌaŶzǁeƌte ;BATͿͿ aŶd seǀeƌal of H“E͛s 
BMGVs (for example, mercury). Health based guidance values are founded on 
12 
biomarker levels not associated with ill health, but associated with airborne exposure. 
For example, both the BEI and BAT are based on an exposure-based value found after 
an 8-hour exposure at either an American or German airborne exposure limit.
9,25
 There 
is a selection of non-health based guidance values. The German Biologischer Leit-Wert 
(BLW) values are for substances that lack the evidence for a BAT value but where 
biological monitoring is considered useful and needed. In Great Britain the focus of 
H“E͛s ŶoŶ-health ďased BMGVs is a uŶiƋue appƌoaĐh ďased oŶ the idea of ͚good 
oĐĐupatioŶal hǇgieŶe pƌaĐtiĐe͛.25 This has no link to health or airborne measurements, 
but is instead the 90
th
 percentile biological monitoring value taken from large-scale 
surveys of workplaces following good occupational practice to control exposure. 
To determine if an individual is occupationally exposed it is important to ascertain the 
levels that chemical substances occur at in the non-occupationally exposed 
background population. HSL has established background unexposed reference ranges 
for many elements based on background level studies,
26
 in addition the German 
Biological Reference Value  (Biologischer Arbeitsstoff-Referenzwert (BAR)) is based on 
the same premise. Unfortunately, many elements do not have established guidance 
values or unexposed reference ranges. Such elements include the individual species of 
arsenic, which is addressed in Chapter 2 of this thesis. The BMGVs and background 
reference ranges for some elements in addition to highlighting those that do not exist 
(listed as not available (N/A)) are shown in Table 2. 
Table 2 Background reference ranges and BMGVs for a variety of elements 
considered carcinogens, mutagens and sensitisers in humans
9,22,23,26 
Element 
Background Reference 
Range 
Biological Monitoring Guidance 
Values 
Antimony HSL   <0.4 µmol/mol creatinine N/A 
Arsenic: 
- Individual species
Established in Chapter 2 of this 
thesis 
N/A 
- Σ of inorganic &
methylated species
N/A 
BAT   50 µg/L (∼55 µmol/mol creatinine) 
BEI   35 µg/L (∼40 µmol/mol creatinine) 
13 
Element 
Background Reference 
Range 
Biological Monitoring Guidance 
Values 
Beryllium 
BAR   <50 ng/L 
HSL   <0.22 µmol/mol creatinine 
N/A 
Cadmium 
Critical Level 
HSL   <0.54 µmol/mol creatinine 
BEI   4 µmol/mol creatinine 
BLW   <0.8 µg/L 
Cadmium (Blood) 
HSL   <9 nmol/L non-smoker 
HSL   <16 nmol/L smoker 
BAR 1 µg/L 
BEI   5 µg/L or 45 nmol/L 
Chromium 
BAR   <0.6 µg/L 
HSL   <2.9 µmol/mol creatinine 
BEI   25 µg/L (∼40 µmol/mol creatinine) 
HSE BMGV   10 µmol/mol creatinine 
Cobalt HSL <2.5 µmol/mol creatinine BEI   15 µg/L (∼20 µmol/mol creatinine) 
Lead inorganic 
(Blood) 
<5 µg/dL 
CLAW suspension limits: 
60 µg/dL 
30 µg/dL – WRA* 
50 µg/dL  young people 
Lead organic HSL   <4.1 µmol/mol creatinine 
CLAW suspension limits 
60 µmol/mol creatinine 
14 µmol/mol creatinine – WRA* 
Manganese HSL   <1.45 µmol/mol creatinine N/A 
Mercury HSL   <1.43 µmol/mol creatinine 
BAT   14 µmol/mol creatinine 
BEI   11 µmol/mol creatinine 
HSE BMGV   20 µmol/mol creatinine 
Mercury (Blood) HSL <16 nmol/L BLV 50 nmol/L 
Nickel 
BAR 3µg/L 
HSL   <10.7 µmol/mol creatinine 
BAT 70 µg/L (∼ͳͲͲ µmol/mol creatinine) –
soluble nickel 
BAT 45 µg/L (∼6Ͳ µmol/mol creatinine) –  
poorly soluble nickel 
Platinum HSL   < 0.01 µmol/mol creatinine N/A 
Selenium HSL   <40 µmol/mol creatinine 
BAT  <150 µg/L (∼ͳ6Ͳ µmol/mol 
creatinine) 
Silicon (Silica) N/A N/A 
Thallium HSL   <0.26 µmol/mol creatinine N/A 
Titanium HSL   <33.6 µmol/mol creatinine N/A 
14 
Element 
Background Reference 
Range 
Biological Monitoring Guidance 
Values 
Vanadium HSL   <10.7 µmol/mol creatinine N/A 
N/A – Not Available 
*WRA – Women of reproductive capacity
1.1.6 Biological Monitoring of Elements 
Metals and metalloids make up 100 of the 118 elements on the periodic table,
27
 of 
which 20 are known to be toxic.
12
 However, it is likely that other elements are also 
toxic but not enough scientific information/evidence has been gathered to categorise 
them as such. In contrast to this, many elements such as copper, iron, manganese, 
selenium and zinc are considered necessary for the everyday functioning of the human 
body. They have essential biological functions forming complexes with proteins and 
enzymes, for example iron, copper and zinc are associated with ferritin and copper 
ǁith α-amylase.28 The insufficient intake of an essential element will result in a 
deficiency however, toxic effects can occur if intake or exposure is high. Some 
elements have species of opposing potency such as chromium (trivalent chromium is 
an essential element whilst hexavalent chromium is toxic). After exposure and uptake 
of an element, it may transform into either a more toxic or less toxic species, but they 
do not break down in the human body, meaning they stay in the body until they are 
excreted.
12,29
 The vast majority of elements are completely eliminated in urine, hence 
being easily and accurately measured in a urine sample. However, elements such as 
mercury and cadmium, depending on the type of exposure are sometimes measured in 
a blood sample and workplace exposure to inorganic lead legally requires the 
measurement of a blood sample as per the Control of Lead at Work Act (CLAW).
8
 As 
previously stated in section 1.1.2, biological monitoring is one way that workplaces can 
demonstrate the exposure practice of ALARP to chemicals categorised as carcinogens, 
mutagens and sensitisers. Elements considered carcinogenic to humans
30-32
 are 
arsenic, beryllium, chromium, lead and nickel, whilst elements such as cobalt, iron, 
platinum, selenium, titanium aŶd ǀaŶadiuŵ aƌe Đlassified as ͞ƌeasoŶaďlǇ aŶtiĐipated to 
ďe͟32 oƌ ͞pƌoďaďlǇ/possiďlǇ͟31 carcinogenic to humans by the Agency for Toxic 
15 
 
Substances and Disease Registry (ATSDR) or the International Agency for Research on 
Cancer (IARC) respectively. Mutagenic elements include cadmium, mercury and 
chromium,
33,34
 whilst elements such as antimony, beryllium, chromium, cobalt, 
manganese, nickel, selenium and tin are considered dermal or respiratory sensitisers.
32
 
As previously stated, blood and urine are the two biological samples most frequently 
used for occupational exposure assessment. However, in recent decades the interest 
in breath analysis in the form of exhaled breath condensate specifically within the field 
of airway and lung inflammation has expanded tremendously.
35
 As the primary route 
of occupational exposure for many industries is by inhalation, it is possible that 
exhaled breath condensate could be useful as a biological matrix for biological 
monitoring purposes, especially for elements where inhalation exposures are not fully 
understood and where biological monitoring is currently not possible. 
16 
1.2 Exhaled Breath Condensate (EBC) 
The potential for breath analysis as a diagnostic tool was identified as early as 1784 
when Antoine Lavoisier proved the consumption of oxygen and production of carbon 
dioxide during each exhalation of breath. Nearly 100 years later, observations were 
made by Anstie in 1874 of alcohol excretions in breath.
36
 The link between diabetes 
and acetone in exhaled breath was demonstrated in 1887 by Nebelthau.
36
 In the early 
1900s the development of alcohol breath tests was started, with the first patented 
device in 1931.
36
 
However, in modern day breath analysis there are two areas of breath research; those 
which concentrate on the gaseous phase of breath and volatile organic compounds, for 
example the electric nose and those which concentrate on the aqueous part of breath, 
known as exhaled breath condensate (EBC). 
Inhalation is one of the primary routes of occupational exposure, with numerous 
inhalation exposures leading to inflammation and oxidative stress causing occupational 
asthma, various respiratory diseases and cancer.
20
 It is thought that EBC might be a 
useful biological monitoring matrix where either biological monitoring is currently not 
possible using traditional biological matrices such as urine or blood (for example 
respirable crystalline silica exposure) or where the interpretation of elemental species 
is difficult in a biological sample (for example hexavalent and trivalent chromium). It 
may also further the understanding of inhalation exposures and how elements behave 
and reside in lungs. 
Scientists in the former Soviet Union were the first to report (in Russian) about EBC 
over 35 years ago.
37
 It took until 1992 for the first EBC paper to be published by 
Western Scientists.
38
 A publication by Dodig and Cepelak
39
 in 2013 stated that 
between the period of 1980 – 2012 there were 869, 917 and 3628 published articles 
on EBC listed on databases PubMed, OVID and Scopus respectively. However, the vast 
majority of EBC publications have a strong emphasis on pulmonary disease diagnosis, 
with those who report a biomarker measurement focused on the study of specific 
17 
 
respiratory diseases such as asthma,
40-44
 chronic obstructive pulmonary disease,
40,44-46
 
silicosis,
47-50
 asbestosis,
47,50,51
 obstructive sleep apnea,
52
 cystic fibrosis
43,53,54
 adult 
respiratory distress syndrome
55
 and lung cancer.
56
 Biomarkers of interest in these 
studies represent oxidative stress and inflammatory derived biomarkers, such as 
cytokines,
56,57
 isoprostanes,
48,49,58,59
 leukotrienes,
48,58,60
 pH changes,
42,61
 nitrogen 
reactive species such as nitrates/nitrites and nitrotyrosineoxides,
42,43,46
 hydrogen 
peroxide,
41,42,62,63
 and aldehydes.
47,49,59,62,63
 These biomarker studies all investigate 
potential applications in: the discrimination of different respiratory inflammatory 
types, early diagnosis of disease, detecting the severity of airway inflammation, the 
monitoring of treatment or disease control and the ability to predict disease 
exacerbation.
64
 Only a handful of publications have investigated EBC as a potential 
biological monitoring matrix to monitor occupational exposure to elements such as 
chromium,
65-68
 nickel and iron,
68
 chromium, nickel and aluminium,
69
 beryllium,
70
 
lead,
71
 cobalt and tungsten,
72,73
 manganese
74
 and potassium, cadmium, copper, 
antimony, zinc and strontium.
75,76
 
1.2.1 What is EBC? 
EBC is a biological fluid. It consists mainly of water vapour but also small droplets of 
airway lining fluid from within the bronchial and alveoli regions of the lungs. However, 
it can also contain droplets from the entire respiratory tract (as shown in Figure 2) 
including the mouth and trachea.
77
 
Within these droplets of airway lining fluid, is an unknown fraction of both volatile and 
non-volatile substances. Volatile substances are in the form of water-soluble 
compounds in the condensed water of the EBC sample such as ammonia, hydrogen 
peroxide and ethanol.
78,79
 Non-volatile substances can include cytokines, lipids and 
salts
78
 but also environmental and occupational contaminants. 
 
 
Figure 2 The respiratory tract created by HSE 
1.2.2 The Mechanisms of EBC Production 
The respiratory epithelium is lined with airway lining fluid. The exact mechanism of the 
aerosolisation of the airway lining fluid is not fully understood
80
 however, two possible 
ŵodels eǆist. The fiƌst ŵodel is teƌŵed ͚tuƌďuleŶt aiƌfloǁ͛. DuƌiŶg ƌegulaƌ tidal 
breathing, a turbulent airflow is created in the respiratory tract due to the opening of 
closed bronchioles and alveoli, causing droplets of the airway lining fluid containing 
non-volatile substances to become aerosolised.
39,81
 The second model is termed 
͚ďƌoŶĐhiole fluid filŵ ďuƌst͛ aŶd ǁas pƌoposed iŶ ϮϬϬ9 ďǇ JohŶsoŶ & Moƌaǁska.82 The 
elastic bronchioles have a surface consisting of longitudinal folds, which are lined with 
epithelial lining fluid. During exhalation, these folds disappear as the bronchiole 
contract and the fluid is expelled. This process continues until a flat, thin film of this 
fluid is formed over the surface blocking the expanding bronchiole, as the bronchioles 
open during inhalation a bubble is created which bursts in droplet aerosols that are 
18 
19 
held in the alveoli until exhalation. The bronchiole fluid film burst mechanism seems 
the likelier of the two concepts due to inaccuracies in the turbulent airflow model 
when respiratory conditions other than regular breathing are applied. For example, 
increased breathing or coughing, which should increase turbulent airflow, does not 
increase aerosol formation.
82
 In addition, the Johnson & Morawska study determined 
that the aerosol formation increased only through increased inhalation rate and not 
during increased exhalation rate, proving that the aerosol formation is produced 
during the inhalation phase of breathing.
82
 
The respiratory zone is a term used to describe the regions of the lungs which 
incorporate the respiratory bronchioles, alveolar ducts and alveoli. The airway lining 
fluid from the respiratory zone contains approximately 80% phospholipids, 10% 
cholesterol, 10% proteins and a very small amount of carbohydrate, which 
corresponds directly with the composition of EBC but in lower concentrations.
39
 
1.2.3 EBC Devices & Collection Technique 
All EBC collection devices are based on a freezing cooling chamber, to cool and 
condense the exhaled breath, consisting of an inert material for the surface of the 
condensing cooling chamber such as glass, aluminium or Teflon as recommended by 
the American Thoracic Society/European Respiratory Society Task Force.
81
 The 
effectiveness of EBC collection depends on the volume of breath passing into the 
condenser and the temperature gradient of the exhaled air to the cooling chamber. 
1.2.3.1 Devices 
Prior to the availability of commercial EBC collection devices, research groups devised 
their own custom-built EBC collection equipment. The custom built devices have 
included: immersing a Teflon lined tube in an ice filled bucket to create a cooling 
chamber
61
 and a double glass wall which icy water can circulate through as the EBC 
collected on the walls of the glass, subsequently dripping into a collection container 
below.
83
 These laboratory limitations resulted in the construction of in-house portable 
20 
devices, some of which included breathing through a straw into a polypropylene tube 
cooled by ice
84
 or cooling gel.
42
 These in-house deǀiĐes aƌe teƌŵed ͚opeŶ-eŶd͛ ŵeaŶiŶg 
there is no recirculation, which results in a collection efficiency of only 50%.
36
 The 
commercially available EBC collection devices used in studies within the literature are 
described below. 
The EcoScreen, (Erich Jaeger GmbH, Hoechberg, Germany) (now discontinued) and the 
EcoScreen2 (FILT, Berlin, Germany).
85
 The EcoScreen was a device using a one-way 
tubing system, saliva trap and a reusable cooled PTFE coated aluminium double lumen 
lamellar system, with a disposable polypropylene collection cup. The cooling system 
was electrically cooled by a standard electrical connection that froze the EBC sample 
during collection. The EcoScreen2 now collects EBC in a disposable polyethylene bag. It 
also claims to have the ability of fractionated EBC collection in two separate chambers 
to distinguish between EBC from the mouth and upper respiratory tract and EBC from 
the lower respiratory tract. This device also has the added extra of a built in 
spirometer, enabling the measurement of exhaled volume. However, neither of the 
two EcoScreen devices is portable, being approximately the size of a desktop PC. This 
type of device is ideal for in-house laboratory research or hospital based research 
where volunteers are able to provide an EBC sample. However, they are not as suitable 
for biological monitoring EBC collection where sampling is usually completed post-
working shift at the place of work. 
RTube (Respiratory Research Inc., Charlottesville, VA, USA).
86
 The RTube is a portable 
device consisting of a disposable t-section containing a non-rebreathing valve and 
saliva separator. It also employs a syringe plunger to remove all EBC sample off the 
surface of the polypropylene collection tube. This device is considered completely 
portable, as it does not require a standard electrical connection to cool the condensing 
chamber. Cooling is achieved by the placement of an aluminium sleeve over the 
collection tube. However, this does mean that the sleeve will need to be chilled in a 
freezer or refrigerator prior to use and that numerous sleeves may be required for 
large or repeat collections, in addition to the temperature of the sleeve increasing over 
the duration of EBC collection. 
21 
The TurboDECCS (Medivac SRL, Parma, Italy; previously by ItalChill).
87
 The TurboDECCS 
(Transportable Unit for the Research on Biomarkers Obtained from Disposable Exhaled 
Condensate Collections Systems) is the EBC collection device used to collect EBC 
samples in the work reported in chapter 4 and chapter 5 of this thesis. The 
TurboDECCS, as shown in Figure 3, is Đoŵposed of tǁo seĐtioŶs. The ͚tuƌďo͛ is the 
refrigeration device that incorporates a Peltier-cooling unit made of aluminium, which 
houses the EBC collection tube. The turbo requires a standard electrical connection to 
cool the condensing chamber however; the temperature is adjustable from -10
o
C to 
ƌooŵ teŵpeƌatuƌe. The ͚DECC“͛ ƌefeƌs to the disposaďle polǇethǇleŶe ƌespiƌatoƌǇ 
system comprising of a mouthpiece connected to a one-way aspiration valve with a 
saliva trap with an EBC collection tube inserted into the chilling unit as shown in Figure 
3. Although the TurboDECCS is restricted to an electrical connection, unlike the
EvoScreen, the unit is small and easily transported to different workplaces to collect 
samples. 
Figure 3 The Turbo-DECCS exhaled breath condensate collection device. 
1.2.3.2 Collection Technique 
The collection of EBC is non-invasive and the sampling of EBC does not cause an 
inflammatory response itself.
88
 EBC is collected through regular, calm tidal breathing 
through the mouth estimated to be approximately 15-20 breaths per minute via a 
mouthpiece.
39
 The exhaled air produced during regular tidal breathing passes into the 
22 
frozen cooling chamber (normally at temperatures between -5
o
C to -30
o
C depending 
on the manufacturer), where the EBC is cooled and collected as a condensate on the 
surface of the chamber or collection vessel. 
Some methodologies suggest subjects wear a nose clip. A study by Hoffmeyer et al
88
 
examining biomarkers of inflammatory response found no difference in pH, nitrogen 
oxides and leukotriene B measurements for EBC samples collected from subjects with 
a nose clip than without, though when subjects wore a nose clip a slightly higher 
volume of EBC was collected. Wearing a nose clip will prevent subjects breathing 
through their nose and the mixing of nasal air with bronchial air.
64
 Nonetheless, the 
discomfort experienced by some individuals when wearing a nose clip has the 
potential to impede volunteer recruitment and increase volunteer dropout. 
It is suggested that EBC samples must be immediately frozen at -80
o
C until analysis,
36,81
 
however this practice must be validated by a stability study of the biomarker or 
element of interest. Chapter 4 of this thesis highlights this issue, where the freezing of 
EBC samples containing chromium species affected the integrity of hexavalent 
chromium, causing it to deteriorate. 
1.2.4 EBC Collection Volume 
The volume of EBC volume collected can vary, with studies suggesting ten minutes of 
tidal breathing will collect an estimated 1 – 2 mL.77 A number of suggestions has been 
made for the difference in EBC volume collected between individuals such as gender, 
age, fitness, smoking status and lung status. A study by Liu and Thomas
44
 investigated 
some of these suggestions by collecting EBC from healthy, asthmatic and chronic 
obstructive pulmonary disease individuals. They found EBC volume was not affected by 
age, gender, disease status or lung function of the individuals. The lack of correlation 
between EBC volume and lung function
55
 is supported by numerous studies, as EBC 
volume is directly correlated to tidal volume and minute/ventilation volume.
44,55,89
 
Tidal volume refers to the volume of air displaced in the lungs between normal 
inhalation and exhalation. In a young human adult this is thought to be approximately 
23 
500 mL per inspiration. Minute/ventilation volume refers to the amount of gas inhaled 
oƌ eǆhaled fƌoŵ aŶ iŶdiǀidual͛s luŶgs iŶ oŶe ŵiŶute. IŶdiǀiduals ǁith higheƌ 
minute/ventilation volume and/or higher tidal volume will produce more EBC. There is 
also a linear correlation between the volume of EBC produced and the length of 
collection time when breathing at a constant respiratory rate.
81
 A study by McCafferty 
et al
89
 reported reduced EBC volume when individuals were inhaling cooler and drier 
air. 
The droplets of airway lining fluid can be considerably diluted by the condensed water 
vapour in EBC samples, which has been reported to only affect the measurement of 
non-volatile substances.
64
 This dilution will vary between individuals, as differences in 
dilution will depend on the size and number of droplets of lining fluid during regular 
tidal breathing. Unfortunately, there is no gold standard dilution marker for EBC.
77
 It 
has been suggested that a stable compound in blood which can diffuse through cell 
membranes in the lungs but is not produced itself in the alveoli or respiratory tract is a 
promising possibility to standardise EBC dilution.
36
 The biomarkers to correct for 
dilution which have been investigated include urea,
55,90
 total protein content,
55
 
ions/electrolytes (potassium, chloride, ammonia)
53,91,92
 and the conductivity of 
lyophilised samples.
91
 Until a suitable biomarker of dilution correction has been found 
the correlation between tidal volume and minute/ventilation volume with EBC volume 
suggests that EBC results should be reported per volume of EBC.
55
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1.3 Arsenic 
1.3.1 Physical Properties 
Arsenic is a metalloid residing directly below phosphorous in group 15 of the period 
table. Arsenic has both metallic and non-metallic properties and, in biological systems, 
arsenic can often substitute for phosphorous because of its close chemical 
characteristics. Arsenic has the atomic number 33 and a mass of 74.922 amu. It is 
mono-isotopic and is an ubiquitous element found in all rock, soil, water and air at 
trace levels.
93
 It is ranked as the 20
th
 ŵost aďuŶdaŶt eleŵeŶt iŶ the eaƌth͛s Đƌust, ϭϰth 
in seawater and 12
th
 in the human body.
94
 More than 200 identified minerals are 
found to contain arsenic such as realgar, orpiment and arsenolite with the most 
abundant arsenic containing mineral being arsenopyrite.
93,94
 
Arsenic displays several valence states: arsine (-3); elemental (0); arsenite (+3) and 
arsenate (+5). There are over fifty identified arsenic compounds or species all of which 
display very different levels of toxicity.
95
  
1.3.2 Arsenic Toxicity and Effects on Human Health 
Arsenic toxicity is dependent on its species and how each species is metabolised in the 
human body.
96
 However, the toxicity of arsenic and its carcinogenicity is still not fully 
understood. The variety of arsenic species provide a range of toxicological behaviours 
and, as arsenic undergoes rapid metabolism in the human body after exposure, it is 
difficult to differentiate which effects come from which species. Arsenic species of 
varying toxicities are shown in Figure 4. 
Arsenic compounds can be categorised by: inorganic and organic compounds, with 
organic compounds composed of species that can be metabolised by humans and 
those that cannot. Inorganic arsenic compounds are considered to be more toxic than 
organic compounds.
94
 The US National Toxicology Program (NTP) has classified 
iŶoƌgaŶiĐ aƌseŶiĐ as a ͞huŵaŶ ĐaƌĐiŶogeŶ͟97 and IARC has classified inorganic arsenic 
25 
as a Gƌoup ϭ ageŶt, defiŶed as ͞ĐaƌĐiŶogeŶiĐ to huŵaŶs͟.31 A common way of 
evaluating the toxicity of a substance is the LD50 value. The International Union of Pure 
and Applied Chemistry (IUPAC) definition of an LD50 is the statistically derived dose of a 
chemical expected to kill 50% of a given population under defined conditions.
11
 
However, these values expressed as unit mass of the toxic substance per unit mass of 
the test subject are not/rarely for humans and are usually for an oral ingested dose. 
The estimated lethal dose for humans ingesting inorganic arsenic is 1 – 3 mg/kg per 
day, however inhalation or skin absorption exposures to inorganic arsenic are not 
associated with acute lethal doses,
98
 unless in the form of arsine (AsH3). Arsine is a gas
which is the most acutely toxic arsenic compound.
28
 Table 3 outlines the LD50 values
for various arsenic compounds. 
The adverse health effects caused by exposure to inorganic arsenic (arsenite (As
3+
) and 
arsenate (As
5+
)) are vast, with health effects differing greatly between acute poisoning, 
long-term exposure and the route of exposure. The initial health effects from oral 
exposures and early signs of poisonings are nausea, vomiting and diarrhoea, 
abdominal pain and dehydration,
99,100
 with acute doses and poisonings resulting in 
confusion, hallucinations and an impaired memory,
101
 which in the long term can 
result in neurological effects. The most characteristic health effect from long-term 
acute oral exposures (commonly seen in arsenic contaminated drinking water) are skin 
manifestations as a result of vascular disease,
101
 such as hyperkeratinisation (excessive 
development of thick horny keratin in the epidermis) on the palms and soles of feet, 
cyanosis and gangrene most commonly known as Blackfoot Disease.
100,101
  However, 
unlike acute poisoning, there is no evidence of neurological effects from long term 
exposure to lower environmental or occupational levels of arsenic.
100
 Arsenic in 
drinking water is also related to increased cancer risks of the skin, lungs, bladder and 
kidney.
100
 The inhalation of inorganic arsenic results primarily in respiratory irritation 
of the mucous membrane which can lead to laryngitis, bronchitis, rhinitis and 
tracheobronchitis with higher exposures resulting in nasal septum perforation.
102
 
Other health effects associated with arsenic exposure through either ingestion or 
inhalation exposures are hypertension, hypotension, cardiovascular problems, 
cardiomyopathy and anaemia.
102
 As a result of repeated exposures, arsenic is known 
26 
to accumulate in both the kidney and liver over repeated exposure, meaning kidney 
and liver diseases are also common.
102
  Both As
3+
 and As
5+
 compounds also have the 
ability to be taken up by foetal blood and readily cross the placenta.
93
 
Table 3  LD50 values of arsenic compounds in laboratory experiments. 
Arsenic Compound Test subject LD50 (mg/kg) Ref 
Arsine Mice/Rat 2-3
103
Arsenic trioxide 
Calcium arsenite 
Sodium arsenite  
Potassium arsenite 
Rat 
Mice 
Rats 
Mice 
Rat 
Rat 
145 
35 
20 
8 
24 
14 
104
105
106
93
93
106
Calcium arsenate 
Lead arsenate 
Sodium arsenate 
Rat 
Rat 
Rat 
Rat 
Rat 
mouse 
20 
53 
>400 (dermal)
231 
>500 (dermal)
21 
106
107
107
107
107
93
DMA Rat 700 – 2600 106
MMA Rat 700 – 1800 106
Arsenobetaine Rat >10000
105
Arsenocholine Rat 6500 
106
Trimethylarsine oxide Rat 10600 
108
Organic arsenic compounds occur when arsenic bonds with carbon. Compounds of 
organic arsenic vary in toxicity and this is primarily due to whether they are human 
metabolites of arsenic such as dimethylarsinate (DMA) and monomethylarsonate 
(MMA) or organic arsenic compounds that are not human metabolites such as 
arsenobetaine (AB) and arsenocholine (AC). 
27 
Figure 4 Structures of arsenic compounds relevant to biological 
monitoringand the work in this thesis. Red structures indicate arsenic 
compounds analysed for biological monitoring purposes at HSL. Blue 
structures indicate those investigated in Chapter 3 of this thesis, but are not 
usually analysed for biological monitoring. 
28 
1.3.3 Arsenic Compounds – Inorganic Arsenic 
In the environment inorganic arsenic is naturally occurring primarily through volcanic 
action, but also as a result of industrial processes such as mining, smelting and burning 
of arsenic rich coal.
93
 Inorganic arsenic exists as the valence states arsenite (+3, 
trivalent: As
3+
) and arsenate (+5, pentavalent: As
5+
). Arsenic trioxide (As2O3), sodium
arsenite (NaAsO2) and arsenic trichloride (AsCl3) are the most common forms of As
3+
compounds.
100,109
 Arsenic pentoxide (As2O5), arsenic acid (H3AsO4) and arsenates such
as lead arsenate (PbHAsO4) and calcium arsenate (Ca3(AsO4)2) are common As
5+
compounds.
100,109
 Trivalent arsenic species are considered more toxic than pentavalent 
ones as reflected by their LD50 values as shown in Table 3. In humans, after exposure to 
inorganic arsenic, it is absorbed into the blood with a half-life of 1 - 2 hours.
15
 In the 
event of As
5+
 exposure, As
5+
 is reduced to As
3+
 mainly in the blood and liver. As
3+
 is 
then taken up into cells where it is converted to methylated metabolites. The main 
excretory pathway is in urine in two phases estimated at 20 and 300 hours.
15
  
1.3.4 Arsenic Compounds – Organic Arsenic 
1.3.4.1 Human Methylated Metabolites 
Most organisms will metabolise inorganic arsenic to monomethylated (MMA) arsenic 
species and dimethylated (DMA) arsenic species, which are shown in Figure 4. Only 
humans excrete significant amounts of the pentavalent monomethylated (MMA
5+
) 
species,
110 
with the pentavalent dimethylated species (DMA
5+
) being the primary end-
point from inorganic exposure in humans and most mammals.
100
 However, in rats 
trimethylarsine oxide (TMAO) is found to be the end-point metabolite from inorganic 
exposure.
15
 The primary site for arsenic methylation is the liver, however studies have 
shown methylating activity in the testes, kidney and lung tissue.
111,112
 For arsenic 
methylation to occur the presence of a methyltransferase enzyme such as As3MT is 
crucial,
113,114
 enabling the transfer of the methyl donor S-adenosylmethionine (SAM) in 
the presence of glutathione (GSH).
115
 This exact sequence of events has not been fully 
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elucidated, however the classical or originally proposed arsenic biotransformation 
pathway in most mammals including humans, is that after the initial reduction step of 
As
5+
 to As
3+
, it is followed by steps of oxidation methylation and reduction methylation 
producing MMA
5+
, MMA
3+
, DMA
5+
 and finally DMA
3+
, as shown in Figure 5.
116
  
 
Figure 5 The proposed classical pathway of inorganic arsenic 
biotransformation of oxidation methylation and reduction methylation steps 
in humans. 
Historically the methylation of arsenic was considered a detoxification pathway until in 
vitro studies found MMA
3+
 to be more toxic than inorganic arsenic whilst both MMA
3+
 
and DMA
3+
 damaged DNA more than As
3+
. 
115,117
 An in vitro study by Mass et al
118
 
supported this viewpoint, determining that both trivalent methylated species caused 
DNA damage to human lymphocytes.  The fact there is a lack of trivalent methylated 
species found in urine, which contradicted DMA
3+
 being the end point metabolite
119
 
and that both MMA
5+
 and DMA
5+
 do not seem to undergo further conversion and are 
found not to be involved in the oxidative methylation pathway,
120
 has led researchers 
to investigate biotransformation and propose new pathways.
121-123
 The proposed new 
pathways, though all slightly different, involve steps of methylation and oxidation to 
produce MMA
3+
 and DMA
3+
 first,
 
followed by MMA
5+
 and DMA
5+ 
second. In addition, 
DMA is not metabolised from MMA. The literature scrutinises the existence of trivalent 
methylated species in human urine due to both their instability and rareity.
119
 Studies 
by Gong et al,
124
 Mandel et al
125
 and Suzuki et al
126
 have reported MMA
3+
 and DMA
3+ 
in 
human urine but subsequently had their sample integrity questioned.
119
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Both MMA and DMA have been shown to cause adverse effects to the bladder, kidney, 
thyroid and gastrointestinal tract in animal studies, with DMA causing carcinogenic 
effects.
109,127
 However, the lack of conclusive evidence for human toxicity, led to IARC 
classifying methylated arsenic species of DMA and MMA as Group 2B agents defined 
as ͞possiďlǇ ĐaƌĐiŶogeŶiĐ to huŵaŶs͟.31 In recent years, the discovery of thio-
dimethylarsinate (thio-DMA) (as discussed in Chapter 3 of this thesis) has led to further 
questions of the credibility of trivalent methylated species.   
1.3.4.2 Non-Human Occurring Metabolites 
Species of arsenic from a dietary source constitute two groups, tetra alkylarsonium 
compounds such as arsenobetaine (AB), arsenocholine (AC) and trimethylarsine oxide 
(TMAO) (as shown in Figure 4) and trialkylarsine oxide compounds like arsenosugars 
(Figure 6). Other additional dietary compounds include thioarsenicals (Figure 4 and 
Figure 6) and arsenolipids (Figure 6). As indicated by their LD50 values in Table 3, AB, 
AC and TMAO are considered to be non-toxic and, as such, IARC has classified AB and 
oƌgaŶiĐ aƌseŶiĐals Ŷot ŵetaďolised ďǇ huŵaŶs as Gƌoup ϯ ageŶts, defiŶed as ͞Ŷot 
Đlassifiaďle as to its ĐaƌĐiŶogeŶiĐitǇ to huŵaŶs͟.31  They are primarily found in marine 
organisms such as algae, seaweed, shellfish, squid and fish
128,129
 with AB being the 
most abundant and wide spread species. Arsenosugars and arsenolipids are also 
associated with marine organisms but will be discussed further in section 1.3.4.3. The 
primary source of arsenobetaine is marine algae.
128
 The cell membranes of marine 
algae have transport systems to take-up essential phosphate from seawater however, 
when arsenate species are present in water, this transport system cannot differentiate 
between the two, therefore leading to arsenic within the cell.
128
 The algae produce 
arsenic species such as AB in addition to methylated species as a way of detoxifying 
As
5+
, hence how these non-human arsenic species and their methylated metabolites, 
in addition to inorganic arsenic, can enter the marine food chain and subsequently 
humans via their diet. Humans and mammals are unable to produce or metabolise AB 
or AC and they are quickly excreted in urine.
130
 The same was thought of TMAO, until 
several studies demonstrated the presence of TMAO in human urine after the 
31 
ingestion and metabolism of an arsenosugar.
131-133
 Although these dietary species are 
predominately found in marine life, it is important to note that they are not confined 
to marine organisms and scientific exploration has found other species capable of 
metabolising AB from inorganic arsenic, such as earthworms, fungi and birds.
134
  
1.3.4.3 New Generation of Oxo- and Thioarsenicals 
Approximately 20 arsenosugars have been identified of which Figure 6 shows the four 
compounds (DMA
5+
-sugar-glycerol, DMA
5+
-sugar-phosphate, DMA
5+
-sugar-sulfate and 
DMA
5+
-sugar-sulfonate) deemed the most widespread.
135
 Arsenolipids are a group of 
compounds which include arsenic fatty acids, hydrocarbons and glycophospholipids.
135
 
Unlike AB and AC, arsenosugars and arsenolipids are metabolised in humans and can 
be transformed after ingestion. However, like AB and AC they are very much 
associated with marine organisms and are found in algae, seaweed and fish 
oils.
132,133,136,137
 Upon ingestion of both arsenosugars and arsenolipids, the major 
metabolite in urine is DMA.
132
 However a number of DMA analogues called 
dimethylarsinoyl compounds (where the arsinoyl group represents either As=O or 
As=S) can also be found in urine. These compounds, termed oxo- and thioarsenicals 
are shown in Figure 4 and include: dimethylarsenoacetate (DMAA); 
dimethylarsenoethanol (DMAE); thio-dimethylarsenoacetate (thio-DMAA); thio-
dimethylarsenoethanol (thio-DMAE); thio-dimethylarsinate thio-DMA (also referred to 
as dimethylthioarsinic acid (DMTA)). The first study to report an oxoarsenical in human 
urine after the ingestion of an arsenosugar was Francesconi et al
131
 in 2002. This study 
reported DMAE alongside the first reporting of methylated TMAO, excreted in human 
urine along with numerous unknowns. The first study to report DMAA was Hansen et 
al
138
 in 2003. DMAE, DMAA and the primary metabolite DMA were identified in the 
urine of sheep located in North Ronaldsway (Scotland), which are unique in the fact 
they are chronically exposed to arsenosugars due to a diet composed primarily of 
seaweed. It was the study of these sheep by the same research group which also 
identified the first thioarsenical
136
 (thio-DMAA) in 2004. Further human dosing studies 
of an arsenosugaƌ ďǇ FƌaŶĐesĐoŶi͛s gƌoup132,133 resulted in the excretion of 12 arsenic 
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compounds including: DMA, TMAO, DMAE, DMAA, thio-DMAA, thio-DMAE, thio-DMA, 
trimethylarsine sulphide (TMAS), the arsenosugar itself, a thio-arsenosugar and two 
remaining unknowns, which were an oxo- thioarsenical pair. The first investigation of 
human metabolism of an arsenolipid was by Schmeisser et al
139
 and resulted in the 
excretion of dimethylarsenopropanoic acid (DMAP), thio-dimethylarsenopropanoic 
acid (thio-DMAP), dimethylarsenobutanoic acid (DMAB) and thio-
dimethylarsenobutanoic acid (thio-DMAB). Two arsenolipid compounds, along with 
DMAP, DMAB, thio-DMAP and thio-DMAB are shown in Figure 6.  
A limitation of the analysis of these compounds is the lack of commercially available 
standards, to either aid identification or to quantitatively analyse them. These arsenic 
compounds will possibly become more prevalent in the human diet and our ability to 
now detect unidentified arsenic species in human urine (thought primarily to be 
because of the advancement in analytical technology), is going to become a concern if 
commercially available standards are not available to help identify and quantify them. 
Chapter 3 of this thesis outlines the prominence of these arsenic compounds within 
routine biological monitoring urine samples and the difficulty in identifying them. 
1.3.5 Toxicity of Arsenosugars, Arsenolipids and their Respective Human 
Metabolites 
This emergence in the identification of numerous new metabolites resulting from the 
ingestion of arsenosugars and arsenolipids in humans, is a toxicological concern. In 
addition, the fact that thio-DMA has been reported in the urine of individuals exposed 
to inorganic arsenic in drinking water
140,141
 raises issues of its carcinogenicity. Of the 
four common arsenosugars shown in Figure 6, in vitro toxicological studies of only 
DMA
5+
-sugar-glycerol and DMA
5+
-sugar-sulphate have been performed and found both 
to be neither genotoxic nor cytotoxic.
142,143
 However, in a study of DMA
3+
-sugar-
glycerol, although never seen in a biological system,
135
 it was observed to be 
significantly cytotoxic to cells in comparison to DMA
5+
 and MMA
5+
, but less so than 
As
3+
 and As
5+
. 
143
 Additionally, another in vitro study found thio-DMA
5+
-sugar-glycerol 
exerted low cytotoxicity.
144
 An in vitro study looking at three arsenic containing 
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hydrocarbons found them to be as cytotoxic as As
3+
 in human bladder and liver cells,
145
 
however no cytotoxicity was found with arsenolipid metabolites DMAP and thio-
DMAP.
146
  
The DMA analogue, thio-DMA has gained the greatest attention as it has been 
reported as a product of both inorganic arsenic
141
 and arsenosugar
95,132
 metabolism. 
All in vitro toxicity tests of thio-DMA, found it to be the same or more toxic than As
3+
 in 
human bladder cells,
147-149
 human lung cells
150
 and human skin cells,
151
 with some 
studies reporting a reduction in cytotoxic effects with GSH depletion and an increase 
with GSH addition.
152,153
 NaƌaŵaŶduƌa͛s ƌeseaƌĐh gƌoup haǀe doŶe ŵuĐh iŶǀestigation 
of thioarsenicals in terms of in vitro toxicity studies, animal studies and metabolism 
determination. A study of human bladder cells found exposure to thio-DMA generated 
a high level of intracellular reactive oxygen species which was suggested to be the 
cause of cell death rather than the thio-DMA itself.
148
 They reported that in hamsters, 
thio-DMA bound to proteins in the same way as trivalent arsenic species, especially 
DMA
3+
 and was efficiently taken up into red blood cells (RBC), converted to DMA
5+
 and 
distributed around the body to the liver, kidneys and lungs.
154
 However, thio-arsenical 
dimethylmonothioarsinic acid (dithio-DMA or DMDTA) did not bind to proteins or 
modify but was excreted unchanged.
154,155
 A study of in vitro human RBC also 
demonstrated that thio-DMA was converted from DMA
3+
, which was swiftly taken up 
into RBC and rapidly released after conversion.
156
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Figure 6 Arsenic compounds known as arsenosugars, arsenolipids and the 
metabolised dimethylated analogues after arsenolipid ingestion.     
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1.3.6 Dietary Influences 
The metabolism of arsenic compounds varies depending on the specific compound and 
the exposure route. The metabolism of arsenic species will also influence the different 
toxicities between these various arsenic compounds and their toxic effects in different 
animal species. For example, the toxicity of an ingested methylated arsenic compound 
in human urine from a dietary source will differ from that of a methylated arsenic 
compound in human urine as a result of inorganic arsenic exposure.
15
  Arsenic is 
ranked as the 12
th
 most abundant element in the human body
117
 and the vast majority 
of this exposure in the general population is through diet. As discussed above, AB, AC, 
TMAO, arsenosugars, arsenolipids and other oxo- and thioarsenicals are all dietary 
species of arsenic. However, inorganic arsenic, DMA
5+
 and MMA
5+
 are also found in 
dietary sources. DMA and sometimes MMA can be found in rice, other plant based 
foods and seafood.  People who eat seafood have increased urinary DMA
5+
 compared 
to those who do not.
157
 Inorganic arsenic can be found in chicken,
109,158
 rice,
158-161
 
cereal,
109,162
 mushrooms,
163,164
 wine and beer,
165,166
 fruit juices
166,167
 and dairy 
products.
109
 Only trace levels are generally found in seafood and seaweed,
130
 with the 
exception of brown algae and bivalves such as blue mussels.
130,135,137,158
 Arsenic exists 
in all natural waters with concentrations ranging from <0.5 to >5000 µg/L,
168
 with 
inorganic arsenic being the predominant species found.
168
 The World Health 
Organisation (WHO) recommends a maximum value for arsenic in drinking water of 10 
µg/L
169
. Although freshwater normally contains less than this, most frequently less 
than 1 µg/L,
170
 ground water drinking supplies with high levels of naturally present 
inorganic arsenic occur in Argentina, Bangladesh, Chile, China, Hungary, India, Mexico, 
the US and Vietnam.
168,170,171
 Elevated levels of arsenic in private drinking water 
supplies of up to 435 µg/L have also been reported in Cornwall, UK.
172,173
  
1.3.7 Industrial and Occupational Exposure to Arsenic 
Occupational exposure to arsenic compounds occurred as far back as 5000 years ago. 
The melting of a glacier caused the frozen body of a man to be discovered in 1991 by 
two German tourists in the Italian Alps.
174
 The ice, which had helped to preserve the 
36 
 
ŵaŶ͛s ďodǇ aŶd his ďeloŶgiŶgs, eŶaďled sĐieŶtists to take biological samples for 
analytical investigation. In addition to dating the body as being 5300 years old, analysis 
of the iĐeŵaŶ͛s haiƌ ƌeǀealed high leǀels of aƌseŶiĐ aŶd Đoppeƌ. AŶ aǆe ǁas fouŶd 
amongst his possessions composed of 99.7% copper; the elevated arsenic and copper 
results have led scientists to believe he may have been involved in copper smelting.
174
  
Occupational exposure to inorganic arsenic can occur in many industries and 
occupations, as outlined in Table 4.  
Table 4 Industries and occupations where exposure to inorganic arsenic 
occurs. 
Industries & Occupations
109
 
Semi-conductor 
Manufacture 
Glass Production Microelectronics 
Wood Preservation 
Burning/Recycling of 
Preserved Wood 
Pesticide Manufacture or 
Use 
Burning of Arsenic Rich 
Coal 
Refining Metal Ore Non-ferrous Smelting  
Copper Smelting Alloy Manufacture 
Assembly/Recycling  of 
Lead Acid Batteries 
Pyrotechnics Pigments & Dyes Electrophotography 
Occupational inhalation of airborne arsenic is in the form of particulate matter that 
deposits in the lungs, followed by absorption.
93
 Little is known about the deposition 
and absorption of inhaled arsenic in humans but it is thought that the form of 
inorganic arsenic is a fundamental factor.
93
 Inhaled insoluble As
5+
 is thought to be 
absorbed at a much lower rate than As
3+
. A study by Yager et al
175
 correlated arsenic 
air measurements with arsenic speciated urinary measurements of boiler maintenance 
workers in coal-fired power plants in the US. The workers were exposed to arsenic in 
the form of calcium arsenate. Yager et al
175
 noted that air measurements for a 8-hour 
time weighted average of 10 µg/m
3
, resulted in a mean sum of inorganic arsenic and 
methylated metabolites in urine a third lower than in copper smelters who were 
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exposed to arsenic trioxide and workers at a arsenic trioxide refinery. However, a study 
by Morton & Mason
157
 found that arsenate exposed timber treatment workers had 
significantly higher urinary levels of inorganic arsenic and methylated metabolites than 
arsenite exposed semi-conductor workers. This difference was judged to be as a result 
of higher levels of exposure, different routes of exposure and poor worker behaviour 
concerning PPE for the arsenate wood preservation workers compared to improved 
engineering controls and PPE of the semi-conductor workers.
157
 In the 1950s, a study 
involving the inhalation of sodium arsenite in eight volunteers (some of whom had 
lung cancer) found the deposition of arsenic particulate in the lungs to be 
approximately 40%, of which 75–85% of this amount was absorbed. This indicated that 
the overall absorption, expressed as a percentage of inhaled arsenic was a total of 30-
34% of the initial inhaled dose.
98
 However, reported results based on individuals with 
ill health must be viewed with caution, as this may not be true of people without lung 
disease. Smelters exposed to arsenic trioxide dusts excreted approximately 40–60% of 
the inhaled arsenic in their urine.
176,177
 Those with the highest urinary arsenic levels 
showed a higher excretionary rate of the absorbed arsenic compared to those with the 
lowest urinary arsenic values.
177
 
When arsenic is ingested more than 90% of the dissolved dose is absorbed from the 
gastrointestinal tract regardless of whether is it As
3+
 or As
5+
.
93
 It is also likely that a 
proportion of the inhaled particles of inorganic arsenic in the form of dusts will be 
swallowed and absorbed from the gastrointestinal tract.
98
 
1.3.8 Biological Monitoring of Arsenic Exposure 
After exposure to inorganic arsenic, it is quickly distributed throughout the body and 
rapidly cleared from the blood in humans.
28
 This rapid clearance of arsenic from blood 
makes it an unsuitable matrix for biological monitoring but it would be suitable for 
investigating very recent and high level exposure,
93
 such as an accidental poisoning. 
The main route of excretion, after either inorganic or organic arsenic exposure, is via 
urine. As As
3+
 binds to proteins, excretion after exposure to As
5+
 tends to be faster 
than As
3+
. 
28
 Regardless of the extent of exposure, the distribution of arsenic in urine of 
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various population groups is reasonably constant with 10-30% inorganic arsenic, 10-
20% MMA and 60-70% DMA.
28
  Though it has been suggested that a higher proportion 
of MMA iŶ uƌiŶe iŶdiĐates aŶ iŶdiǀidual͛s pooƌ ŵethǇlatioŶ ĐapaĐitǇ.137  
Total arsenic analysis is now considered completely inappropriate due to the inability 
to distinguish between non-toxic AB and toxic inorganic species. Speciation methods 
often have long sample acquisition times making them unsuitable for routine analysis, 
therefore the analytical method of choice for many laboratories is hydride generation. 
Hydride generation eliminates dietary AB and AC due to them not forming a hydride, 
but instead through reduction and hydride generation gives a total combined value of 
the inorganic arsenic species and the methylated metabolites, DMA and MMA. 
Unfortunately, the increased incidence of DMA and MMA in food and drink has 
resulted in hydride generation being deemed no longer fit for purpose due to the 
inability to distinguish methylated metabolites of dietary exposure from methylated 
metabolites of inorganic arsenic exposure. Furthermore, it is known that the technique 
of hydride generation struggled to convert 100% of the DMA present in a urine sample 
to As
3+ 
to form a hydride. The only way to accurately determine the type of exposure 
and distribution of arsenic species in a urine sample is to perform speciation analysis. A 
difficultly with this approach is that there are no background reference values for any 
of the five species of arsenic. Chapter 2 of this thesis attempts to rectify this issue by 
demonstrating a routine fast arsenic speciation method and reporting a mean and 90
th
 
percentile values for five species of arsenic in a background occupationally unexposed 
population. Another problem is the lack of BMGV for any of the five species of arsenic, 
however there is the U.S. BEI  of 35 µg/L (approximately 40 µmol/mol creatinine) and 
the German BAT of 50 µg/L (approximately 55 µmol/mol creatinine); both are based 
on the sum of inorganic species and methylated species. 
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1.4 Chromium 
1.4.1 Physical Properties 
Chromium (Cr) is the first metal of group 6 in the periodic table. Chromium has the 
atomic number 24 and a mass of 51.996 amu. It has four stable isotopes of which 
52
Cr 
(83.76%) is the most abundant, 
50
Cr (4.31%), 
53
Cr (9.55%) and 
54
Cr (2.38%) being the 
other three. Chromium is ubiquitous and classed as the 24
th
 most naturally occurring 
element
178
 found in rock, soil, plants, animals and volcanic dusts, however not 
naturally in air. 
Chromium is a transition element that exhibits nine valence states from -2 to +6. 
However only +3 and +6 are environmentally and thermodynamically stable and are 
considered the only species of interest in relation to human exposure. Hexavalent 
chromium exists in the valence state +6/Cr(VI) such as chromate (CrO4
2-
) or dichromate
(Cr2O7
2-
) and is toxic. Trivalent chromium exists in the valence state +3/Cr(III) (CrCl3 and
Cr2O3) and is deemed an essential element in humans, needed for the metabolism of 
sugar, protein and fat.
179
 
The stability of both species of chromium is heavily dependent on pH, with trivalent 
chromium being stable under acidic conditions and hexavalent chromium under more 
alkaline conditions. Stability and pH conditions of both chromium species are discussed 
further in Chapter 4 of this thesis. 
1.4.2 Chromium Toxicity and Effects on Human Health 
Chromium toxicity is dependent on its species, with Cr(VI) being considerably more 
toxic than Cr(III). After exposure to Cr(VI), it is naturally reduced to Cr(III) by biological 
reduction processes. Although Cr(III) is an essential element, dermal exposure can still 
result in health effects such as skin irritation and allergic contact dermatitis,
180
 
however due to its poor solubility it is far less efficient at producing an allergic 
40 
response than Cr(VI).
180
 Cr(III) is not considered carcinogenic,
28
 with IARC classifying it 
as a Gƌoup ϯ ageŶt, defiŶed as ͞Ŷot Đlassifiaďle as to its ĐaƌĐiŶogeŶiĐitǇ to huŵaŶs͟.31 
Hexavalent chromium however is considered to be carcinogen in addition to being a 
mutagen, asthmagen and inducer of skin dermatitis.
178
 It is rarely found naturally in 
the environment only occurring as the mineral crocoite (PbCrO4),
181
 therefore most
environmental Cr(VI) existence is normally as a result of industrial processes and man-
made production. IARC has classified Cr(VI) as a Group 1 agent, defined as 
͞ĐaƌĐiŶogeŶiĐ to huŵaŶs͟.31 Compounds of Cr(VI) can be soluble or insoluble which is 
also linked to toxicity. Water soluble Cr(VI) compounds, such as sodium chromate 
(NaCrO4), sodium dichromate (Na2Cr2O7), potassium chromate (K2CrO4) and potassium 
dichromate (K2Cr2O7), are more toxic than less soluble Cr(VI) compounds such as 
barium chromate (BaCrO4) and lead chromate (PbCrO4).
28,109
 The health effects
associated with Cr(VI) exposure are vast, with the route of exposure resulting in 
different toxicity endpoints. Acute ingestion of Cr(VI) can cause gastroenteritis, 
gastrointestinal haemorrhage and renal failure.
181
 Skin contact with Cr(VI) compounds 
can cause dermal irritation and allergic contact dermatitis, ulceration and burns to the 
skin.
16,181
 Inhalation exposures can result in respiratory effects such as ulceration of 
the nasal mucosa, perforation of the nasal septum, bronchitis, occupational asthma, 
pneumonia and cancers such as nasal, sinus and lung, in addition to other health 
effects such as a weakened immune system and/or kidney and liver damage.
16,179
  
As demonstrated in Table 5, the LD50 of Cr(VI) for an oral ingested dose is compound 
dependent. There are several suggestions in the literature estimating the human lethal 
dose to Cr(VI) of from 1 to 3 g,
181
 between 50 to 70 mg/kg body weight for soluble 
chromate
17
 and 0.5 to 1.0 g for potassium dichromate.
182
 However, concentrations of 
Cr(VI) >200 mg/L which are non-fatal to humans can result in gastritis, nephrotoxicity 
and hepatotoxicity.
183
 It is thought that due to limited information and conflicting 
studies there is insufficient evidence to suggest that Cr(VI) is carcinogenic to humans 
when exposure is via ingestion.
183,184 
This is thought to be due to it being reduced to 
Cr(III) by the gastrointestinal system prior to absorption.
28
 However accidental or 
suicidal ingestions of extremely high doses (for example, a 44-year-old male ingested 
41 
an estimated 4.1 mg/kg chromic acid,
185
 a 33-year-old male ingested 125 mL of 
chromic acid
186
 and a 17-year-old male ingested 5g of potassium dichromate
182
) have 
resulted in fatalities. Conversely, there has been a report of a 58-year-old male 
surviving an ingestion of 30 g/L (estimated 3 g) of potassium dichromate and being 
discharged with no renal or liver failure.
187
 Table 5 also shows there is a stark 
difference between the LD50 value for male and female rats, with females showing a 
much a greater sensitivity to the toxicity of Cr(VI) compounds than males.   
Table 5 LD50 values of chromium compounds in laboratory experiments 
Species Chromium Compound Test subject 
LD50 
(mg/kg) 
Ref 
Cr(VI) Strontium chromate (SrCrO4) Male rats 811 
16
Cr(VI) Chromium trioxide CrO3 
Female Rats 
Male Rats 
25 
29 
16
Cr(VI) Sodium chromate (Na2CrO4) 
Female Rats 
Male Rats 
13 
28 
188
Cr(VI) Sodium dichromate (Na2Cr2O7) 
Female Rats 
Male Rats 
14 
21 
188
Cr(VI) Potassium dichromate (K2Cr2O7) 
Female Rats 
Male Rats 
17 
26 
188
Cr(VI) Calcium chromate (CaCrO4) 
Female Rats 
Male Rats 
108 
249 
189
Cr(VI) Ammonium dichromate ((NH4)2Cr2O7) 
Female Rats 
Male Rats 
19 
22 
188
Cr(III) Chromium acetate Cr(CH3COO)3 Rats 2365 
16
Cr(III) Chromium nitrate Cr(NO3)3 
Female Rats 
Male Rats 
183 
200 
189
The toxicity and especially genotoxicity of Cr(VI) is linked to its ability to cross cell 
membranes and although it has been shown to be unreactive towards DNA,
184
 it has 
the ability to undergo intracellular reduction which produces the reactive chromium 
species and oxygen radicals which cause the DNA damage.
28
 Ascorbate with 
glutathione are the principal reducers of Cr(VI)
190,191
 however, cysteine, hydrogen 
42 
peroxide and mitochondrial enzymes have all been found to aid the reduction of Cr(VI) 
to Cr(V), Cr(IV) and subsequently Cr(III).
28
 During this process reactive hydroxyl radicals 
and reactive oxygen species (ROS) are generated
184
 leading to oxidative stress and 
damage to DNA, affecting DNA replication.
28
 The reason that Cr(III) is considerably less 
toxic is because of its poor ability to permeate cell membranes, therefore Cr(VI), which 
is reduced to Cr(III) prior to cell absorption, has its genotoxic abilities supressed. 
Although Cr(III) can be oxidised to Cr(VI) in alkaline conditions, there is no evidence 
that biological systems can convert Cr(III) to Cr(VI).
181,184
   
1.4.3 Industrial and Occupational Exposure to Chromium 
In an occupational setting exposure to chromium is primarily through inhalation, 
however, skin absorption and ingestion are also exposure pathways. Chromium is a 
multi-functional metal that has the ability to provide alloys and materials with added 
strength, hardness and resistance to temperature, in addition to wear and corrosion 
resistance.
192,193
 For example, chromium is used to harden steel during the 
manufacture of stainless steel, chromium plating provides a hard shiny coating to 
other metals and plastics to restrict corrosion and provide an enhanced appearance 
and chromium is added to paints and pigments for its corrosive resistant abilities in 
extreme conditions such as those required in the maritime and aeronautic 
industries.
193,194
 Table 6 outlines many of the industries, occupations and activities 
where exposure to Cr(VI) occurs. 
Table 6 Industries and occupations where exposure to hexavalent chromium 
occurs. 
Industries & Occupations Involved with the Production 
 or Use of Chromium Containing Metals and Goods  
33,179,195
 
Production 
Chromates  Stainless Steel Chrome Paints 
Chrome Pigment & Dye Chromium Alloys 
43 
Industries & Occupations Involved with the Production 
 or Use of Chromium Containing Metals and Goods  
33,179,195
 
Industries 
Chrome plating Leather tanning Steel mills 
Foundries Wood preservation Construction 
Plasma Cutting Pulp production 
Industrial processes 
Welding Grinding Polishing 
Pesticides Paint spraying / removal Smelting 
The industries with the highest exposure to Cr(VI) compounds include chromate 
production, ferrochrome and chrome pigment production, chrome plating and 
stainless steel welding.
16
 Therefore it might not be surprising that there is an increased 
risk of occupational cancer amongst several of these types of industries and notably 
amongst chromate production workers, surface engineering chrome-platers and 
pigment production workers.
183,195,196
 Other health effects associated with inhalation 
exposure such as respiratory irritations have also been reported at concentrations as 
low as 2 µg/m
3
 in the chrome plating industry.
183
  In contrast to the LD50 of an oral
ingested dose in rats (see Table 5), strontium chromate and zinc chromate due to their 
solubility are associated with the greatest risk of developing lung cancer.
181
 Table 7 
shows the different industrial uses of specific chromium compounds.  
Table 7 The purpose and use of specific compounds of hexavalent and 
trivalent chromium in different industries. 
Hexavalent Chromium 
Compound 
Industrial Uses
109,195
 
Ammonium dichromate Leather Tanning Textile pigments & dyes 
Barium chromate 
Corrosion inhibitors 
Paint, Ink & Plastic pigments 
& dyes 
Pyrotechnics 
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Hexavalent Chromium 
Compound 
Industrial Uses
109,195
 
Calcium chromate Corrosion inhibitors 
Paint, Ink & Plastic pigments 
& dyes 
Chromic trioxide 
Corrosion inhibitors Metal finishing 
Wood Preservation 
Lead chromate 
Paint, Ink & Plastic pigments 
& dyes 
Chrome yellow paint 
(automotive finishes) 
Synthetic resins 
Potassium chromate Textile pigments & dyes 
Potassium dichromate Paint, Ink & Plastic pigments & dyes 
Sodium chromate 
Textile pigments & dyes 
Paint, Ink & Plastic pigments 
& dyes 
Wood Preservation Corrosion inhibition 
Leather tanning Catalysts 
Sodium dichromate 
Manufacture of chromium 
chemicals 
Leather tanning 
Textile pigments & dyes 
Strontium chromate Metal finishing 
Zinc chromate 
Paint, Ink & Plastic pigments 
& dyes 
Metal coating primer 
Trivalent Chromium 
Compounds 
Industrial Uses
195
 
Chromium acetate Emulsion Hardener 
Paint, Ink & Plastic pigments 
& dyes 
Chromium nitrate Corrosion inhibitor Textile pigments & dyes 
Chromic Sulfate 
Surface Engineering Ceramic Glazes 
Textile pigments & dyes 
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1.4.4 Biological Monitoring of Chromium Exposure 
No matter the route of exposure, Cr(VI) is eventually reduced by all biological fluids to 
Cr(III). It is possible to measure chromium exposure in urine, red blood cells (RBC) and 
plasma. However, the measurement of urine and plasma samples results in the 
inability to distinguish between Cr(VI) and Cr(III). The measurement of RBC is indicative 
of Cr(VI) exposure only, (measured as Cr(III), due to Cr(VI) cell permeation) however it 
has been shown that some Cr(VI) will also be reduced in the plasma, limiting RBC 
penetration.
192
 In addition, chromium concentration within the RBC will remain 
elevated for the life of the cell.
192
 Due to its invasive nature and the need for trained 
medical staff, neither employers or employees favour providing a blood sample for 
biological monitoring of Cr(VI) exposure assessment. Therefore, a urine sample is 
widely accepted and, although this is not an ideal approach to determining Cr(VI) 
exposure, it is a practical one and is widely used.
192
 Furthermore, for interpretation of 
results there are several BMGVs for chromium in urine. Virtually all food contains 
chromium in the trivalent form
193
 and a background unexposed reference range based 
on the 95
th
 percentile has been established for a UK population of <2.9 µmol/mol 
creatinine.
26
 Because trivalent chromium is very poorly absorbed from the 
gastrointestinal tract, approximately only 1% of an ingested oral dose is excreted in 
urine.
193
 This helps to eliminate the high variability in the dietary contribution of 
chromium from urinary total chromium measurements, which is very common with 
total arsenic analysis and dietary arsenic. The current chromium HSE BMGV
24
 of 10 
µmol/mol of creatinine is based on the 90
th
 percentile of data from companies deemed 
to have good occupational practice to control exposure. The BEI for total chromium 
based on urine collected at the end of shift at the end of the working week is 25 µg/L 
(40 µmol/mol creatinine).
22
 
Urinary chromium levels can reflect both past and recent exposure to Cr(VI), with daily 
accumulation occurring through the working week of the occupationally exposed,
192
 
therefore it is suggested that urine samples are taken towards the end of the working 
shift towards the end of the working week. The absorption and excretion of Cr(VI) in 
the urine is dependent primarily on the type of Cr(VI) compound and its solubility but 
46 
also the route of exposure, the level of exposure, the dose, body burden and the 
length of exposure. Studies in welders have suggested the excretion of chromium in 
urine after exposure by inhalation as a two or three stage process with elimination 
half-lives of 7 hours, 15-30 days and 3-5 years.
16,17
 Studies in chrome platers have 
shown a two-stage process with half-lives of 2-3 days followed by 1 month.
197
 One 
study investigating chromium levels in a 44-year-old plasma cutter found the 
chromium body burden so high after many years of exposure that the half-life of 
chromium in urine was 129 months after exposure ceased.
198
  
As the primary route of exposure to Cr(VI) is by inhalation
192,199
 an alternative 
biological monitoring matrix to help further understand Cr(VI) inhalation exposures 
and how Cr(VI) resides and behaves in the lungs and is subsequently excreted might be 
EBC. Chapter 4 of this thesis describes the first publication to report a speciation 
method to simultaneously separate both Cr(III) and Cr(VI) in EBC samples using micro 
liquid chromatography coupled to inductively coupled plasma mass spectrometry (µLC-
ICP-MS). In addition, Chapter 5 of this thesis describes the first published investigation 
of both Cr(III) and Cr(VI) levels in EBC samples of occupationally exposed individuals 
and a control group. Both of these studies are the initial investigations into 
understanding EBC in relation to the inhalation of Cr(VI) compounds. 
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1.5 Silicon and Silica 
1.5.1 Physical Properties 
Silicon (Si) is a metalloid in group 14 of the periodic table. Silicon has the atomic 
number 14 and a mass of 28.086 amu. It has three stable isotopes of which 
28
Si 
(92.23%) is the most abundant, the other two being 
29
Si (4.67%) and 
30
Si (3.10%). 
Silicon is Đlassed as the ϮŶd ŵost aďuŶdaŶt eleŵeŶt iŶ the Eaƌth͛s Đƌust ďeiŶg found in 
most of the woƌld͛s ƌoĐks ;igŶeous, sediŵeŶtaƌǇ aŶd ŵetaŵoƌphiĐͿ, saŶds aŶd soils, iŶ 
addition to water and plants. 
Silicon, like carbon, has four electrons in its outer orbital and although it exhibits eight 
valence states, only -4 and +4 are stable. Silicon itself is considered harmless and is 
rarely found naturally in the environment; its strong affinity with oxygen ensures most 
silicon is in the form of silica (SiO2) or in the form of silicates. 
As shown in Table 8, silica can be found in two forms: crystalline and amorphous. 
Table 8 The classification of silica forms
 200
Silica Form Origin Classification 
Crystalline 
Natural 
α-quartz 
α-tridymite 
α-cristobalite 
Coesite 
Moganite 
β-quartz 
β-tridymite 
β-cristobalite 
Stishovite 
Synthetic 
Keatite 
Porosils 
Silica W 
Amorphous 
Natural 
Opal 
Diatomaceous earths 
Vitreous silica 
Biogenic silica 
Silica fibres 
Synthetic 
Fused silica 
Precipitated silica 
Silica gel 
Fumed silica 
Colloidal silica 
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The difference between crystalline and amorphous silica relates to the particle 
structure.
200
 Silicon-oxygen tetrahedra (SiO4) make up all forms of crystalline and 
amorphous silica (with the exception of stishovite).
200
 Each silicon-oxygen tetrahedron 
consists of a silicon atom surrounded by four oxygen atoms; each oxygen atom is 
shared by two tetrahedra.
200
 The difference is that the tetrahedra of crystalline silica 
produce a regular three-dimensional framework, which shares each corner with other 
tetrahedra. The pattern of the crystal structures created are specific to the type of 
crystalline silica.
200
 Whereas, the tetrahedra in amorphous silica are not regular and 
the orientation is random which does not result in a crystal structure.
200
 
α-Quartz is the thermodynamically stable form of crystalline silica (other forms exist in 
a metastable state) and as such makes up the majority of natural crystalline silica.
109
 
Commercial silica is obtained from this naturally occurring source, of which sand and 
gravel, quartz crystals and diatomites make up the three major commercial products. 
Rocks and stones composed of crystalline silica include agate, flint, jasper, sandstone, 
and chert.
109
 Cristobalite is a natural constituent of volcanic lava and is produced when 
either quartz or amorphous silica are subject to very high temperatures.
201
 Cristobalite 
is also formed in the manufacture of silica bricks that are used in industrial furnaces. 
1.5.2 Silica Toxicity and Effects of Human Health  
Amorphous silica is considered non-toxic however crystalline silica has been classified 
as a group 1 agent by IARC, defined as ͞ĐaƌĐiŶogeŶiĐ to huŵaŶs͟ ďut oŶlǇ ǁheŶ it is 
inhaled in its quartz or cristobalite forms.
31
 In addition, both the National Toxicology 
Program (NTP) and the American Conference on Governmental Industrial Hygienists 
(ACGIH) label crystalline silica as a human carcinogen
97
 and suspected human 
carcinogen, respectively. Amorphous silica is classified as a group 3 agent by IARC, 
defiŶed as ͞Ŷot Đlassifiaďle as to its ĐaƌĐiŶogeŶiĐitǇ to huŵaŶs͟.31  
Silica as a whole is the most abundant dietary element in humans after iron and 
zinc.
202
 Its health benefits include the reduced risk of cardiovascular disease and 
alopecia along with strengthening of bones, skin and blood vessels.
202
 Humans can be 
49 
exposed to silica from a variety of sources including cosmetics (lipsticks and powders), 
toiletries (toothpaste), creams (hand and nail) and detergents in addition to cosmetic 
and medical implants. However the greatest source of exposure is from diet, with an 
estimated intake of between 20 – 50 mg silica per day in Western populations.203,204 
This concentration of dietary intake is more than twice that of a typical dietary intake 
of zinc and iron.
205
 As silica is taken up and accumulated in plants for structural 
purposes, it makes plant based foods (especially cereals)
202
 a high contributor of silica 
in the diet.
202,205
 Beer is said to be one of the highest dietary contributors of silica in a 
Western diet, especially in men.
205,206
  
Exposure to crystalline silica associated with the inhalation of crystalline particulate is 
linked to various lung diseases including emphysema, COPD, lung cancer and fibrotic 
pneumoconiosis, more commonly known as silicosis.
97
 Silicosis is the hardening and 
scarring of lung tissue that results in the loss of lung function.
207
 It is a terminal, 
irreversible, fibrotic pulmonary disease, with no treatment or cure, with effects that 
will continue to develop and progress well after exposure has ceased.  
For exposure to occur, crystalline silica has to be small enough to enable it to become 
airborne (mostly as a dust fraction) and inhaled into the alveoli region of the lungs. 
Many sizes of crystalline silica have the potential to become airborne if the conditions 
are right. Respirable crystalline silica (RCS) however, is the portion of airborne 
crystalline silica small enough to enter the gas-exchange regions of the lungs (alveoli) 
when inhaled. Therefore, the RCS particles must have an aerodynamic diameter less 
than approximately 10 µm.
208
 For instance, upon inhalation of airborne dust containing 
particles of crystalline silica there are three particle size fractions: inhalable, thoracic 
and respirable. The inhalable fraction is related to the largest particle sizes that are 
breathed into the nose and mouth only. The thoracic fraction relate to smaller 
particles that are able to penetrate the head airways and enter the airways of the 
lungs (bronchial tubes). The respirable fraction relates to smallest particles (<10 µm) 
and it is this fraction, termed RCS, that is capable of penetrating beyond the terminal 
bronchioles and into the gas exchange region of the lungs (alveoli). 
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1.5.3 Silicosis 
Silicosis is believed to only be an occupational disease, as environmental levels of silica 
dust are not considered high enough to cause silicosis in the general background 
population. However, this is obviously dependent on environment and circumstance, 
as silicosis has been found in both men and woman of Himalayan villages due to 
frequent exposure to crystalline silica through dust storms.
209
    
Silicosis is categorised into three types, with chronic silicosis being the most 
common.
207
 
1. Acute – Silicosis develops very quickly from a few months up to as long as 2 years
after exposure. It results from exposure to very high levels of RCS over a short
period of time.
2. Accelerated – Silicosis usually develops 5 – 10 years after exposure to high levels of
RCS. The onset of symptoms is longer than with acute silicosis however,
progression of the disease is fast.
3. Chronic – Silicosis usually develops from between 10 years up to 40 years after
exposure. Exposure is in the form of long term low level exposure to RSC.
207
Symptoms of silicosis are similar to many other lung disorders, which is one reason for 
under diagnosis of the disease in the past. Symptoms begin with shortness of breath, 
development of a cough, continuing to a fever, cyanosis (bluish discolouration of the 
skin around either the lips or tips of the fingers), loss of appetite, fatigue, pulmonary 
edema, pneumonia, chest pain and finally respiratory failure.
201,210,211
 In addition, 
sufferers of silicosis have an increased risk and susceptibility towards other health 
conditions such as mycobacterial infections, tuberculosis, autoimmune disease and 
lung cancer.
201,212
  
After inhalation, RCS deposits in the lungs causing epithelial injury and macrophage 
activation, which in turn leads to inflammation. RCS persists and accumulates in the 
lungs which causes three reactions:
97
 
1. The release of cytokines and growth factors from macrophages and epithelial cells
51 
2. The release of reactive oxygen and nitrogen intermediates
3. Stimulation of oxidative stress in the lungs
It is these three reactions or pathways, which contribute to silicosis and other lung 
diseases.  
1.5.4 Industrial & Occupational Exposure to Silica 
Throughout history, occupational exposure in the form of inhalation of dusts has been 
linked to lung related diseases. Afflictions termed ͞ŵiŶeƌs͛ phthisis,͟ ͞dust 
ĐoŶsuŵptioŶ,͟ ͞ŵasoŶ͛s disease,͟ ͞gƌiŶdeƌs͛ asthŵa,͟ ͞potteƌs ƌot͟ aŶd ͞stoŶeĐutteƌs 
disease͟ aƌe all Ŷoǁ ĐolleĐtiǀelǇ Đalled siliĐosis.212 The number of industries and 
occupations where the potential for inhalation of RCS occurs is vast, as displayed in 
Table 9, however many of these industries and occupations are dependent on certain 
activities (outlined in Table 10) within the workplace to create the correct environment 
for RCS exposure.  
Table 9 Occupations and industries where exposure to RCS occurs 
Industries & Occupations
200,201,208
 
Construction Quarrying Milling 
Mining Tunnelling Grindstone Production 
Tombstone production Stone Mason Foundries 
Boiler scaling Agriculture Potteries 
Arts & Sculpture Jewellery Making 
Glass Manufacture & 
Recycling 
Road & Highway 
Excavations 
Ceramics Shipbuilding & Repair 
Auto-mobile repair Hydraulic Fracturing 
Worktop Manufacture & 
Fitting 
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Interestingly, high instances of RCS exposure and silicosis have been reported in dry 
cutting workers of artificial stone in Israel
213
 and the manufacturers of 
kitchen/bathroom worktops in Spain
214,215
, North America
216
 and an unspecified 
location,
217
 both of which had not previously been recognised as industries of RCS 
exposure. 
Table 10 Workplace activities that create RCS when working with crystalline 
silica containing rock, soil, sand, gravel, resources and products 
Activities creating aerosolised dust containing RCS particulate
200,201,208
 
Drilling Breaking Crushing 
Cutting Sawing/Slicing Abrasive blasting 
Sand blasting Grinding Sanding & scaling 
Excavation & Digging Hammering Casting & Moulding 
Furnace installation Dry sweeping Pressurised air blowing 
Polishing & Buffering Mixing Ploughing & Harvesting 
Demolition Blasting Etching & Engraving 
1.5.5 Biological Monitoring of Silica 
Unfortunately, biological monitoring is not available to assess and monitor exposure to 
RCS. This is mainly due to urinary levels of silica being so high, due to the sheer 
abundance of silica in the environment, diet and from general human lifestyle. Silica 
(measured as silicon) measurements at mg/L concentrations have been reported in 
urine,
19,218,219
 blood
219
 and serum
19
 by either graphite furnace atomic absorption 
spectroscopy (GFAAS) or inductively coupled plasma atomic emission spectrometry 
(ICP-EAS) of control populations not occupationally exposed to silica. The fact that 
there is large inter-individual variation of background urinary silica levels within 
populations
19,218
 and that the excretion of an ingested silica dose is under 24 hours
19
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all add to the difficulty of occupational silica measurement. There is also the additional 
problem of how to distinguish between occupational RCS and the high levels of 
amorphous silica. Total silica in urine measured as silicon by inductively coupled 
plasma mass spectrometry (ICP-MS) at HSL has experienced an inability to distinguish 
differences between occupational samples and background population samples. 
Analysis of silicon by ICP-MS also has its own challenges. Firstly, silicon is not 
analytically sensitive (i.e. has a high limit of detection) due to elevated background 
levels of silicon on an ICP-MS, meaning the change in response from background to 
stimulus is low. The natural abundance of silicon in the materials of the ICP-MS 
hardware, the quartz sample introduction set-up and analytical reagents all contribute 
to high background levels of silicon. Secondly, silicon has several polyatomic 
interferences (
1
H
27
Al, 
14
N2, 
12
C
16
O) which collision/reaction cell technology cannot
sufficiently reduce to achieve the low limits of detection usually associated with and 
expected of ICP-MS. Furthermore, RCS is soluble only in hydrofluoric acid or strong 
alkaline conditions such as potassium hydroxide and sodium hydroxide. Strong 
concentrations of sodium or potassium hydroxide are not conducive to ICP-MS analysis 
and hydrofluoric acid requires a specialist sample introduction system, together with 
platinum-tipped cones for ICP-MS use. In addition, insoluble particles in a liquid sample 
are not compatible with ICP-MS analysis. It is also important to note that it is not 
known whether urinary measurements would be representative of inhaled RCS that 
deposits and accumulates in the lungs after exposure.  
The only way of assessing workplace exposure is environmental air monitoring of 
which there is an HSE workplace exposure limit (WEL) of 0.1 mg/m
3
 based on an 8 hour 
time weighted average.
24
 However, RCS levels in coal mines and mills, granite 
quarrying and processing other stone crushing industries, foundries, ceramic 
industries, construction and sandblasting operations frequently exceed the WEL.
200
 
Therefore, limiting occupational exposure is fully reliant on engineering controls such 
as ventilation, extraction, suppression of dust and dust collection along with 
respiratory protective equipment (RPE) such as dust masks. However, with no 
biological monitoring, it is not known how effective any of these controls are both in 
54 
terms of worker behaviour (for example correctly wearing RPE) or how successful they 
are at stopping or reducing exposure to the respirable fraction of RCS whose particle 
sizes are mostly not visible to the human eye. For example, it is unknown whether the 
smallest particles of RCS are able to penetrate through the tiny holes within the fabric 
of dust masks.  
A global estimate suggests that 28 000 people die annually from occupational 
exposure to RCS,
220
 of which Britain contributes approximately 800 deaths,
221
 
averaging 15 people a week. Exposure to RCS is a global problem and it is clear from 
the number of estimated annual deaths that the past, present and future process of 
assessing and controlling workplace exposure to reduce the risk of future ill health has 
been and will continue to be a difficult task for environmental monitoring alone. The 
development of a biological monitoring method to assess exposure to RCS would be a 
significant improvement in the battle to reduce the risk and occurrence of silicosis and 
other health effects associated with RCS exposure. Chapter 6 of this thesis investigates 
the initial stages of developing a method to measure RCS in EBC samples by ICP-MS, 
with the aim of establishing a biomonitoring method for RCS. 
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1.6 Speciation 
1.6.1 Definition 
The International Union for Pure and Applied Chemistry (IUPAC) defined chemical 
species as chemical compounds that differ in isotopic composition, conformation, 
oxidation state or in the nature of their complexed or covalently bonded 
substituents.
222
 This itemised distinction of a chemical species has led to three 
definitions to describe speciation: 
1. Chemical Species – Chemical elements: specific form of an element defined 
as to isotopic composition, electronic or oxidative state, complex or 
molecular structure 
2. Speciation Analysis – Analytical chemistry: analytical activities of identifying 
and/or measuring the quantities of one or more individual chemical species 
in a sample. 
3. Speciation of an element – Distribution of an element amongst defined 
chemical species.
222
 
Elemental speciation is the separation of an element into its different oxidation states 
or chemical forms and subsequent quantification. Elemental speciation is considered 
crucial when the toxicity of an element is dependent on its oxidation state or chemical 
form. 
The speciation of elements such as chromium, arsenic and silicon is vital because the 
toxicity and biological availability of these and other elements depend on their 
different oxidative states or chemical compounds in addition to the quantity. For 
example, there have been over fifty identified arsenic species in the literature all with 
varying toxicities.
95
 For compounds associated with human occupational exposure, 
arsenic speciation not only separates oxidative states As
3+
 and As
5+
 but can also 
separate organic arsenic compounds such MMA and DMA. Chromium is an excellent 
example of the differing toxicities of two oxidation states of the same element and the 
importance of speciation to distinguish between an essential element and a 
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carcinogen. The separation of crystalline silica from amorphous silica is an example of 
chemical composition speciation, in addition to further separation of crystalline silica 
by size. 
It should be noted, the value of speciation and the separation and quantification of 
each individual species depends entirely on maintaining the integrity of the species 
throughout any extraction, dilution and analytical measurement. 
1.6.2 Speciation using Hyphenated Separation Techniques 
Elemental speciation is most commonly achieved by the hyphenation of a 
chromatographic separation technique to an elemental detection system. Such 
separation techniques include liquid chromatography (LC), gas chromatography (GC) 
and capillary electrophoresis (CE).
223
 Detection techniques are generally spectroscopy 
based and include inductively coupled plasma mass spectrometry (ICP-MS), ICP atomic 
emission spectrometry (ICP-AES) and atomic absorption spectroscopy (AAS). The most 
utilised elemental speciation technique is the hyphenation of LC to ICP-MS. The first 
study to couple LC and ICP-MS was published in 1986.
224
 It is considered the best 
combination
225
 because of its simplicity, robustness and reliability.
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In this work a range of analytical techniques were utilised. LC-ICP-MS was used for 
arsenic and chromium, time of flight tandem mass spectrometry (TOF-MS/MS) for 
arsenic and single particle ICP-MS for silica analysis. The next section will describe 
these techniques and the reason for their selection in more detail. 
1.6.2.1 Liquid chromatography (LC) 
The hyphenation of LC to ICP-MS is very straightforward; the column outlet is simply 
connected to the nebuliser of the ICP by narrow bore tubing, whose length should be 
kept to a minimum. Figure 7 shows a schematic of the components of LC-ICP-MS. Due 
to the small particle size of the stationary phase, the mobile phase must be pumped 
through the column, with the sample being introduced to the eluent via an injection 
port prior to being carried to the column where the separation of species takes place. 
57 
Separation in LC depends on the interactions of the analyte with a stationary phase 
(contained in the chromatographic column) and the liquid mobile phase. The mobile 
phase can be either an isocratic or gradient elution. In an isocratic elution the 
concentration and/or constituents of the mobile phase are constant during the 
chromatographic run, as opposed to a change in mobile phase concentration and/or 
constituents associated with a gradient elution. The polarity, solubility, ionic charge 
and molecular mass of the elemental species of interest will determine the type of 
chromatographic column (stationary phase) and subsequently the type of mobile 
phase to be used.
223,226
  
Figure 7 Block diagram showing components of a traditional LC system 
coupled to a detector. 
1.6.2.2 Columns and Stationary Phases 
The chromatographic columns that are commonly used for elemental speciation have 
included ion exchange, reverse phase and size exclusion based stationary phases. 
Ion exchange columns normally contain stationary phases with charged organic 
functional groups, which are either anionic or cationic. Anionic and cationic columns 
can be categorised as either strong or weak. The functional group in a strong ion 
exchange column would mostly be quaternary amines and sulfonic acid for anion and 
cation exchange respectively. An example of weak ion exchange functional groups 
would be primary amines and organic acids, for anions and cations respectively.
225,227
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Therefore, ion exchange is suitable for the separation of ionic compounds based on 
charge, where species are retained on the stationary phase of the opposite charge. For 
example, the stationary phase of a cation exchange column has negatively charged 
sites which positively charged species interact with. The opposite is true for anion 
exchange, where negatively charged species interact with positively charged sites in 
the stationary phase. 
Commonly used reverse phase columns are known as C18 or C8 columns, because they 
are packed with silica bonded to 18-carbon or 8-carbon aliphatic chains. This non-polar 
stationary phase works with a polar mobile phase to partition the elemental species of 
interest. Strongly retained species have a greater affinity for the stationary phase than 
the mobile phase. Different mixtures of solvents or a gradient elution with an 
increasing organic solvent content are common mobile phases for reverse phase 
chromatography to elute strongly retained species. Mobile phase pH can also influence 
separation. Reverse phase is the most commonly used column for traditional LC
225
 
mostly because it has a stable stationary phase, showing good resolution and high 
reproducibility. Unfortunately, this technique is limited because most organic solvents 
are not compatible with ICP-MS, reducing the scope and number of applications 
suitable for LC-ICP-MS.
223,225
 
Size exclusion chromatography columns work on the premise of separation by 
hydrodynamic radius size. The stationary phase consists of a gel with pores of a specific 
dimension; species that are too large for these pores are not retained and elute from 
the column first. Smaller species that are able to interact with the pores of the 
stationary phase are retained. The mobile phases used in size exclusion 
chromatography do not play a critical role in the interactions of the stationary phase 
and the species of interest like the techniques mentioned above, as separation is 
effected by physical interactions between the species and the stationary phase. 
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1.6.3 Elemental Detection 
1.6.3.1 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
Inductively coupled plasma - mass spectrometry (ICP-MS) is the analytical technique 
used for the work reported in this study for the measurement of arsenic, chromium 
and silicon. ICP-MS is ideal due to its ability to: analyse liquid samples, low detection 
limits, capability of dealing with argon and polyatomic interferences and its selective 
range of elemental and isotopic choice. 
ICP-MS can measure trace metals, metalloids and inorganic elements in liquid samples. 
The technique is relatively new compared to other atomic spectrometry 
instrumentation but has become the method of choice for elemental analysis as a 
result of it being a fast and accurate technique that can analyse, detect and measure 
either single or multi-elements in a single sample either semi-quantitatively or fully-
quantitatively at low detection limits (ppt range). It does this by using an argon plasma 
to ionise atoms of the element to be detected. A quadrupole mass spectrometer then 
detects the ions by their mass to charge ratio (m/z). 
Since the first publication introducing ICP-MS in 1980
228
 and the first available 
commercial ICP-MS in 1983
229
 this analytical technique, used to measure trace multi-
elements, has greatly developed by: increasing sensitivity, further reducing detection 
limits and eliminating argon polyatomic interferences. As such, ICP-MS is widely and 
routinely used in a variety of different scientific fields such as clinical, industrial, 
environmental, geological and pharmaceutical. The dexterity of ICP-MS allows it to 
analyse practically all the elements in the periodic table with the exception of those 
located at the top right hand side of the periodic table (helium, carbon, nitrogen, 
oxygen, fluorine and neon) in addition to hydrogen and argon. 
As demonstrated in Figure 8, an ICP-MS is comprised of four components: a sample 
introduction system, plasma generation, sampling interface and ion optics and the 
mass analyser/detector.  
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An argon plasma is equivalent to a very hot flame operating at temperatures up to 
7000
o
C and is generated by applying a radio frequency (RF) to a stream of argon gas. 
The stream of argon passes through a quartz torch that at one end is placed within a 
copper load coil. When the RF power is applied this creates a current that oscillates 
creating a magnetic field. An ignition spark is then applied to the argon gas, which 
strips electrons from argon atoms, which become trapped in the magnetic field. As 
argon gas continues to flow through the torch these electrons collide with more and 
more argon atoms. A schematic diagram of a plasma is shown in Figure 9. This 
continuing process of collisions enables a self-sustaining plasma to be created. This is 
called inductive coupling hence the name inductively coupled plasma.
230
   
Figure 8  A schematic diagram of a quadrupole ICP-MS with 
collision/reaction cell 
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Sample uptake is controlled by the peristaltic pump via a sample probe to the 
nebuliser and spray chamber. Within the nebuliser, the sample is met with a stream of 
argon gas, which causes the sample to aerosolise. Only 1 – 4 % of the sample creates 
this aerosol
231
 (the rest going to waste). The argon then carries the aerosolised sample 
into the torch and the argon plasma where it is vaporised, atomised and ionised, to 
give positively charged ions. 
The mass analyser section of the ICP-MS is kept under vacuum and to separate the 
high temperatures and pressure difference of the plasma from the vacuum of the MS 
an interface consisting of a sample and skimmer cone (of either nickel or platinum) 
plus a series of ion lenses is required. This interface allows only the positively charged 
ions to move into the MS (any negatively charged ions including electrons are 
discarded).
232
 The most common MS in an ICP is known as a quadrupole MS as it 
contains four parallel rods (as demonstrated in Figure 10) that hold opposing positive 
and negative charges for the ions to pass through.  
Figure 9  A schematic diagram of a plasma (adapted with permission 
from Nelms, 2005)
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Figure 10  Quadrupole rods within the mass analyser section of an ICP-MS 
The RF and direct current (DC) voltage charge on the rods is specific to the element of 
interest being detected, meaning only elements of a single m/z find a stable trajectory 
to the detector and all other ions of a different m/z are defocused within the rods and 
lost.
232
 Multi element analysis is achieved by changing the charge on the rods to favour 
each selected m/z to allow sequential measurement of the different masses.
232
 
One of the limitations of ICP-MS is spectral interferences. Whereas isobaric 
interferences can occur from isotopic overlap between the elements, polyatomic 
interferences occur when ions either from the plasma and/or other atoms in the 
sample matrix interfere with the ions of the element of interest, meaning the MS 
cannot differentiate between them (as shown in Table 11). To eliminate isobaric 
interferences, it may be possible to select an alternative elemental isotope that does 
not have the same influence of interference, for example 
111
Cd instead of 
114
Cd and 
118
Sn instead of 
114
Sn. On the other hand, if the removal of the interfering ions from 
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the sample matrix is not possible, polyatomic interferences can only be reduced by 
collision or reaction cell technology. The use of collision or reaction cells to eliminate 
iŶteƌfeƌeŶĐes is ĐoŵŵoŶplaĐe iŶ todaǇ͛s ICP-MS instrumentation and applications. The 
collision/reaction cell is positioned before the quadrupole of the MS. An inert gas is 
introduced (for example helium) which will either react with the interfering ion (and 
not the ions of interest) or collide with the polyatomic ions subsequently breaking 
bonds to produce single ion masses the quadrupole rods can discard, reducing the 
interference. 
Table 11  Examples of isobaric and polyatomic interferences of ions seen in 
ICP-MS applications. 
Element & Mass of 
Interest 
Isobaric Interferences 
Polyatomic 
Interferences 
28
Si - 
1
H
27
Al, 
14
N2,  
12
C
16
O
52
Cr - 
40
Ar
12
C, 
36
Ar
16
O 
75
As - 
40
Ar
35
Cl 
78
Se 
78
Kr 
14
N
64
Zn 
80
Se 
80
Kr 
40
Ar2, 
40
Ar
40
Ca
Table 11 shows some of the spectral interferences of ICP-MS applications and the 
polyatomic interferences of silicon, chromium and arsenic which are relevant to the 
ICP-MS applications discussed in this thesis. 
1.6.3.2 Single Particle ICP-MS 
Single particle ICP-MS (spICP-MS) analysis is a relatively new addition to the scope of 
ICP-MS. The first publication to test the theory of ICP-MS to analyse single particles 
(gold colloid) was by Degueldre et al in 2003,
233
 however it was several years until 
interest in spICP-MS expanded.  
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Natural and engineered particles are added to food, packaging, hygiene products and 
clothing in addition to widespread industrial uses.
234
 Therefore, the detection and 
characterisation of single particles or nanoparticles in both food, water and biological 
samples is considered essential in understanding the potential risks of exposure to 
both elemental engineered nanoparticles and single particle particulate
235
 such as 
respirable crystalline silica. The introduction of spICP-MS offers the potential to 
measure individual particles of a known elemental status. 
As previously stated in section 1.6.3.1, the liquid sample to be analysed by the ICP-MS 
is aerosolised within the spray chamber before being vaporised, atomised and ionised 
in the plasma. During regular ICP-MS analysis the element of interest within a sample 
is homogenously distributed meaning that the ions produced in the plasma and 
travelling to the detector, do so at a constant rate producing a steady signal. However, 
with single particle analysis, the element of interest within the sample is not 
homogenously distributed and, as each single particle passes into the plasma, it is 
desolvated and ionised creating a cloud or plume of ions (rather than a continuous 
stream) which is measured as a single pulse.  
To perform spICP-MS, the ICP-MS data are collected in time resolved analysis (TRA) 
mode, with a low flow rate and a much reduced data acquisition time (dwell time) of 3 
ms. Regular ICP-MS analysis at the HSL would use a dwell of 100 ms.   Figure 11 
demonstrates the difference in the detection of ions for a 1 µg/L ionic gold standard 
over an acquisition time of 60 s with a dwell time of 100 ms compared to that with a 
dwell time of 3 ms. 
Assuming the quantity of suspended particles in the sample is not too concentrated; 
this setup allows the ICP-MS to detect each individual pulse, which represents a single 
particle as shown in Figure 12. 
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Figure 11 Time scan of a 1 µg/L ionic gold standard over a 60 s acquisition 
time, demonstrating the difference in the signal obtained by the detection of 
gold ions when the dwell time is 100 ms compared to 3 ms using spICP-MS. 
Figure 12 Time scan of a 25 ng/L 30 nm gold particle certified reference 
material using spICP-MS. 
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 Therefore, the assumption is that the frequency of pulses is directly linked to the 
number concentration of particles, whilst the intensity of the pulse is proportional to 
the mass of the element. From the intensity of the pulse, a particle mass and diameter 
can be calculated from an ionic calibration curve and a known particle size reference 
material assuming the sample flow rate, nebulisation efficiency, density of the particle 
and the sensitivity of the ICP-MS for the element of interest in counts per second (cps) 
per µg/L are already known. The limit of detection for spICP-MS is related to the size of 
the particle, as the detection is based on the single particle generating a large enough 
plume of ions to create a pulse detectable from the continuous background baseline, 
hence why peak height relates to particle size. 
spICP-MS is a relatively new concept and although the ICP-MS hardware could 
measure single particles the software was not capable of calculating particle number 
concentration or particle size from the data it generated. Initial work on spICP-MS 
demanded offline data processing of numerous mathematical equations; the details to 
these approaches can be found in the literature.
233,235-239
 However, in 2015 many of 
the ICP-MS manufacturers launched single particle software as an update to existing 
software. Chapter 6 of this thesis discusses spICP-MS and its potential in the 
development of a biological monitoring method for RCS in EBC samples. The 
fundamentals of spICP-MS will be explained further in the discussion.  
1.6.3.3 Tandem Mass Spectrometry – MS/MS 
Tandem mass spectrometry, known as MS/MS, involves a multiple step of mass 
selection, with some form of mass fragmentation. The initial stage (MS1) of MS/MS is 
where an ion of interest is selected and measured according to its m/z. The second 
stage allows the selected ion to be subsequently broken down to its fragment or 
product ions by collision induced dissociation followed by detection, separation and 
measurement by the second MS of these fragment or product ions according to their 
m/z (MS2). This production of fragment ions helps to provide structural and molecular 
information to aid identification of a polyatomic compound. The spectrum provided by 
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MS2 would only consist of product ions from the initial ion of choice, with the 
elimination of any background or matrix components. 
Collision induced dissociation is a similar concept to collision cell technology found in 
ICP-MS where the ion of interest is subjected to a neutral gas (argon, helium or 
nitrogen) causing collisions which break down the chemical bonds of the ion revealing 
the polǇatoŵiĐ ĐoŵpouŶd͛s fƌagŵeŶt ioŶs. 
1.6.3.4 Time of Flight (TOF) MS/MS 
Time of flight (TOF) MS detects ions according to their m/z by means of their flight 
times.
240
 The mass analyser region unlike in ICP-M“ ;ǁheƌe Ƌuadƌupole ƌod͛s ǀoltages 
change) operates under the same conditions. All the ions are subjected to an electric 
field giving the same kinetic energy to achieve a mass-dependent velocity to the 
detector.
240,241
 Lighter m/z ions will achieve a higher velocity than heavier ions,
240
 
resulting in measurements of the intensity and flight time producing a mass spectrum 
representative of all the ions present in the sample.
241
  
A common ionisation technique for TOF is electrospray ionisation (ESI). The sample 
containing the element of interest is injected with a mobile phase, consisting usually of 
an organic-aqueous solvent (such as formic acid with methanol and water or 
acetonitrile and water)
242
 through a needle to create an aerosol. The needle is 
attached to a high voltage power supply, where the element of interest is ionised by 
gaining a proton (known as protonation) from the solvent it was injected with as it 
leaves the tip of the needle. This technique produces ions of a positive charge and 
mass [M + 1]
+
. It is also possible to achieve negative ionisation [M – 1]- with the use of 
ammonia solution as the mobile phase enabling deprotonation of the sample during 
ionisation. 
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1.6.4 Chromatographic Column and LC System used in this Study. 
1.6.4.1 DionexTM  IonPacTM AG7 Anion Exchange Column 
The Dionex IonPAC AG7 (Thermo Scientific, Hemel Hempstead, UK) is a 4 mm x 50 mm, 
10 µm i.d anion exchange column ideally suited to the separation of polyvalent anions; 
polyvalent anions and chelating agents; and complex sample matrices. It is also 
marketed as a column suitable for the determination of cyanide, sulphide, iodide, 
hexavalent chromium and arsenic species. The IonPAC AG7 is suitable for eluents of pH 
0 – 14 with a maximum flow rate of 3.0 mL/min. It is marketed as a speciality packed 
column as it contains both anionic and cationic ion-exchange capabilities. The 
patented column packing consists of three regions: 
 Inert, nonporous, chemically and mechanically stable core A core surface completely covered by a sulfonated region An outer layer of permanently attached submicron anion exchange
MircoBeads
TM
 with an alkyl quaternary ammonium functional group.
1.6.4.2 Micro-flow Liquid Chromatography (µLC) System 
The oneFAST system was designed as a high throughput sample introduction system 
for ICP-MS or ICP-AES by Elemental Scientific (Warrington, UK). However, its 
automated sample injection valve designed to speed up sample uptake and rinse times 
was reminiscent of the rheodyne valve found on traditional HPLC systems, giving it the 
potential to be adapted as an LC system for speciation. For busy commercial 
laboratories, due to its size and the considerable price difference, the oneFAST system 
has some advantage over traditional LC systems. The oneFAST system comprises of a 
vacuum pump and small switching valve unit (Figure 13) which can easily fit between 
the auto-sampler and ICP-MS spray chamber (Figure 13) to enable coupling to the 
anion exchange column. 
Figure 13 The oneFAST system comprising of a vacuum pump and switching 
valve unit (left) kindly supplied by Elemental Scientific. The oneFAST 
hyphenated to and, situated alongside the ICP-MS (right). 
The switching valve of the oneFAST system consists of 6 ports allowing connections 
for: sample introduction; anion exchange column; mobile phase; waste and the sample 
loop (taking up two connections of the switching valve). A traditional LC system 
incorporates a LC pump to control the flow of mobile phase onto the column; the 
oneFAST system lacks this ability and so a constant flow rate of both mobile phase and 
injection of sample onto the column is controlled by the peristaltic-pump of the ICP-
MS. 
The default position of the switching valves is SAMPLE LOAD; in this position, mobile 
phase is constantly taken up and injected onto the column and into the ICP-MS. The 
auto-sampler probe goes to the sample in the auto-sampler rack to be analysed and 
the sample is loaded into the sample loop by the vacuum pump, with any excess 
sample going to waste, as shown in Figure 14. When the sample loop is full, the 
switching valve shifts to SAMPLE INJECTION. As shown in Figure 14, in SAMPLE 
INJECTION the sample already loaded in the sample loop is injected onto the column 
and ICP-MS, followed by the mobile phase. When the length of time allocated to inject 
the sample onto the column has expired, the switching valve reverts to SAMPLE LOAD, 
any remaining sample still in the sample loop goes to waste and the mobile phase 
continues to be pumped onto the column as before. 
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Figure 14  Switching valve positions of the oneFAST system, demonstrating 
uptake of mobile phase and sample 
The advantages of the oneFAST system are that it works at low pressure, it uses 
smaller chromatographic columns and the analysis uses less mobile phase hence 
producing less waste. There are two limitations to the oneFAST system. Firstly, as the 
peristaltic-pump of the ICP-MS is controlling the flow rate onto the column, enough 
pressure cannot be generated on longer length chromatographic columns to pump the 
sample and mobile phase through the column; in addition the pressure cannot be 
monitored like a traditional LC system. The second limitation is the oneFAST system is 
only capable of an isocratic mobile phase or a step gradient mobile phase. A linear 
gradient mobile phase is not possible, however Elemental Scientific have since rectified 
this issue with the development of numerous improved speciation specific products. In 
the system used here, the use of a gradient mobile phase was achieved by injecting a 
different mobile phase onto the column in the same way the sample was injected.  
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1.7 Aims & Objectives 
This work was funded by the Health & Safety Executive and the Health & Safety 
EǆeĐutiǀe͛s Health & “afetǇ LaďoƌatoƌǇ iŶ aŶ effoƌt to fuƌtheƌ ďiologiĐal ŵoŶitoƌiŶg 
research of elements which are of carcinogenic, occupational concern: inorganic 
arsenic, hexavalent chromium and respirable crystalline silica. Current biological 
monitoring methods are either no longer deemed fit for purpose (arsenic), not ideal 
(chromium) or are not available (silica).  
The aims of this PhD project were: 
1. To develop new analytical speciation methods for arsenic, chromium and silica, to 
assess occupational exposure.  
2. To evaluate exhaled breath condensate, for its potential as a new biological matrix 
for speciation analysis of chromium and, single particle analysis of respirable 
crystalline silica.  
To achieve these aims, the following objectives were set: 
 To develop an arsenic speciation method that can be employed for routine analysis 
and to establish an unexposed background reference range for each of the five 
species of arsenic to aid the interpretation of biological monitoring results.  To develop a chromium speciation method to simultaneously detect and separate 
both hexavalent and trivalent chromium during a single sample injection of the 
same analysis.  To investigate exhaled breath condensate as a potential biological matrix for the 
exposure assessment of hexavalent chromium and respirable crystalline silica.   To develop a methodology using spICP-MS to detect and separate respirable 
crystalline silica in exhaled breath condensate samples, in an effort to quantify 
particle number and particle size.  
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This study provides background levels for five arsenic species in urine,
based on urinary data obtained from 95 nonoccupationally exposed
volunteers based in the UK. Using a novel, sensitive, robust and reliable
speciation methodology, five species of arsenic (arsenobetaine [AB],
arsenite [As31], arsenate [As51], monomethylarsonic acid [MMA51]
and dimethylarsinic acid [DMA51]) were determined in urine samples
collected from 95 adults. The analytical instrumentation used to analyze
the urine samples was a hyphenated micro liquid chromatography
(mLC) system coupled to an inductively coupled plasma mass spectrom-
etry (ICP-MS). Separation was achieved using an anion exchange
micro-sized column. The results presented give the 95th percentile of
concentrations, both uncorrected for creatinine (mg/L) and creatinine
corrected (mmol/mol) in urine for the 95 volunteers. Statistical analysis
was performed on the dataset using a Bayesian model to determine
and quantify effects of gender, smoking and diet. The statistical results
show that the consumption of fish, shellfish and red wine has a signifi-
cant elevating effect on AB, DMA and MMA urinary concentrations;
however, no significant effect was observed for smoking. The regres-
sion model results indicate that creatinine correction was effective for
arsenic species As31, MMA, DMA and AB. The background levels
established here can be used as reference values to help aid interpret-
ation of arsenic speciation results and better assess exposure.
Introduction
The International Agency for Research on Cancer (IARC) has
classified inorganic arsenic as a Group 1 agent, defined as car-
cinogenic to humans (1). Thus, it is imperative that exposure be
adequately controlled. Biological monitoring assesses whether a
person has been exposed to a substance or its metabolites, as it
encompasses all routes of potential exposure. Inorganic arsenic
exists as arsenite (trivalent, As3þ) and arsenate (pentavalent,
As5þ). When humans are exposed to inorganic arsenic, the
arsenic is reduced and methylated in the body to produce a
range of organic arsenic species, including dimethylarsinic acid
(DMA5þ) and monomethylarsonic acid (MMA5þ) (2). Pentavalent
methylated species are considered relatively nontoxic, since it is
thought that they cannot bind with molecules in the body (3). In
the UK, the most common route of exposure to arsenic is from
dietary sources. Dietary species of arsenic known as tetra alkylar-
sonium compounds include arsenobetaine (AB), arsenocholine
and trimethylarsine oxide, and are thought to be nontoxic (4).
The dietary sources of these species of arsenic include seafood,
shellfish, poultry and rice (4–8), and following ingestion, they are
eliminated in the urine unchanged (4).
Urine is the main excretory pathway for elimination of arsenic
from the body, in the general proportion 10–30% of inorganic
arsenic, 10–20% of MMA5þ and 60–80% of DMA5þ are eliminated
primarily via this route after inorganic exposure (2). The ease and
noninvasive sample collection makes it the biological sample of
choice in most studies, although determination of arsenic levels in
blood (9, 10) and serum (11) has been reported.
Currently, there are no unexposed background reference
values or exposed UK guidance values for any individual arsenic
species in urine. The US biological exposure index (BEI) (12)
and the German biological tolerance value (BAT) (13) are 35 and
50 mg/L, respectively, which are based on the summation of in-
organic arsenic and its metabolites, but not including AB. This is
a controversial, less well-understood area, because there seems
to be increasing numbers of foodstuffs containing other arsenic
compounds, e.g., DMA (6, 7), and therefore, exposure to arsenic
compounds either from environmental or from occupational
sources could be overestimated. The BEI and BAT approach of the
sum of the species less AB is an attempt to correct for dietary ex-
posure, but does not account for dietary DMA, MMA and arsenosu-
gars. To better assess environmental and occupational exposure,
arsenic speciation must be undertaken as a routine assay.
There are several population studies from around the world
that have reported urinary arsenic concentrations in unexposed
individuals. The two most comprehensive are the National Health
and Nutrition Examination Survey (NHANES) (14) in the USA,
where 2557 participants’ urine samples were measured for seven
species of arsenic, and the Human Biomonitoring of Environmental
Chemicals in Canada (HBECC) (15), where ≏6400 participants’
urine samples were measured for six species of arsenic. In addition,
similar national surveys have been conducted in France (n¼ 2102
participants) (16) and Korea (n¼ 5087 participants) (17).
However, both these studies used a total inorganic arsenic and the
metabolites minus AB technique to measure arsenic (16, 17). There
is also urinary arsenic speciation data for unexposed individuals in
smaller scale clinical studies from around the world such as
Germany (18), UK (19, 20), Italy (21) and Spain (22).
It is generally accepted that urinary arsenic speciation provides
the most coherent and detailed picture of exposure to arsenic
species and compounds. However, there is still a lack of established
reference values to usewhen trying to assess exposure to individual
species. By improving and modifying a novel micro liquid chroma-
tography (mLC)–inductively coupled plasma mass spectrometry
(ICP-MS) speciation method, previously developed at the Health
and Safety Laboratory (20) to have greater sensitivity and lower
limits of quantification (LOQs), this paper aims to provide reference
background values of five arsenic species in the urine of unexposed
individuals from a cohort of UK samples. Information on diet and
lifestyle was collected by questionnaire, as exposure to arsenic can
occur through diet and environmental sources. Such data will
provide a valuable contribution to the knowledge in this area.
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Experimental
Instrumentation
Separation was achieved using a hyphenated mLC system with an
ICP-MS (XSERIES 2, Thermo Fisher Scientific, Hemel Hempstead,
UK). The separation of arsenic species As3þ, As5þ, MMA5þ,
DMA5þ and AB was achieved using a 5-cm anion exchange guard
column (Dionex AG7 4 mm � 50 mm i.d., Thermo Fisher
Scientific). The micro-flow delivery of sample and mobile phase
was accomplished using an ESI OneFAST system (Elemental
Scientific, Warrington, UK), which consists of a six port switch-
ing value and a 1-mL sample loop. The delivery of mobile phase
and sample onto the column was controlled by the ICP-MS peri-
staltic pump at a constant rate of 0.2 mL/min. The ICP-MS was
operated in a collision cell mode using 7% hydrogen in helium
(≏3.5 mL/min). The ICP-MS conditions were optimized using a
10-mg/L tuning solution containing arsenic, cobalt, indium and
uranium [made in 1% (v/v) nitric acid from 1000 mg/L stock
standards (ICP-MS standards, BDH, Poole, UK)].
Reagents
Arsenic speciation compounds sodium arsenite (NaAsO2),
sodium arsenate (Na2HAsO4.7H2O) and sodium cacodylate
(DMA; Na(CH3)2AsO2.3H2O) were all purchased from Fisher
Scientific (Loughborough, UK). Disodium methyl arsenate (99%
MMA; CH3AsO(OH)2) was purchased from ChemService (West
Chester, PA, USA). AB (C5H11AsO2) was purchased from
Sigma-Aldrich (Dorset, UK). Single standard stock solutions of
1000 mg/L were prepared in 1% (v/v) nitric acid (Romil,
Cambridge, UK) of As3þ, As5þ, MMA, DMA and AB in plastic volu-
metrics. All stock solutions were stored at 48C. The separation of
five arsenic species used a mobile phase of ammonium carbon-
ate purchased from VWR (Leicestershire, UK). Two mobile
phases were prepared daily by dissolving ammonium carbonate
in ultrapure deionized water (18.2 MVhm cm) from a Millipore
system (Merck Millipore, Billerica, MA, USA) to make 2 mM
(mobile Phase A) and 70 mM (mobile Phase B) solutions.
A 1-mg/L mixed species solution of all the five species was
prepared in 1% (v/v) nitric acid from the individual 1000-mg/L
single standard stock solutions on a weekly basis. Using the
1-mg/L mixed species solution standards of 0.5, 1, 2, 5, 10 and
20 mg/L were prepared daily in 2 mM of ammonium carbonate
(mobile Phase A).
Study group and sample collection
The volunteers in this study (n ¼ 95) consisted of 53 males and
42 females who were not occupationally exposed to arsenic. All
volunteers were over the age of 18 years, with the mean age of
people in this study 41.1 years. Individuals volunteered in re-
sponse to an email outlining the study sent to everyone at the
Health and Safety Laboratory (HSL), UK, and the Biomedical
Research Centre, Sheffield Hallam University, Sheffield, UK.
Participating volunteers were provided with informed consent,
as granted by the NRES Committee East Midlands–Leicester,
REC number 12/EM/0314. Volunteer information was collected
via a questionnaire, which was returned by post with the urine
sample. The information collected included: gender, age,
smoking habits and diet including vitamin and supplement use
in the previous 7 days. All urine samples were collected in 25 mL
urine collection bottles (Sterilin Ltd., Newport, UK) and sent to
the HSL by first class post. All urine samples had creatinine
content analyzed upon arrival and were then kept frozen at
2808C until analysis.
Sample preparation and analysis
Urine samples were thawed and mixed on a roller mixer before
analysis. Samples were diluted 1 in 15 with 2 mM ammonium
carbonate solution. All samples were analyzed in duplicate.
The certified reference materials (CRMs) used were Clinchek
urine control for arsenic species Level 1 and 2 (Lot 923) (Recipe,
Munich, Germany). In addition, a blank urine and spiked urine
sample (blank urine with all the five species of arsenic added at a
concentration of 10 mg/L) was analyzed at the beginning and the
end of each series of analyses and after every 10 samples. External
quality assurance for four of the arsenic species (not AB) was
undertaken in November 2012 by participation in the G-EQAS
(Friedrich-Alexander-University, Erlangen-Nuremberg, Germany)
trace element quality schemes.
Urinary creatinine concentrations were determined on all urine
samples by the Jaffe alkaline picrate method (23) on a Cobas Mira
Plus (Horiba Diagnostics, Northampton, UK). Creatinine (a break-
down product of creatine phosphate in muscle, and is usually pro-
duced at a fairly constant rate by the body) allows a urine sample
to be normalized for dilution or concentration. In determining the
creatinine levels using mathematical modeling, it was possible to
investigate the effectiveness of this correction for each arsenic
species.
Statistical analysis
The relationship was modeled between urinary concentration
and several factors (including gender, smoking and dietary
habits) using a multiple regression model. The Bayesian regres-
sion model used in this study had the form
1n(Asi)¼mþb11n(creatininei)þb2I ðsmokingiÞþb3I ðgenderiÞ
þb4I ðsupplementsiÞþb5I ðfishiÞþb6I ðshellfishiÞ
þb
7
I ðseaweediÞþb8I ðriceiÞþb9I ðmushroomsiÞ
þb
10I ðredwineiÞb11I ðrealaleiÞþb12I ðpoultryiÞ
þb
13
I ðricemilkiÞb14I ðbraniÞþ1i
where Asi is the urinary concentration of arsenic on the ith indi-
vidual; m, the mean concentration (on the log scale) of a non-
smoking female who has not taken dietary substances
represented in the model; creatininei, the creatinine concentra-
tion with associated effect b1; I(smokeri) ¼ 0, if sample was from
a nonsmoker and 1 if smoker (b2 represents the smoking adjust-
ment to the mean concentration); I(genderi) ¼ 0, if the urine
sample was from a female and 1, if male (b3 represents the male
adjustment). Indicator variables and adjustments for the intake of
supplements, fish, shellfish, seaweed, rice, mushrooms, red wine,
real ale, poultry, rice milk and bran are similarly represented. 1i
are normally distributed residual errors with mean zero and stand-
ard deviation s.
One of the difficulties in analyzing urinary data is that mea-
surements are often below the LOQ (referred to as nondetects).
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However, it is known that these measurements lie between zero
and the LOQ, i.e., they are left censored. The data were modeled
using Markov Chain Monte Carlo (MCMC) methods in WinBUGs
(24) within a Bayesian framework, treating the nondetects as
left-censored.
Results
Analytical method
The method described in this study is a sensitive, robust and re-
producible method for the routine determination of five species
of arsenic in a urine sample. The chromatograms in Figure 1
show that this optimized speciation method achieves full separ-
ation in ,6 min. The calibration range was 0–20 mg/L for all the
five species of arsenic. The limit of detection (LOD) was calcu-
lated as three times the standard deviation of the blank; this was
between 0.003 and 0.051 mg/L for all the five species of arsenic.
The LOQ for undiluted urine was calculated as 15 times the
mean background equivalent concentration (BEC) for all the five
species of arsenic. The BEC, LOD and LOQ for each arsenic
species are summarized in Table I. Of the 95 volunteer urine
samples measured, no level was below the LOQ for DMA and
only 1% of AB, 2% of MMA and 12% of As3þ were less than the
LOQ. However, 63% of the As5þ values were less than the LOQ of
0.04 mg/L
Analytical validation
The results for the in-house spiked urine quality control sample
shown in Table II gave an average recovery of 93% for As5þ,
MMA, DMA and AB and 90% for As3þ in the daily spiked urine
samples (n ¼ 29). The external quality assurance and CRMs ana-
lyzed are presented in Table II. Clinchek Levels 1 and 2 are certi-
fied for arsenic species; analyses gave good results for arsenic
species As5þ, MMA, DMA and AB, which were all within target
range, whereas As3þ did not show good agreement and gave a
result below the target range. However, the method is continual-
ly validated through participation in the German External
Quality Assessment Scheme (GEQAS); the results for the 50th
GEQAS in November 2012 being shown in Table II. The results
were within the target criteria for all the five species of arsenic.
This may suggest possible instability of As3þ in the Clinchek
CRMs.
Figure 1. Chromatograms showing full separation of five arsenic species in ,6 min using an ESI OneFAST system coupled to a 5-cm Dionex AG7 anion exchange column, with
mobile phases 2 and 70 mM of ammonium carbonate solution. (A) Overlay of the individual standard calibration chromatograms of 0–20 mg/L calibration. (B) CRM Clinchek 1 for
arsenic species in urine. (C) A urine sample of an unexposed individual adult.
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Study results
Of the 95 volunteers who participated, 82 were nonsmokers (33
females and 49 males) and 13 were smokers (9 females and 4
males). The urine results are summarized in Table III; the
median and the 95th percentile concentrations are expressed
both uncorrected for creatinine (mg/L) and creatinine corrected
(mmol/mol) in urine to adjust for urinary dilution. Creatinine
concentration ranged between 0.89 and 26.45 mmol/L. Nine
individuals had a low (below 3 mmol/L) or high (above
30 mmol/L) creatinine; however, creatinine concentration was
not an exclusion criterion (the reason being that excluding
these individuals would exclude a much higher proportion of
females than males). As 63% of As5þ measurements were below
the LOQ, the median As5þ concentration could not be quanti-
fied. The 95th percentiles for As3þ and As5þ were 0.54 (0.99
mmol/mol creatinine) and 0.23 mg/L (0.35 mmol/mol creatin-
ine), respectively. MMA, DMA and AB gave 95th percentiles of
2.37 (3.08 mmol/mol creatinine), 12.68 (16.08 mmol/mol cre-
atinine) and 126.7 mg/L (174.7 mmol/mol creatinine), respect-
ively. The median and 95th percentile concentrations for male
and female urinary arsenic species are also presented in
Table III. Females were observed to have lower median and 95th
percentiles of uncorrected for creatinine (mg/L) concentrations
for arsenic species As3þ, As5þ and MMA. However, for the
creatinine-corrected data, females show a lower median concen-
tration than males, but a higher 95th percentile for As3þ.
Statistical results
General statistical analysis using Prism Graphpad version 4 for
Windows was performed, comparing each arsenic species in re-
lation to gender and smoking habits. Using a two-tailed Mann–
Whitney nonparametric statistical test, there was no significant
difference between smokers and nonsmokers for inorganic
arsenic. Furthermore, no significant difference was found
between females and males for As3þ, As5þ, MMA or AB; however,
a statistically significant higher value for DMA was found in
females in the creatinine-corrected values only. The most likely
reason for this could be that women tend to have lower creatin-
ine levels than men (23), resulting in a higher corrected DMA
value for women than for men.
The Bayesian regression model was fitted separately for As3þ,
MMA, DMA and AB; however, due to the large proportion (63%)
of As5þ measurements below the LOQ, the analysis was not
carried out for As5þ. When the model was fitted to the data, a
creatinine coefficient of one was highly plausible for As3þ, MMA,
DMA and AB (i.e., the credible interval for the parameter b1 for
each of these species included unity). This indicated that a cre-
atinine correction may be effective for these species. The model
was subsequently refitted to the data with b1 set to unity, which
corresponds to fitting a regression model to creatinine-
corrected concentrations. The model considered all the vari-
ables including gender, smoking and dietary factors. Variables
that were considered to be nonsignificant at the 5% level were
subsequently removed from the model.
Table I
The background equivalent concentration (calibration curve intercept), LOD (signal-to-background
noise) and limit of quantification for all the five species of arsenic in mg/L, in addition to the
number and percentage of samples less than the LOQ
Arsenic
species
BEC
(mg/L)
LOD 3� SD of the
blank (mg/L)
LOQ
(mg/L)
No. of samples
,LOQ
%
,LOQ
As3þ 0.001 0.004 0.02 11 12
As5þ 0.003 0.051 0.04 60 63
MMA 0.002 0.030 0.04 2 2
DMA 0.003 0.003 0.04 0 0
AB 0.002 0.003 0.03 1 1
Table III
Statistical summary of median and 95th percentile concentrations for all the five species of arsenic in both mg/L and mmol/mol creatinine, for both total urine samples and female and male urine samples
As3þ As5þ MMA DMA AB
mg/L mmol/mol creatinine mg/L mmol/mol creatinine mg/L mmol/mol creatinine mg/L mmol/mol creatinine mg/L mmol/mol creatinine
Total: n ¼ 95
Median 0.11 0.19 ,LOQ ,LOQ 0.56 0.90 2.44 4.30 3.87 10.0
95th Percentile 0.54 0.99 0.23 0.35 2.37 3.08 12.68 16.08 126.7 174.7
Females: n ¼ 42
Median 0.07 0.15 ,LOQ ,LOQ 0.48 0.95 2.43 5.35 6.77 19.4
95th percentile 0.44 1.05 0.15 0.38 2.10 3.42 12.68 26.7 333.9 672.8
Male: n ¼ 53
Median 0.15 0.22 ,LOQ ,LOQ 0.57 0.90 2.44 4.10 3.42 6.10
95th percentile 0.6 0.97 0.31 0.97 2.67 2.69 12.59 11.1 101.5 129.4
Table II
Results obtained for five species of arsenic in urinary CRM and an external quality assurance scheme
Arsenic species In-house spiked urine (10 mg/L)
% recovery (n ¼ 29)
Clinchek Level 1–923
(Cert As species mg/L)
Clinchek Level 2–923
(Cert As species mg/L)
G-EQAS—Round
50 (mg/L)
50–2A 50–2B
Target Result Target Result Target Result Target Results
As3þ 9.0+ 0.8 (90%) 1.44–3.84 0.5+ 0.1 7.05–11.8 2.9+ 0.6 1.7–4.1 2.2 4.9–9.1 8.1
As5þ 9.3+ 0.9 (93%) 2.10–4.90 4.2+ 0.3 18.9–31.5 30.5+ 1.8 3.8–8.6 6.0 13.5–24.3 21.8
MMA 9.3+ 1.0 (93%) 1.50–3.50 2.8+ 0.5 5.03–8.38 7.2+ 0.5 1.0–2.8 1.7 6.8–11.6 10.9
DMA 9.3+ 1.1 (93%) 5.88–13.7 9.5+ 0.5 32.6–54.3 43.6+ 1.8 8.3–14.9 11.6 64.8–96 95.9
AB 9.3+ 1.8 (93%) 12.6–21.0 15.4+ 1.1 23.0–34.6 27.7+ 1.2 – – – –
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The results of the Bayesian model showed that there was no
significant dietary difference between females and males.
However, it did show a statistically significant difference
between gender for arsenic species AB and DMA only. The mean
urinary AB and DMA values for females were ≏77 and 28%
higher than males. In agreement with the nonparametric statis-
tical test, the Bayesian model found no significant difference
between smokers and nonsmokers; however, there were only 13
smokers (14% of the study group) in the dataset. As expected,
the consumption of fish resulted in increased urinary AB and
DMA concentrations. Volunteers who had eaten fish had urinary
DMA concentrations twice as high as that in those who had not
eaten fish and AB concentrations 10 times higher than that in
those who had not eaten fish. The Bayesian model also showed
that the mean concentration for urinary MMA was twice as high
for those who had consumed fish than that in those who had
not. However, the consumption of shellfish did not have an
effect on urinary MMA concentrations and showed only a 27%
increase in urinary DMA concentrations and a 2-fold increase in
urinary AB concentrations. Red wine also had a statistically sig-
nificant effect on urinary AB; the consumption of red wine was
found to increase AB concentrations by 79% even after adjusting
for consumption of fish and shellfish (of the 31 individuals who
had consumed red wine, nine had consumed neither fish nor
shellfish). Other dietary factors such as rice, mushrooms, real
ale, poultry, rice milk and bran were not found to be statistically
significant in the model for any of the four arsenic species.
To quantify and compare the variation of lognormally distribu-
ted measurements between the different arsenic species, the
geometric coefficient of variation (GCV) was determined. The
GCV quantifies intrasubject variability and is calculated as:
GCV =
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
es
2
� 1
p
where s is the standard deviation of the data after a lognormal
transformation. The greater the GCV, the greater the variability
in the measurements. AB showed the greatest variability with a
GCV of 2.96, and DMA showed the lowest variability with a GCV
of 0.77. As3þ and MMA had a GCV of 1.38 and 0.80, respectively.
The correlation between species was determined by calculat-
ing Pearson’s correlation coefficient (a measure of the linear as-
sociation between two variables) for the natural logarithm of the
pairs of species. Nondetects were dealt with by imputation,
whereby their values were replaced with the corresponding
central estimates from the MCMC analysis, rather than by a
common fixed value. This ensured that the nondetects did not
introduce an artificial pattern to the data at low concentrations
that could potentially dominate the dataset (25). A strong posi-
tive correlation was found between MMA and DMA; a moderate
correlation was found between As3þ and MMA, As3þ and DMA,
MMA and AB as well as DMA and AB. A very weak correlation was
found between As3þ and AB. The correlation coefficient was not
calculated for As5þ due to the very high proportion (63%) of
measurements below the LOQ.
Discussion
Exposure to arsenic can occur through diet, environmental or
occupational sources. Reported here is the determined urinary
arsenic speciation concentrations collected from 95 volunteers
who are not occupationally exposed to arsenic. The median un-
corrected for creatinine (mg/L) concentrations for all the five
species of arsenic gave good agreement with other studies
where ‘control’ unexposed samples were reported and for back-
ground level studies (14, 15, 19, 21). Both the NHANES (14) and
HBECC (15) studies quantified DMA and AB only, due to the
large proportion of reported nondetects for As3þ, As5þ and
MMA. The LODs reported in the NHANES study were 1.2 mg/L
for As5þ, 1 mg/L for As3þ, 0.9 mg/L for MMA, 1.7 mg/L for DMA
and 0.4 mg/L for AB (26), and most of the 95th percentiles
reported in the HBECC study are marked as ‘use with caution’ or
‘unreliable to publish’ (15). It could be argued that both of these
arsenic speciation methods are not suitable for the analysis of
control samples. The LOD and LOQ values reported for this
novel arsenic speciation method demonstrated in this study are
lower and, therefore, better suited to the analysis of background
samples. The LOQs reported in both Heitland and Koster (18)
and Morton and Leese (20) could not achieve LOQ concentra-
tions of ,0.1 mg/L for any of the five species of arsenic, whereas
in this study the LOQ ranges from 0.02 to 0.04 mg/L. Despite dif-
fering LOD and LOQ, the 95th percentile uncorrected for
creatinine concentrations (mg/L) for all the arsenic species
apart from AB gave very good agreement with those reported by
both the NHANES (14) study for US unexposed residents
and Heitland and Koster (18) for German unexposed residents
(n ¼ 98). The median and the 95th percentile for creatinine-
uncorrected concentration (mg/L) for total inorganic arsenic
and methylated metabolites (not including AB in this study) are
3.1 and 15.1 mg/L, respectively, which are both lower than the
BEI (12) and BAT (13) values of 35 and 50 mg/L, respectively. In
this study, the 95th percentile concentration for AB gave a much
higher value of 126.7 mg/L (174.7 mmol/mol creatinine), com-
pared with 35.0 (13) and 22.7 mg/L (18) reported in other
studies. However, the HBECC (15) study gave a slightly higher
95th percentiles of 4.5 mg/L for As3þ and 30 mg/L for DMA, al-
though their reported value of 110 mg/L for AB is similar to that
obtained in our study. The predominant dietary species of
arsenic (AB) is found primarily in seafood, shellfish, algae and
seaweed products; however, it can also be found in poultry (5)
and cereal products such as rice and bran (6). AB is thought to
be the end point of arsenic metabolism in marine animals. It is
not, however, believed to be accumulative in humans, and fol-
lowing ingestion, AB is eliminated unchanged in urine, within a
couple of days. However, a study by Newcombe et al. (7)
reported that AB was present in the urine of volunteers after 12
days of an AB-free diet (no seafood or shellfish, chicken or mush-
rooms), however rice was consumed. Newcombe et al. (7) sug-
gested that dietary arsenic (AB) is present in rice. In our study,
11 urine samples had AB present, when no fish, seafood or
seaweed products had been eaten in the preceding 7 days, but
red wine, poultry and rice had been consumed. The median and
95th percentile concentrations for DMA in this study are 2.44
(4.30 mmol/mol creatinine) and 12.68 mg/L (16.08 mmol/mol
creatinine), respectively. The presence of methylated metabo-
lites in urine samples, which show no exposure to inorganic
arsenic, suggests that dietary sources are not only responsible
for the presence of AB in urine, but also DMA and to a lesser
extent MMA. Pearson et al., (8) also reported that methylated
metabolites can be from dietary sources, showing that excretion
of DMA in urine increased after eating American long-grain rice.
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Elevated DMA in urine after the consumption of different types
of fish has also been reported (4).
The regression model allowed us to investigate whether cre-
atinine correction to the uncorrected data is appropriate. The
results indicated that creatinine correction was effective for
each of the arsenic species, where regression modeling was
carried out (As3þ, MMA, DMA and AB).
Conclusion
The arsenic speciation method described in this paper has been
used to determine urinary arsenic speciation results in a cohort
of nonoccupationally exposed volunteers in the UK. This speci-
ation method demonstrates high sensitivity, enabling accurate
determinations of five species of arsenic in control urinary
samples. Despite this, 63% of samples had no As5þ present.
Statistical analysis indicated that creatinine correction was ef-
fective for each of the arsenic species, where regression modeling
was carried out (As3þ, MMA, DMA and AB). Fish consumption was
associated with higher levels of MMA, DMA and AB, shellfish with
higher levels of DMA and AB and red wine with higher levels of AB.
It can be expected that dietary sources of arsenic are not only
responsible for the presence of AB, but also for DMA and pos-
sibly MMA. The existence of methylated metabolites in a urine
sample does not necessarily equate to evidence of inorganic
arsenic exposure and its subsequent methylation. Therefore, a
method where an amalgamated value (total less AB) is deter-
mined is not an accurate measurement of exposure. To make an
inferred exposure assessment, a speciation result is required and
this could be further improved by keeping a diet log. There is a
need for a detailed characterization of arsenic content in food-
stuffs and beverages to make a more informed assessment. It
would also be useful to establish further occupational exposure
levels based on speciation results.
The results from this study mean that 95th percentile back-
ground reference ranges have been established for As3þ, As5þ,
MMA, DMA and AB. This will allow better interpretation of any
subsequent exposure.
Acknowledgments
The authors thank all the volunteers for participating in this
study and Kate Jones from the Health and Safety Laboratory for
her help and support during this project.
Funding
This publication and the work it describes were funded by the
Health and Safety Executive (HSE). Its contents, including any
opinions and/or conclusions expressed, are those of the authors
alone and do not necessarily reflect HSE policy.
References
1. IARC. (2011) Agents Classified by the IARC Monographs, Vol. 1–
105. UK: IARC. World Health Organisation. http://monographs.iarc.
fr/ENG/Classification/index.php (11 June 2013, date last accessed).
2. Huang, Y.K., Huang, Y.L., Hsueh, Y.M., Yang, M.H., Wu, M.M., Hsu, L.I.
et al. (2008) Arsenic exposure, urinary speciation, and the incidence
of urothelial carcinoma: a twelve year follow up study. Cancer
Causes and Control, 19, 829–839.
3. Saha, J.C., Dikshit, A.K., Bandyopadhyay, M. (1999) A review of
arsenic poisoning and its effects on human health. Critical Reviews
in Environmental Science and Technology, 29, 281–313.
4. Heinrich-Ramm, R., Mindt-Prufert, S., Szadkowski, D. (2002) Arsenic
species excretion after controlled seafood consumption. Journal of
Chromatography, 778, 263–273.
5. Pinel-Raffaitin, P., Le Hecho, I., Amouroux, D., Potin-Gautter, M.
(2007) Distribution and fate of inorganic and organic arsenic species
in landfill leachates and biogases. Environmental Science and
Technology, 41, 4536–4541.
6. Cleland, B., Tsuchiya, A., Kalman, D.A., Dills, R., Burbacher, T.M.,
White, J.W. et al. (2009) Arsenic exposure within the Korean com-
munity (United States) based on dietary behaviour and arsenic levels
in hair, urine, air and water. Environmental Health Perspectives,
117, 632–638.
7. Newcombe, C., Raab, A., Williams, P.N., Deacon, C., Haris, P.I., Meharg,
A.A. et al. (2010) Accumulation or production of arsenobetaine in
human? Journal of Environmental Monitoring, 12, 832–837.
8. Pearson, G.P., Greenway, G.M., Brima, E.I., Harris, P.I. (2007) Rapid
arsenic speciation using ion pair LC-ICPMS with a monolithic silica
column reveals increased urinary DMA excretion after ingestion of
rice. Journal of Analytical Atomic Spectrometry, 22, 361–369.
9. Sleijkovec, Z., Falnoga, I., Goessler, W., Van Elteren, J.T., Raml, R.,
Podgornik, H. et al. (2008) Analytical artefacts in the speciation of
arsenic in clinical samples. Analytica Chimica Acta, 607, 83–91.
10. Ito, K., Palmer, C.D., Steuerwald, A.J., Parsons, P.J. (2010)
Determination of five arsenic species in whole blood by liquid
chromatography coupled with inductively coupled plasma mass
spectrometry. Journal of Analytical Atomic Spectrometry, 25,
1334–1342.
11. Hasegawa, T., Ishise, J., Fukumoto, Y., Matsuura, H., Zhu, Y., Umemura,
T. et al. (2007) Chemical speciation of arsenic species in human blood
serum by liquid chromatography using phosphatidylcholine-coated
ODS column with detection by ICP-MS. Bulletin of the Chemical
Society of Japan, 80, 498–502.
12. American Conference of Governmental Industrial Hygienists. (2012)
TLVs and BEIs: Threshold Limit Values for Chemical Substances
and Physical Agents. USA: Signature Publications. www.acgih.org.
13. DFG German DRF Deutsche Forschungsgemeinschaft. (2012) List of
MAK and BAT Values 2009. Germany: Wiley-VCH.
14. Centres for Disease Control and Prevention. (2009) Fourth National
Report on Human Exposure to Environmental Chemicals. Centres for
Disease Control and Prevention. http://www.cdc.gov/exposurereport/
(11 June 2013, date last accessed).
15. Health Canada. (2013) Second Report on Human Biomonitoring of
Environmental Chemicals in Canada. Health Canada. www.
healthcanada.gc.ca/biomonitoring (15 May 2013, date last accessed).
16. Saoudi, A., Zeghnoun, A., Bidondo, M.L., Garnier, R., Cirimele, V.,
Persoons, R. et al. (2012) Urinary arsenic levels in the French adult
population: the French National Nutrition and Health Study, 2006–
2007. Science of the Total Environment, 433, 206–215.
17. Lee, J.W., Lee, C.K., Moon, C.S., Choi, I.J., Lee, K.J., Yi, S.M. et al.
(2012) Korea national survey for environmental pollutants in the
human body 2008: heavy metals in the blood or urine of the Korean
population. International Journal of Hygiene and Environmental
Health, 215, 449–457.
18. Heitland, P., Koster, H.D. (2008) Fast determination of arsenic
species and total arsenic in urine by HPLC-ICP-MS: concentration
ranges for unexposed German inhabitants and clinical case studies.
Journal of Analytical Toxicology, 32, 308–314.
19. Morton, J., Mason, H. (2006) Speciation of arsenic compounds in
urine from occupationally unexposed and exposed persons in the
UK using a routine LC-ICP-MS method. Journal of Analytical
Toxicology, 30, 293–301.
20. Morton, J., Leese, E. (2011) Arsenic speciation in clinical samples:
urine analysis using fast micro-liquid chromatography ICP-MS.
Analytical and Bioanalytical Chemistry, 399, 1781–1788.
Unexposed Urinary Arsenic Speciation Reference Values 29
21. Apostoli, P., Bartoli, D., Allesio, L., Buchet, J.P. (1999) Biological moni-
toring of occupational exposure to inorganic arsenic. Occupational
and Environmental Medicine, 56, 825–832.
22. Torra, M., Auge, J.M., Ballell, B., Rodamilans, M., Casoliva, C., Corbella, J.
(2004) Biological monitoring of environmental exposure to arsenic in
urine samples from residents of the city of Barcelona, Spain, after se-
lective extraction of the toxicologically relevant arsenic forms. Trace
Elements and Electrolytes, 21, 248–251.
23. Cocker, J., Mason, H.J., Warren, N.D., Cotton, R.J. (2011) Creatinine
adjustment of biological monitoring results. Occupational Medicine,
61, 349–353.
24. Lunn, D.J., Thomas, A., Best, N., Spiegelhalter, D. (2000) Winbugs—a
Bayesian modelling framework: concepts, structure and extensibility.
Statistics and Computing, 10, 325–337.
25. Helsel, D. (2009) Much Ado about next to nothing: incorporating
nondetects in science. The Annals of Occupational Hygiene, 54,
257–262.
26. Caldwell, K.L., Jones, R.L., Verdon, C.P., Jarrett, J.M., Caudill, S.P.,
Osterloh, J.D. (2009) Levels of urinary total and speciated arsenic in
the US population: national health and nutrition examination survey
2003–2004. Journal of Exposure Science and Environmental
Epidemiology, 19, 59–68.
30 Leese et al.
82 
Chapter 3. 
The Investigation of Unexpected Arsenic 
Compounds Observed in Routine Biological 
Monitoring Urinary Speciation Analysis 
E. Leese, M. Clench, J. Morton, P.H.E. Gardiner and V.A. Carolan. Toxics., 2017, 5(2):
doi:10.3390/toxics5020012  
Published – Creative Commons Re-use Open Access Licence 
http://www.mdpi.com/2305-6304/5/2/12 
toxics
Article
The Investigation of Unexpected Arsenic Compounds
Observed in Routine Biological Monitoring Urinary
Speciation Analysis
Elizabeth Leese 1,2,*, Malcolm Clench 2, Jackie Morton 1, Philip H.E. Gardiner 2 and
Vikki A. Carolan 2
1 Health and Safety Executive, Harpur Hill, Buxton, Derbyshire SK17 9JN, UK; jackie.morton@hsl.gsi.gov.uk
2 Biomolecular Sciences Research Centre, Sheffield Hallam University, Howard Street, Sheffield S1 1WB, UK;
m.r.clench@shu.ac.uk (M.C.); p.h.gardiner@shu.ac.uk (P.H.E.G.); v.a.carolan@shu.ac.uk (V.A.C.)
* Correspondence: liz.leese@hsl.gsi.gov.uk; Tel.: +44-129-821-8434
Academic Editor: Wayne Briner
Received: 24 April 2017; Accepted: 18 May 2017; Published: 20 May 2017
Abstract: This study investigates the identity of two unexpected arsenic species found separately in
a number of urine samples sent to the Health and Safety Executive’s Health and Safety Laboratory
for arsenic speciation (arsenobetaine, AB; arsenite, As3+; arsenate, As5+; monomethylarsonic
acid, MMA5+; and dimethylarsinic acid, DMA5+). Micro liquid chromatography coupled to
inductively coupled plasma mass spectrometry (µLC-ICP-MS) and electrospray time of flight
tandem mass spectrometry (ESI-QqTOF-MS/MS) were used to identify the two arsenic peaks by
comparison to several characterized arsenicals: arsenocholine, AC; trimethyl arsine oxide, TMAO;
dimethylarsenoacetate, DMAA; dimethylarsenoethanol, DMAE; thio-dimethylarsinate, thio-DMA;
thio-dimethylarsenoacetate, thio-DMAA and thio-dimethylarsenoethanol, thio-DMAE. The results
from both the ICP-MS and ESI-QqTOF-MS/MS investigations indicate that the unexpected arsenic
species termed peak 1 was thio-DMA. While the unexpected arsenic species termed peak 2 has yet
to be identified, this investigation shows that it was not AC, TMAO, DMAA, DMAE, thio-DMA,
thio-DMAA or thio-DMAE. This study demonstrates the incidence of unexpected arsenic species in
both routine and non-routine urine samples from both workers and hospital patients.
Keywords: arsenic; speciation; thioarsenical; thio-DMA; urine; exposure; ICP-MS; oxoarsenicals
1. Introduction
Identifying arsenic species in urine samples presents both an analytical and biological challenge,
as the metabolism and biotransformation of arsenic compounds in humans is complex [1]. In part
this is due to the fact that there is no exact agreed process for this human metabolic pathway
of arsenic in the literature, with Hayakawa [2], Naranmandura [3] and Wang [4] all proposing
slightly different biomethylation pathways. In 1945, the Challenger pathway [5] was first proposed
in humans suggesting an initial reduction of arsenate to arsenite followed by steps of oxidation
methylation and reduction methylation as follows: arsenate > arsenite > monomethylarsonic acid >
monomethylarsonous acid > dimethylarsinic acid > dimethylarsinous acid (As5+ > As3+ > MMA5+
> MMA3+ > DMA5+ > DMA3+). More recent studies [2–4] have suggested that the pentavalent
methylated species are not intermediates as presumed in the Challenger pathway but rather an end
product of arsenic biotransformation. It has also been shown that the presence of the mammalian
methyltransferase enzyme As3MT [6,7] (previously named Cyt19) [8] is crucial for arsenic metabolism,
as it enables the transfer of the methyl donor S-adenosyl-L-methionine (SAM) in the presence of
glutathione (GSH) [2,9]. It is suggested that the primary site of arsenic methylation in humans is the
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liver [8,10], because the liver retains and accumulates arsenic [11] in addition to being a rich source of
GSH [12].
In the general population, the primary source of arsenic exposure is through ingestion from
dietary and water sources. It is also possible that workplace exposure could occur in industries such
as semiconductors (using gallium arsenide and arsine gas) and glass making. Inorganic arsenic
and the methylated metabolite DMA can be found in rice and rice products [13,14]. The most
common non-rice based dietary arsenic compounds are arsenobetaine [AB], arsenocholine [AC],
trimethylarsine oxide [TMAO] and arsenosugars. These dietary species are found in marine algae,
squid, crustaceans, bivalves and fish [15,16]. Humans are unable to further metabolise AB and
AC after ingestion [17–19], as a result of four stable carbon bonds making them quasi-inert [19].
Subsequently, AB and AC are excreted in the urine unchanged and assumed to be completely
non-toxic [17–19]. Arsenosugars, unlike AB and AC, are bio-accessible and can be transformed
into other metabolites after human ingestion. These possible metabolites are DMA5+ (the major
metabolite) and numerous DMA analogues: dimethylarsenoacetate [DMAA]; dimethylarsenoethanol
[DMAE]; thio-dimethylarsenoacetate [thio-DMAA]; thio-dimethylarsenoethanol [thio-DMAE]; and
thio-dimethylarsinate or dimethylthioarsinic acid [thio-DMA / DMTA]. These compounds are named
dimethylarsinoyl compounds where the arsinoyl group represents either As=O or As=S and so are
commonly termed oxo- and thioarsenicals [20]. Both monomethylated and di-thiolated forms such as
dimethyldithioarsinic acid [dithio-DMA/DMDTA], monomethylthioarsonic acid [thio-MMA/MMTA]
and monomethyldithioarsonic acid [dithio-MMA/MMDTA] have also been proposed [21–25].
The first study to report a thioarsenical metabolite in “natural” biological samples was from the
urine of sheep that inhabit the beaches of North Ronaldsway (Orkney Island, Scotland). These sheep
were unique in that they are chronically exposed to arsenosugars as a result of their diet of seaweed [26].
The study determined and confirmed the thioarsenical using anion exchange high performance liquid
chromatography (HPLC) coupled to an inductively coupled plasma mass spectrometry (ICP-MS)
and electrospray mass spectrometry (ES-MS) [26]. Studies published by Francesconi’s research
group [15,27,28] have reported the almost complete biotransformation of an ingested synthetically
prepared arsenosugar, resulting in the excretion of a mix of twelve thio- and oxoarsenicals in urine.
The investigation of these twelve arsenicals was performed using HPLC-ICP-MS and HPLC-ES-MS,
with anion, cation or reverse phase chromatography to ensure full separation of all the arsenicals.
In later studies, thio arsenicals were reported in human urine samples from population
studies [29–31]. These groups recognized the importance of accurate identification and employed
ES-MS in addition to HPLC-ICP-MS. It is already known that DMA5+ is the major human urinary
metabolite following both inorganic arsenic exposure and dietary arsenosugar exposure [32];
the literature implies perhaps the same premise for thio-DMA and possibly other thio-arsenicals
being metabolites following both inorganic exposure or dietary arsenosugar exposure. This will be of
some concern as toxicological studies have shown thio-DMA to be genotoxic, cytotoxic and as toxic or
more cytotoxic than arsenite in studies with rats [33,34], human bladder cells [23,35,36] and human
lung cells [37–39], with one study describing thio-DMA as “one of the most toxicologically potent
arsenic species, relevant to arsenic induced carcinogenicity” [23].
Since 2010, the Health and Safety Executive’s (HSE’s) Health and Safety Laboratory, based in
Buxton, England, has been using a sensitive, robust and reliable speciation method for determining five
species of arsenic in urine (arsenobetaine [AB], arsenite [As3+], arsenate [As5+], monomethylarsonic
acid [MMA5+] and dimethylarsinic acid [DMA5+]) using a micro LC system coupled to an ICP-MS
with a specialty anion exchange micro column. In this study, we investigate two different unexpected
arsenic peaks observed in the analysis of urine samples from forensic cases, occupational exposure,
hospital patients and as part of a background level study. The two unexpected peaks have been termed
peak 1 and peak 2. Identification was facilitated using micro liquid chromatography coupled to ICP-MS
(µLC-ICP-MS) and electrospray time of flight tandem mass spectrometry (ESI-Qq-TOF-MS/MS).
Toxics 2017, 5, 12 3 of 15
Previous unidentified DMA analogues which include; DMAA, DMAE, thio-DMAA, thio-DMAE
and thio-DMA have been reported in urine of specific population studies exposed to inorganic
arsenic contaminated drinking water [29,31], populations exposed to excessive amounts of
arsenosugars [26,30,40] and in specific human dosing or ingestion studies [15,27,28,41,42]. However,
this is the first study to report the observation of these similar or same arsenic compounds not
from specific epidemiological populations, but routine biological monitoring urine samples. These
samples are from a variety of industrial companies and geographical locations with no unifying
commonalties as to the source of exposure to help aid either the identification of the arsenic species
or with interpretation/feedback for customers. Based on an extensive review of the literature and on
the availability of arsenic compounds, seven arsenicals (DMAA, DMAE, thio-DMAA, thio-DMAE,
thio-DMA, TMAO and AC) were used to help determine the two unexpected arsenic peaks. These
two arsenic peaks to date have not been observed at the same time in the same urine sample. Arsenic
structures in addition to the structures of the seven arsenic compounds investigated in this study can
be found in Figure S1 in the supplementary information.
2. Materials and Methods
2.1. Standards and Reagents
Arsenic speciation compounds sodium arsenite (NaAsO2), sodium arsenate (Na2HAsO4.7H2O)
and sodium cacodylate (DMA; Na(CH3)2AsO2.3H2O) were all from Fisher Scientific (Loughborough,
UK). Disodium methyl arsenate (99% MMA; CH3AsO(OH)2) was from ChemService (West Chester,
PA, USA). Arsenobetaine (AB; C5H11AsO2) was from Sigma-Aldrich (Dorset, UK). Arsenocholine
(AC; C5H14AsBrO) and trimethyl arsine oxide (TMAO; C3H9AsO) were both from Argus Chemicals
(Vernio, Italy). Analytical quantities of the oxoarsenicals and thioarsenicals dimethylarsenoacetate
(DMAA), dimethylarsenoethanol (DMAE), thio-dimethylarsinate (thio-DMA; (CH3)2As(S)OH),
thio-dimethylarsenoacetate (thio-DMAA) and thio-dimethylarsenoethanol (thio-DMAE) were all
synthesized by Kevin Francesconi’s group at Karl-Franzens University Graz. Ammonium carbonate
and hydrogen peroxide were from VWR (Leicestershire, UK). All water used was ultrapure deionized
water (18.2 MΩhm cm) from a Millipore system (Merck Millipore, Billerica, MA, USA).
Single standard stock solutions of 1000 mg·L−1 of AB, As3+, As5+, DMA, MMA, AC and TMAO
were prepared in 1% (v/v) nitric acid, and stored at 4 ◦C. The analytical grade quantities of DMAA,
DMAE, thio-DMAA, thio-DMAE and thio-DMA were reconstituted with 1 mL of water. Individual
aliquots of 200 µL were stored at −80 ◦C until analysis.
2.2. Instrumentation
2.2.1. Species Identification by µLC-ICP-MS
Separation was performed using a hyphenated µLC system with an ICP-MS (XSERIES 2, Thermo
Fisher Scientific, Hemel Hempstead, UK). The separation of arsenic species was achieved using a
5 cm anion exchange guard column, (Dionex IONPAC AG7 4 mm × 50 mm i.d., 10 µm, Thermo
Fisher Scientific). The micro-flow delivery of sample and mobile phase was accomplished using an ESI
OneFAST system (Elemental Scientific, Warrington, UK), which consists of a six port switching valve
and 1 mL sample loop. The ICP-MS was operated in collision cell (CCT) mode using 7% hydrogen in
helium (approximately 3.5 mL/min), RF power 1400 W, using a Ni Xt skimmer and a Pt sample cones.
The delivery of mobile phases and sample onto the column was controlled by the ICP-MS
peristaltic pump at a constant 0.2 mL/min. The µLC-ICP-MS method used comprises of a step gradient
using two mobile phases of 2 mM ammonium carbonate (mobile phase A) and 70 mM ammonium
carbonate (mobile phase B). Total acquisition time is 360 s with a sample injection time of 10 s. Mobile
phase A is the carrier solution, 120 s after the injection of the sample, mobile phase B is injected for
120 s.
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2.2.2. Species Identification by ESI-QqTOF-MS/MS
Molecular identification was performed using an electrospray ionization quadrupole-time of
flight (ESI-QqTOF) mass spectrometer (QStar XL MS-MS, Applied Biosystems, Concord, ON, Canada)
with a turbo ion-spray source. The MS/MS experiments were carried out in positive ion mode with a
collision energy of 20 eV using argon as the collision gas. Samples were injected separately into the
ESI-QqTOF-MS using syringe infusions.
2.3. Sample Collection
All participating individuals were provided with informed consent, in accordance with HS(G)
167 [43]. All urine samples analyzed for arsenic speciation were received at the Health and Safety
Laboratory as part of the analytical service for biological monitoring to assess arsenic exposure. From
2012 to 2016, an unexpected peak was observed in 4% of urine samples analyzed. The urine samples
arrive with little contextual data apart from name, date of birth and details of the sender. Urine samples
containing an unidentified arsenic peak were from UK semi-conductor workers, South African miners,
forensic incidents, hospital patients and a participant of an arsenic-unexposed background level
study [44]. It is important to note that urine samples from South African Miners and hospital patients
were only received at the Health and Safety Laboratory for arsenic speciation analysis if total arsenic
concentrations exceeded the US biological exposure index (BEI) [45] of 35 µg·L−1 (approximately
40 µmol/mol creatinine) at other laboratories. Upon receipt at the laboratory all urine samples for
arsenic speciation are stored frozen at approximately −20 ◦C until analysis. For this study, samples
that contained an unexpected peak had 1 mL aliquots taken and stored at −80 ◦C until identification
analysis. Urine samples are not filtered prior to analysis and sample preparation involves only a
15-fold dilution with mobile phase A.
3. Results
3.1. Identification of Unexpected Arsenic Peaks by µLC-ICP-MS
During analysis of urinary arsenic speciation, both peak 1 and peak 2 eluted at different retention
times to the five arsenic species routinely determined at the Health and Safety Laboratory (AB, As3+,
As5+, DMA andMMA) (Figure 1A). Figure 1 shows that peak 1 (Figure 1B) is eluted between DMA and
MMA at a retention time of 216 s, peak 2 (Figure 1C) is eluted between MMA and As5+ at a retention
time of 240 s.
The analytical quantities of DMAA, DMAE, thio-DMAA, thio-DMAE, thio-DMA at approximate
concentrations of 20–100 µg·L−1, and 5 µg·L−1 standards of AC and TMAO were injected onto the
Dionex AG7 column. It was possible to observe each of the seven additional arsenic compounds with
the existing µLC-ICP-MS method, although not all species would be fully separated if injected together.
Figure S2 in the supplementary information shows the elution retention times of each of these six oxo-
and thioarsenicals and AC when compared to the original five arsenic species.
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Figure 1. Chromatograms of arsenic species analyzed using an ESI OneFAST system coupled to a
Dionex AG7 anion exchange column and ICP-MS using mobile phases 2 mM and 70 mM ammonium
carbonate solution (A) A 5 µg L−1 standard of the five arsenic species. (B) A urine sample containing
peak 1. (C) A urine sample containing peak 2.
3.2. Investigation of Peak 1 by µLC-ICP-MS
The urine samples analyzed where the arsenic peak, termed peak 1 was observed came from
four different groups of individuals. The first group consisted of urine samples from two separate
forensic cases, one of which was from a fatal arsenic poisoning where the approximate total arsenic
concentration was 4800 µg·L−1 (–11,500 µmol mol creatinine) and contained the highest concentration
of peak 1 in this study (approximate concentration 2800 µg·L−1). The second group consisted of
occupational samples from South African miners, where 33% of urine samples analyzed contained
peak 1. The third group were from hospital patients within the UK, where the presence of peak 1
accounts for 21% of all hospital patient samples analyzed, and the fourth group was a volunteer who
participated in a study to determine unexposed background reference values for five arsenic species
in a UK population. The approximate concentration of peak 1 in other urine samples presented here
were all less than 50 µg·L−1.
The urine samples that contained peak 1 varied in pH from pH 4–pH 7.2. These differences in pH
of the urine samples did not affect the retention time of peak 1. The chromatogram of a urine sample
containing peak 1 is shown in Figure 2B. When a urine sample containing peak 1 was spiked with
a 20 µg·L−1 solution containing the standard five species, peak 1 eluted separately from the other
five arsenic species, however as shown in Figure 2A, peak 1 elutes on the shoulder of the MMA peak.
Of the six oxo- and thioarsenicals (DMAA, DMAE, thio-DMA, thio-DMAA and thio-DMAE) and AC
injected onto the column, thio-DMA and AC were the only species that had a similar retention time
to peak 1 (see Figure 2B,D,E). When the urine sample containing peak 1 was spiked with thio-DMA
at an approximate concentration of 90 µg·L−1, the peak at the retention time of peak 1 increases (see
Figure 2C).
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Figure 2. hro atogra s of arsenic species analyzed using an ESI neF ST syste coupled to a
Dionex AG7 anion exchange column and ICP-MS using mobile phases 2 mM and 70 mM ammonium
carbonate solution. (A) A urine sample containing peak 1 spiked with a 20 µg·L 1 solution of the
standard five species. (B) An unspiked urine sample containing peak 1. (C) The urine sample containing
peak 1 spiked with an approximate concentration of 40 µg·L−1 thio-DMA standard. (D) A thio-DMA
standard at an approximate concentration of 40 µg·L−1 and (E) A 5 µg·L−1 AC standard. (F) The urine
sample containing peak 1. (G) The urine sample with 10% v/v H2O2 added (H) The urine sample
with 100% H2O2 added (I) Thio-DMA standard spiked into ‘blank urine’ not containing peak 1 (J) The
spiked urine sample from chromatogram D with 10% v/v H2O2 added.
When 10% v/v of H2O2 was added to a urine sample containing peak 1, the height of peak 1
reduced while the DMA peak height increased (see Figure 2F,G). When this was repeated with 100% of
H2O2, peak 1 completely disappeared and the DMA peak increased accordingly (see chromatogram H
of Figure 2). When thio-DMA was treated with 10% v/v H2O2, the thio-DMA peak was completely
converted to a peak at the same retention time as DMA (see Figure 2I,J). When AC was treated with
100% of H2O2 the AC peak did not change retention time or reduce in peak height nor was there an
effect on any of the other peaks. Therefore, this is evidence that peak 1 is not AC.
Interestingly, one particular urine sample containing peak 1 received from a hospital patient also
showed the presence of an arsenic compound that eluted post column and was observed as a carryover
peak following the injection of mobile phase B in the following sample. A repeat injection of the urine
sample followed by the injection of a mobile phase A blank sample showed the presence of the same
peak as shown in Figure 3. Unfortunately, further investigation of this peak was prohibited due to
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conversion of this peak to peak 1 and DMA during weekend storage in the fridge at 4 ◦C. The addition
of 100% H2O2 converted the very small remainder of this parent compound and all of peak 1 to DMA.
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Figure 3. Chromatograms of arsenic species using an ESI OneFAST system coupled to a Dionex AG7
anion exchange column and ICP-MS using mobile phases 2 mM and 70 mM ammonium carbonate
solution. (A) A urine sample from a hospital patient containing peak 1. (B) The post column carryover
peak of an unknown into the blank sample immediately after the urine sample containing peak 1.
(C) Chromatogram of the 5-day-old urine sample with 100% H2O2 added.
3.3. Investigation of Peak 1 by ESI-QqTOF-MS/MS
AC was not thought to be the identity of peak 1 because the arsenic compound termed peak 1,
was affected by the addition of H2O2 and AC was not. Early investigations using tandem mass
spectrometry (not cited in the methodology) showed that when monitoring the protonated molecule
[M + H]+ m/z 165 of AC, no signal was observed at the retention time of an AC standard, when the
urine sample containing approximately 2800 µg·L−1 of peak 1 was injected into the MS/MS.
While the µLC-ICP-MS investigations of peak 1 had indicated that this peak was thio-DMA,
further confirmation was sought using mass spectrometry. As shown in Figure 4, the [M + H]+ ion of
thio-DMA is m/z 155, with expected product ions of m/z 137, 121, 109, 107 and 75.
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Since it was not possible in our laboratory to simultaneously analyze the arsenic species by
coupling µLC-ICP-MS with ESI-QqTOF-MS/MS, samples had to be analyzed separately using
ESI-QqTOF-MS/MS. The samples were injected into the ESI-QqTOF-MS/MS using syringe infusion.
To undertake this, an aqueous standard solution of thio-DMA of approximate concentration of
1600 µg·L−1 was injected into the ESI-QqTOF-MS/MS (see Figure 4A). In a product ion scan of
m/z 155, signals at m/z 155, 137 and 109 were observed, and additionally a small product ion at m/z 107.
Other minor peaks that were observed in the spectra of the thio-DMA standard were m/z 127, 113,
99 and 95. In addition, a urine sample containing peak 1 has been fraction collected using the LC
system on the ICP-MS and the fraction containing peak 1 was injected into the ESI-QqTOF-MS/MS
(see Figure 4B). Again, the product ion mass spectrum of m/z 155, gave peaks at m/z 155, 137, 109
corresponding to the product ion spectrum of the thio-DMA standard. The dominant peak was m/z 95
with intermediate peaks at m/z 137, 113 and 109 and with smaller peaks at m/z 155 and 127, all of which
concurred with the spectra of the thio-DMA standard.
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Figure 4. The chemical structure of thio-DMA, with suggested fragment ions when measured in
positive ion mode by ESI-QqTOF-MS/MS within the two ESI-QqTOF-MS/MS spectra from product
ion scans of m/z 155, when infusing (A) Thio-DMA standard at an approximate concentration of
1600 µg·L−1. (B) Fraction of a urine sample containing peak 1 with blank urine correction from a urine
sample not containing peak 1.
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3.4. Investigation of Peak 2 by µLC-ICP-MS
The urine samples containing the unexpected arsenic peak termed peak 2 came from two different
groups of individuals. The first group were from different hospital patients, in separate hospitals
within the UK. The symptoms of both individuals varied but both were surmised to have ingested an
excessive amount of herbal remedies purchased online. The two individuals had consumed a different
herbal remedy, one was kelp powder, administered orally by adding to food, the ingredient of the
second herbal remedy was unknown, but was a black colored tablet administered orally. In total peak 2
has been observed in 9% of all hospital samples analyzed. The second group consisted of occupational
urine samples from UK semi-conductor workers, peak 2 has been observed in 1% of all urine samples
from semi-conductor workers.
The urine samples that contained peak 2 varied in pH, from pH 5.5–pH 7.8. These differences in
pH of the urine samples did not affect the retention time of peak 2. When a urine sample containing
peak 2 was spiked with a 20 µg·L−1 five species standard mix of arsenic species, peak 2 eluted
separately from the other five arsenic species (see Figure 5A). Of the six oxo- and thioarsenicals
(DMAA, DMAE, thio-DMA, thio-DMAA and thio-DMAE, TMAO) and AC injected onto the column,
none matched the retention time of peak 2; however thio-DMAA is the closest. When a urine sample
containing peak 2 was spiked with a standard of thio-DMAA, although not fully separated, two
unresolved peaks were observed (see Figure 5B).
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Figure 5. Chromatograms of arsenic species analyzed using an ESI OneFAST system coupled
to a Dionex AG7 anion exchange column and ICP-MS using mobile phases 2 mM and 70 mM
ammonium carbonate solution. (A) Chromatogram of a urine sample containing peak 2 spiked
with a 20 µg·L−1 standard mix of the five species of arsenic. (B) Chromatogram of the urine sample
spiked with thio-DMAA.
When thio-DMAA was treated with 50% v/v H2O2, the thio-DMAA peak was mostly converted
to a peak at the same retention time as DMAA, leaving a much reduced sized peak of thio-DMAA.
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However when a urine sample containing peak 2 is treated with 100% H2O2, the peak does not reduce
or change in retention time and there is not a peak at the location assigned to DMAA. Chromatograms
are shown in Figure S3 in the supplementary information.
3.5. Investigation of Peak 2 by ESI-QqTOF-MS/MS
Considerable efforts were made to analyze the urine samples with peak 2 by ESI-QqTOF-MS/MS.
Two different tandem mass spectrometry instruments were used, different solvents were investigated
and the fraction-collected peaks were freeze dried and reconstituted in an attempt to concentrate
the samples. However, due to the inherent problems surrounding the difficulty in ionizing oxo- and
thioarsenicals by MS-MS, there was insufficient sensitivity using the ESI-QqTOF-MS/MS to identify
the protonated [M + H]+ ion of thio-DMAA at m/z 197, or its expected product ions of m/z 165, 151,
137, 107 and 75. Using negative ion mode was also unsuccessful. No definitive signal was observed
across the mass range. The approximate concentration of the arsenic compound of peak 2 in all the
urine samples used in this study was considered too low (estimated concentrations < 50 µg·L−1) to
detect any [M + H]+ or product ions which corresponded to DMAA, DMAE, thio-DMAA, thio-DMAE
or thio-DMA. To aid identification of peak 2, no other analytical techniques were investigated as it
was deemed that the ESI-QqTOF-MS/MS would have the lowest LOD to facilitate the identification of
arsenic compounds at such low concentrations.
To date we have been unable to identify peak 2, however this arsenic compound seems stable
in urine, and to date has not converted to another peak when stored for 12 months frozen at either
−80 ◦C or −20 ◦C.
4. Discussion
The investigation, by both µLC-ICP-MS and ESI-QqTOF-MS/MS, has determined that peak 1
is thio-DMA. Unfortunately, peak 2 has not been identified, although it has been possible to
eliminate seven arsenic species in the process. This is not the only study to report unsuccessful
identification of arsenic peaks in similar investigations [15,27,28,41,43,46]. While a human dosing study
reported the almost complete biotransformation of an ingested synthetically prepared arsenosugar
(2,3-dihydroxypropyl 5-deoxy-5-dimethylarsinoyl-β-D-riboside), which resulted in the excretion of
twelve arsenicals in urine [15,27,28], initially only three of the twelve could be identified [15], which
were DMA5+, TMAO and DMAE. Repeat studies further identified DMAA, thio-DMAA, thio-DMAE,
the arsenosugar and thio-arsenosugar and trace amounts of thio-DMA and TMAS, with two species
remained unidentified [27,28]. All information in this challenging analytical field is valuable and
contributes to the scientific knowledge and future studies of a similar nature.
The urine samples which contained thio-DMA (peak 1) were obtained from four sources consisting
of two separate forensic cases, occupational exposure samples, a hospital patient and an individual
participating in a background levels study. Only the urine samples from the two forensic cases had
clear evidence of inorganic arsenic exposure (inorganic arsenic and elevated DMA5+ and MMA5+ were
observed during speciation analysis). The urine sample of the additional hospital patient saw the
elution of a further arsenic compound eluting post column in the following sample (Figure 3). This
compound is potentially a “parent” arsenic compound and it was found to be quite unstable, as it
had completely converted to thio-DMA after refrigeration at 4 ◦C and subsequently DMA5+ after
the addition of hydrogen peroxide. The presence of this parent compound has not been observed
previously or since, nor has it been observed in urine in the current literature to provide an identification
suggestion. It is common knowledge in the literature [23,25,26,30,38,47] that treatment of DMA5+ with
hydrogen sulphide will produce thio-DMA. Furthermore, it is known that continued treatment of
thio-DMA with hydrogen sulphide will produce dithio-DMA [47,48] and the subsequent addition of
hydrogen peroxide can convert dithio-DMA back to thio-DMA [49]. The study by Conklin [49] found
the conversion between DMA, thio-DMA and dithio-DMA in aqueous standards was pH specific, with
DMA only converting to its thio-analogues when the pH range was between pH 5–7. Unfortunately, in
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our study, due to the rapid degradation of this observed parent compound in the urine sample and the
lack of a dithio-DMA standard to match retention time, the authors were unable to make any initial
analytical confirmation of the identity of the compound and can therefore only postulate the parent
compound’s identity as dithio-DMA.
It is possible that the source of peak 1 in the urine samples from the South African miners is either
from dietary or occupational sources. However, in these samples inorganic arsenic was not observed,
with the dominant species being DMA5+ and MMA5+ with smaller concentrations of AB. These mixed
findings of both inorganic exposure and dietary arsenosugar exposure are similar to those found in the
literature. A study looking at women in Bangladesh exposed to inorganic arsenic in their drinking
water found that 44% of urine samples from 75 women contained thio-DMA [31]. A similar study
looking at a population exposed to inorganic arsenic through drinking water in West Bengal found
thio-DMA in both urine and nails [29]. A noteworthy study by Raml [30] in 2006 determined thio-DMA,
thio-DMAA and thio-DMAE in a human urine reference material, NIES 18. The thioarsenicals were
reported to represent approximately 10% of the total urinary arsenic. Interestingly, the human urine
used to produce this reference material is not spiked with arsenic species but is collected from Japanese
men who were not occupationally exposed to arsenic, but whose diet is rich in seafood, algae and
mollusks [30]. Studies have also shown that inorganic arsenic can be converted to thioarsenicals
in ground water [48] and algae has also shown to be able to convert inorganic arsenic into both
methylated oxo- and thioarsenicals [48], with arsenosugars being the major arsenic compound found
in marine algae [50]. This goes some way to explain why thio-DMA is found in human urine from a
variety of possible sources of exposure.
The ESI-QqTOF-MS/MS analysis in this study of thio-DMA is in agreement with the
LC-ESI-MS/MS analysis of a thio-DMA standard by Fricke [47], who also found product ions at
m/z 137, 121 and 109. However, the ESI-QqTOF-MS/MS analysis in this study also produced product
ions corresponding to m/z 127 and 113. The peak at m/z 127 is in agreement with Hansen [51] however
the actual molecular structure for this signal and m/z 113 is unknown.
A study that found an unknown arsenic peak during the speciation of a rice extract (from rice
cooked in arsenic contaminated water), also determined their unknown peak to be thio-DMA [52].
They employed the same analytical techniques used in this study to determine its identity; thio-DMA
spikes, conversion using H2O2 and IC-ESI-MS analysis. However, they used negative ion mode MS,
meaning peaks were identified at m/z 153, 138, 123 and 105.
The urine samples which contained peak 2 came from two sources consisting of two separate
hospital patients and UK semi-conductor workers. The only other arsenic species present in both
the urine samples of the two separate hospital patients apart from peak 2 was arsenobetaine. This
would suggest that the presence of peak 2 was not from inorganic arsenic exposure but most likely
from dietary exposure. Furthermore, while the source of exposure for the semi-conductor workers
potentially could be occupational inorganic exposure, the speciation analysis of their urine samples
indicated otherwise.
Several studies have reported differences in the excretion of oxo- and thioarsenical metabolites
after the ingestion of arsenosugars [28,40,53]. Suggested possible reasons for this human metabolic
variationmight be differences in biotransformation enzymes found in the liver, people’s differing ability
to transform or degrade arsenosugars, differences in gut flora or the ability to uptake arsenosugars [28].
This individual metabolic variation/uniqueness may suggest why these oxo- and thioarsenicals are
not seen as frequently as other dietary compounds such as AB during our general arsenic speciation
analysis at the Health and Safety Laboratory.
The results outlined in Figure 2F–J and Figure S3 show that when thioarsenicals, thio-DMA
and thio-DMAA, are oxidized with H2O2 they begin to convert to their oxo analogues; DMA
5+ and
DMAA respectively. However as shown in Figure S2C,F, thio-DMAE and DMAE have identical
retention times using the chromatographic conditions used in this study, therefore it is difficult to say
if the same oxidation process also applies to thio-DMAE. The fact that peak 1 (thio-DMA) follows
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this same oxidative process and peak 2 does not, may suggest that peak 2 is not a thioarsenical;
this hypothesis would agree with the literature where it is stated that the oxidizing agent hydrogen
peroxide converts thioarsenicals to their oxoarsenical analogues [27,48]. Therefore, peak 2 could be
one of the oxoarsenicals or an arsenosugar not analyzed in this study. The study by Raml [27] reported
traces of an arsenosugar in urine but it was not sufficiently separated from the other arsenicals
when using an anion exchange column. In addition a study in 2006 by Schmiesser [42] found
arsenolipid metabolites in human urine after the ingestion of cod liver, known as arsenic fatty acids
such as dimethylarsenopropanoic acid (DMAP), thio-dimethylarsenopropanoic acid (thio-DMAP),
dimethylarsenobutanoic acid (DMAB) and thio-dimethylarsenobutanoic acid (thio-DMAB), with all
but DMAP were determined using anion exchange chromatography.
Several research groups have recently attempted to better explain arsenic metabolic pathways
using the liver of rats [54] and rat or mouse cecum [48,55]. Wang [48] suggests that pre-absorptive
methylation of thioarsenicals is facilitated by gastrointestinal microbiota before transport across the
gastrointestinal barrier, and post-absorptive formation of thio-arsenicals occurs when oxoarsenicals
are converted due to the presence of H2S formed in tissues. They also postulated that during in-vitro
reactions both thio-DMA and dithio-DMA occur from DMA3+, while in-vitro human red blood cells
take up DMA3+ and quickly convert it to thio-DMA. This research does advance the understanding of
these pathways but it is worth noting that Wang [48], Suzuki [54] and Kubachka [55] have all proposed
different possible pathways for the in vitro methylation, reduction and thiolation of inorganic arsenic
as well as to mono-, di- and trimethylated species with a range of oxo- and thioarsenical products.
5. Conclusions
In conclusion, the investigation, by both µLC-ICP-MS and ESI-QqTOF-MS/MS, has determined
that peak 1 is thio-DMA. Peak 2 has not been identified to date. However, this study has established
that peak 2 is not thio-DMA, DMAA, thio-DMAA, DMAE, thio-DMAE, AC or TMAO. The fact that
peak 2 occurs with AB in the samples could suggest that its presence is a result of the consumption of
seafood. In addition this study has shown that these two compounds occur in urine samples collected
from normal and abnormal sources, they have not been observed in the same urine sample and that
there may be a suggestion that thio-DMA is a breakdown product of dithio-DMA. The identification
of these new arsenicals is extremely challenging for a combination of factors; there is a lack of
available compounds; the sensitivity of organic mass spectrometric techniques used for the molecular
identification of arsenic compounds and the overall knowledge of arsenic processes. Nevertheless, it is
hoped that this study will inform and contribute to the continued research in oxo- and thioarsenicals
in human urine samples.
Supplementary Materials: The following are available online at www.mdpi.com/2305-6304/5/2/12/s1,
Figure S1: Structures of inorganic arsenic, methylated metabolites, oxo- and thio- dimethylated analogues
and dietary arsenic compounds. The structures in blue indicate the seven arsenicals investigated in this study,
Figure S2: Chromatograms of seven additional arsenic species and their retention times analysed using an ESI
OneFAST system coupled to a Dionex AG7 anion exchange column and ICP-MS using mobile phases 2 mM and
70 mM ammonium carbonate solution (A) the standard five arsenic species (B) DMAA, (C) DMAE, (D) thio-DMA,
(E) thio-DMAA (F) thio-DMAE (G) AC and (H) TMAO, Figure S3: Chromatograms of arsenic species analysed
using an ESI OneFAST system coupled to a Dionex AG7 anion exchange column and ICP-MS using mobile phases
2 mM and 70 mM ammonium carbonate solution. (A) A urine sample containing peak 2. (B) The urine sample
with 100% v/v H2O2 added. (C) A thio-DMAA standard spiked into ‘blank urine’ (only containing AB arsenic
species). (D) The spiked urine sample from chromatogram C with 50% v/v H2O2 added. (E) DMAA standard
spiked into ‘blank urine’ (only containing AB arsenic species).
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Figure S1. Structures of inorganic arsenic, methylated metabolites, oxo- and thio- dimethylated 
analogues and dietary arsenic compounds. The structures in blue indicate the seven arsenicals 
investigated in this study. 
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Figure S2. Chromatograms of seven additional arsenic species and their retention times analysed 
using an ESI OneFAST system coupled to a Dionex AG7 anion exchange column and ICP-MS using 
mobile phases 2 mM and 70 mM ammonium carbonate solution (A) the standard five arsenic species 
(B) DMAA, (C) DMAE, (D) thio-DMA, (E) thio-DMAA (F) thio-DMAE (G) AC and (H) TMAO.
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Figure S3. Chromatograms of arsenic species analysed using an ESI OneFAST system coupled to a 
Dionex AG7 anion exchange column and ICP-MS using mobile phases 2 mM and 70 mM ammonium 
carbonate solution. (A) A urine sample containing peak 2. (B) The urine sample with 100 % v/v H2O2 
added. (C) A thio-DMAA standard spiked into ‘blank urine’ (only containing AB arsenic species). (D) 
The spiked urine sample from chromatogram C with 50 % v/v H2O2 added. (E) DMAA standard 
spiked into ‘blank urine’ (only containing AB arsenic species). 
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Additional Information 
The first paragraph of section 3.3 in Chapter 3 of this thesis states ͞EaƌlǇ iŶǀestigatioŶs 
using tandem mass spectrometry (not cited in the methodology) showed that when 
monitoring the protonated molecule[M + H]+ m/z 165 of arsenocholine (AC), no signal 
was observed at the retention time of an AC standard, when the urine sample 
containing approximately 2800 µgL
-1
 of peak ϭ ǁas iŶjeĐted iŶto the M“/M“͟. The 
methodology for this is as follows: 
Analysis was performed using a liquid chromatography tandem mass spectrometer 
(LC-MS/MS) (AB Sciex 3200, Warrington, UK). A 1 mg/L standard solution of AC was 
injected into the LC-MS by syringe infusion to identify the parent ion m/z 165 of AC. 
Using the automated software of the LC-MS, daughter ions m/z 165 and 105 were 
identified. A 0.1 mg/L AC standard and the urine sample containing peak 1 were 
injected separately into the LC-MS and analysed using the ion transition m/z 165/122 
and m/z 165/105. 
The two chromatograms shown in Figure 15, show that the retention time of the 0.1 
mg/L AC standard is 2.14 min whilst the retention time of the unknown in the urine 
sample is 2.56 min. In addition, the ratio of the ion transition m/z 165 to 122 and 105 
for the 0.1 mg/L AC standard is nearly 1:1, whereas for the unknown in the urine 
sample the second transition is approximately less than 20%. Therefore, AC was not 
thought to be the identity of the peak 1. 
102 
Figure 15 Comparative chromatograms showing the different retention times and ion transition ratios of a 0.1 mg/L standard 
of arsenocholine (top) and, a urine sample with unknown peak 1 (bottom). Ion transition ratios monitored were m/z 165/122 
and m/z 165/105.
103 
Chapter 4. 
Development of a Method for the 
Simultaneous Detection of Cr(III) and 
Cr(VI) in Exhaled Breath Condensate 
Samples using µLC-ICP-MS. 
E. Leese, J. Morton. P.H.E. Gardiner and V.A. Carolan. J. Anal. At. Spectrom., 2016,
31(4): 924-933. 
Published – Creative Commons Re-use Open Access Licence 
 http://pubs.rsc.org/en/content/articlelanding/2016/ja/c5ja00436e#!divAbstract 
Development of a method for the simultaneous
detection of Cr(III) and Cr(VI) in exhaled breath
condensate samples using mLC-ICP-MS
Elizabeth Leese,*ab Jackie Morton,a Philip H. E. Gardinerb and Vikki A. Carolanb
The method described in this study is a robust and sensitive method for the simultaneous determination of
trivalent and hexavalent chromium (Cr(III) and Cr(VI)) in an exhaled breath condensate (EBC) sample and
drinking water proﬁciency testing material sample. The method uses a hyphenated micro liquid
chromatography (mLC) system coupled to inductively coupled plasma mass spectrometry (ICP-MS). The
optimised method incorporates a pH adjusted EDTA complexation step to stabilise Cr(VI) and Cr(III).
Separation was achieved using an anion exchange micro-sized column. The limits of quantiﬁcation were
0.040 mg L1 and 0.013 mg L1 for Cr(III) and Cr(VI) respectively. EBC is the non-invasive collection of
condensate from cooled exhaled breath during regular tidal breathing. We propose that EBC may be
a suitable alternative biological matrix to give a more comprehensive picture of exposure to Cr(VI)
following an inhalation exposure. This study shows that water samples and EBC samples containing Cr(III)
and Cr(VI) can be stored in the fridge (4 C) for up to 6 weeks when they have been diluted 10 fold with
an EDTA solution, and that EBC samples must not be frozen after collection if the integrity of Cr(VI) is to
be maintained. This study has demonstrated a practical approach to collecting EBC samples from
workers potentially occupationally exposed to hexavalent chromium and that the integrity of the
chromium species will be maintained prior to analysis.
Introduction
Trivalent chromium is biologically important as an essential
element for humans, needed for glucose and lipid metabolism.1
Hexavalent chromium however is considered toxic and IARC
has classied it as a group 1 agent, dened as carcinogenic to
humans.2 Hexavalent chromium is known to cause lung and
nasal cancer as well as other health conditions such as skin
allergies, skin ulcerations, nasal perforations, respiratory
problems, kidney and liver damage.3 Trivalent chromium [+3,
Cr(III)] is the most common form of chromium, whilst hex-
avalent chromium [+6, Cr(VI)] is rarely found naturally in the
environment, therefore the majority of hexavalent chromium is
a product of industry and manufacturing.4
Chromium compounds are occupationally important in
many industries such as the production and welding of stain-
less steel including cutting and nishing, electroplating,
smelting, pigments and paints used in aerospace and maritime
industries, construction and those using pesticides and tanning
agents.4 Exposure to Cr(VI) and its compounds can occur by
ingestion or dermal exposure but in some industries the
inhalation of fumes and mists is most likely. Upon exposure to
Cr(VI), the body naturally reduces Cr(VI) to Cr(III)5,6 before it is
excreted in the urine, with studies suggesting occupational
exposure to chromium mainly via inhalation results in elimi-
nation half-lives of 7 hours and 15–30 days.7 Apart from in
bacterial cells, there is no evidence of humans or other bio-
logical systems having the ability to re-oxidise Cr(III) back to
Cr(VI).8 One approach to assessing occupational exposure uses
biological monitoring, involving the measurement of total
chromium (without diﬀerentiation of Cr(III) and Cr(VI)) in
a urine sample. Background unexposed reference ranges and
occupational guidance values for total chromium in urine have
been established in the UK,9 Germany10 and the US.11 Cr(VI) has
the ability to permeate cell membranes meaning Cr(VI) can also
be measured in red blood cells (RBC),12,13 determined as Cr(III).
Once inside RBCs Cr(VI) is rapidly reduced to Cr(III) as it binds
with haemoglobin and other proteins.6,12 Methods for the
separate measurements of Cr(III) and Cr(VI) have focused on the
assessment of environmental sources of exposure such as
natural water,14,15 drinking water,14,15 waste water16 and indus-
trial waste.17
Whilst the measurement of total chromium in urine is
a practical bio-monitoring approach, it does not give
a comprehensive picture of exposure. It is possible that an
alternative biological matrix to measure exposure to Cr(VI) for
those exposed through inhalation might be exhaled breath
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condensate (EBC). EBC is the non-invasive collection of
condensate from cooled exhaled breath during regular tidal
breathing. The collection of exhaled air will contain mostly
water vapour but also droplets of uid from the respiratory
tract,18 meaning EBC measurements will reect markers and
molecules from the mouth, tracheobronchial system and the
alveoli.19 EBC is reported to contain both volatile substances in
the gaseous phase along with low volatile and non-volatile
substances in droplets.20 The non-volatile substances will
include salts, proteins, lipids, and environmental contami-
nants.18–20 Because EBC is relatively free of the interfering
solutes found in other biological matrices it represents a suit-
able biological matrix for elemental analysis to assess inhala-
tion exposure to trace elements. Studies have already shown
that occupationally inhaled elements have been detected in EBC
for cobalt and tungsten,21,22 iron, nickel and total chromium,23,24
manganese25 and hexavalent chromium (using liquid/liquid
solvent extraction and analysis by electrothermal atomic
absorption spectrometry).26 There are currently no publications
for the simultaneous detection and determination of Cr(III) and
Cr(VI) in an EBC sample. Due to the diﬀerence in toxicities of
Cr(III) and Cr(VI) and the conversion from Cr(VI) to Cr(III) in the
human body aer exposure, it is important to measure both
species of chromium to enable amore comprehensive picture of
exposure assessment.
In order to measure Cr(III) and Cr(VI) it is necessary to
maintain the integrity of each species in the sample. The
stability of both trivalent and hexavalent chromium depends on
pH. In acidic solutions, trivalent chromium compounds mainly
exist as Cr(H2O)6
3+ and hydrolyse to a hydroxide in less acidic
and alkaline conditions. Hexavalent chromium compounds
exist either as a chromate (CrO4
2, HCrO4
, H2CrO4) or
dichromate (Cr2O7
2).3,27 In extremely acidic conditions only,
hexavalent chromium exists as H2CrO4; in these acidic condi-
tions hexavalent chromium is a potent oxidant, which aer
oxidising can also begin to reduce to trivalent chromium
compounds. In the pH range of 2–6 hexavalent chromium
compounds exist as HCrO4
 and HCr2O7
, with HCr2O7

reducing to Cr2O7
2 at concentrations higher than 102 M.
Above pH 6, hexavalent chromium only exists as CrO4
2.3,8,27,28
Due to this pH dependence and the fact that trivalent chro-
mium compounds are typically cationic in solution and hexa-
valent chromium compounds are typically anionic in solution,
speciation using ion exchange chromatography methodologies
is an analytical challenge. These challenges have resulted in
analysis either only determining Cr(VI) using colorimetric
analysis with diphenylcarbohydrazide (DPC)15 or by deter-
mining both Cr(VI) by anion chromatography and total chro-
mium to calculate Cr(III) by subtraction.14 Cr(III) and Cr(VI) have
been simultaneously determined by ICP-MS using reverse phase
chromatography combined with ion-pairing reagents.27,29 The
use of non-traditional HPLC chromatographic methods such as
solid phase extraction based fractionation,14,30,31 micro columns
(PTFE tubes lled with activated alumina)32–35 and short column
capillary electrophoresis36 with subsequent detection by AAS,
ICP-AES or ICP-MS have all been employed as simple tech-
niques to separate and determine Cr(III) and Cr(VI). Whilst all
these methods have their own advantages and disadvantages
(such as interferences, contamination, raised backgrounds,
unsuitable limits of detection and time consuming procedures),
it has meant that other research has focused on anion exchange
chromatography coupled to ICP-MS. Both Chen et al.37 and
Pantsar-Kallio and Manninen38 employed a dual column
approach to overcome the issue of the opposite charges of the
chromium species. Other authors overcame this ionic challenge
by using derivatisation, where Cr(III) is complexed with EDTA to
change the ionic charge from a cation to an anion complex,
enabling separation of the two chromium species using the
same sample injection on an anion exchange column.39,40
Suzuki and Serita41 were the rst to report this technique using
HPLC-AAS, with Chen et al.37 reporting that alternative com-
plexing agents such as diethylenetriaminepentaacetic acid
(DTPA) and 2,6-pyridinedicarboxylic acid (PDCA) were not as
eﬀective as EDTA. Other publications have reported the
successful speciation of Cr(III) and Cr(VI) using newly introduced
speciality anion columns with sulfonic and alkyl quaternary
ammonium functional groups which boast both anionic and
cationic properties, and have been employed by authors con-
cerned with species' integrity related to sample pre-
treatment.42–44
The initial aim of this study was to develop a speciation
method to simultaneously determine both Cr(III) and Cr(VI)
using a small anion exchange speciality column with cationic
capabilities using a OneFAST system coupled to an ICP-MS. The
method developed was then used to investigate the stability of
both chromium species in an EBC sample with the view to
establishing a viable technique to employ for workplace moni-
toring. The objective, being to establish a method to allow the
collection and analysis of EBC samples from workers who may
be occupationally exposed to hexavalent chromium.
Experimental
Reagents
Chromium speciation compounds potassium dichromate
(K2Cr2O7) and chromium(III) chloride (CrCl3) were obtained
from Fisher Scientic (Loughborough, UK). Ammonia solution
(NH3), UpA nitric acid and UpA hydrochloric acid was supplied
by Romil (UK). Butan-1-ol was from Fisher Scientic (Lough-
borough, UK).
All solutions were made using ultrapure deionised water
(18.2 MUhm cm) from a Millipore system (Merck Millipore,
Billerica,MA, USA). Single standard stock solutions of 1000mg L1
of Cr(III) and Cr(VI) were prepared fresh in water for each day of
analysis.
A commercially available prociency testing material (PTM)
from Sigma Aldrich (UK) for Cr(VI) in drinking water (Sample
WS13-4 Lot LRAA1427) was used to validate the method.
Manufacturer instructions suggest the PTM is diluted 100 fold
in water. However for this study the PTM was diluted 1000 fold
in water to more accurately reect the levels of Cr(VI) expected in
EBC samples. Previous studies that measured total chromium
in EBC24 or Cr(VI) only in EBC45 reported levels less than 10 mg
L1 and 5 mg L1 of chromium in EBC respectively.
This journal is © The Royal Society of Chemistry 2016 J. Anal. At. Spectrom., 2016, 31, 924–933 | 925
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Instrumentation
Separation was achieved using a hyphenated mLC system with
an ICP-MS (XSERIES 2, Thermo Fisher Scientic, Hemel
Hempstead, UK). The separation of Cr(III) and Cr(VI) was ach-
ieved using a 5 cm anion exchange guard column, (Dionex
IONPAC AG7 4 mm  50 mm i.d., 10 mm, Thermo Fisher
Scientic). The Dionex AG7 anion exchange column has
cationic exchange capability due to the presence of sulfonic and
alkyl quaternary ammonium functional groups, and is suitable
for a full pH range of 0–14. The micro-ow delivery of both
sample and mobile phase was accomplished using an ESI
OneFAST system (Elemental Scientic, Warrington, UK), with
a six port switching valve and 500 mL sample loop. The ICP-MS
was operated in collision cell (CCT) mode using 7% hydrogen in
helium (approximately 3.5 mL min1). The ICP-MS conditions
were optimised daily using a 10 mg L1 tuning solution con-
taining arsenic, chromium, cobalt, indium and uranium (made
in 1% (v/v) nitric acid from 1000 mg L1 stock standards (ICP-
MS standards, BDH, Poole, UK)). Table 1 summarises the ICP-
MS and OneFAST operating conditions.
Exhaled breath condensate collection
EBC was collected using a portable TURBO-DECCS condenser
(Transportable Unit for Research on Biomarkers Obtained from
Disposable Exhaled Condensate Collection Systems) from Ital-
Chill (Parma, Italy). This technique consists of a disposable
respiratory system comprising of a mouthpiece connected to
a one-way aspiration valve and saliva trap with an EBC sample
collection tube at the end inserted into a temperature controlled
chilling unit set at 5 C (see Fig. 1). The collection of exhaled
air results in low sample volumes of EBC; 15 minutes of regular
tidal breathing will typically provide less than 2 mL of EBC
sample. It was necessary to collect large volumes of EBC from
a volunteer not occupationally exposed to hexavalent chromium
for use in method development as a blank sample and for
recovery. In addition to the volunteer supplying the bulk EBC,
ve further volunteers supplied EBC samples for the optimised
method applications. Blank EBC was collected from the volun-
teer by regular tidal breathing through the mouth piece of the
TURBO-DECCS. For the most part a complete seal around the
mouthpiece with the mouth is maintained allowing periodic
swallowing of any accumulated saliva.
Method development
See Fig. 2 for a ow chart outlining the six stages of the method
development.
Sample storage experiment
1. Standards made in water. Individual chromium species
standards of Cr(III) and Cr(VI), along with a mixed species
standard, at a concentration of 5 mg L1 were prepared in water.
Four aliquots of each of the three standards were pipetted into
individual sample tubes. The rst set of aliquots was analysed
by mLC-ICP-MS immediately aer preparation; the remaining
sets were capped and one of each standard was stored in the
freezer (20 C), the fridge (4 C) and at laboratory room
temperature (22 C) for 24 hours. Aer 24 hours storage each
aliquot was removed from their respective storage conditions,
placed on a roller mixer and le to reach room temperature.
Aer reaching room temperature each aliquot was analysed by
mLC-ICP-MS.
2. Derivatisation by complexation of Cr(III) with EDTA. A
solution of 0.5 mM EDTA was made in water and used to
prepare a 5 mg L1 Cr(III) standard. The standard was analysed
immediately and again in 1 hour aer being le to stand at
room temperature.
Table 1 Operating conditions of the ICP-MS and OneFAST system
XSERIES2 ICP-MS Settings Parameters
RF power 1400 W
Nebuliser gas ow 0.89–0.90 L min1
Sample/skimmer cones Ni/Ni Xt cones
Collision gas 7% He+H2 ow rate 3.5 mL min
1
Isotope monitored 52Cr
Dwell time 100 ms
mLC conditions Parameters
Analytical column Dionex IONPAC AG7 (4 mm
 50 mm, 10 mm)
Mobile phase 4% v/v ammonia solution &
3.2% v/v nitric acid, pH
1.8–2
Sample injection time 30 s
Flow rate 1 mL min1
Total acquisition time 230 s
Sample loop 500 mL
Peristaltic pump tubing Green/orange 0.38 mm
ESI switching valve P6 – 6 port
Valve to column connector 0.25 ID (green)
Column to ICP-MS nebuliser 0.5 ID (orange)
Nebuliser PFA-ST
Fig. 1 TURBO-DECCS condenser consisting of a disposable respira-
tory system comprising of a mouthpiece connected to a one-way
aspiration valve and saliva trap with an EBC sample collection tube
at the end inserted into a temperature controlled chilling unit set at
5 C.
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3. Eﬀect of pH on the EDTA–Cr(III) complex and Cr(VI). In
a preparation of 0.5 mM EDTA in water, the pH is 5. Six solu-
tions of 0.5 mM EDTA were prepared; ve of those solutions
were adjusted to achieve six diﬀerent pH readings; pH 4, 5, 7,
7.6, 8 and 9. 10% v/v nitric acid was used to adjust to pH 4
and 10% v/v ammonia solution was used to adjust to pH 7, 7.6, 8
and 9.
4. Concentration of EDTA. To investigate the inuence of
the concentration of the EDTA solution on either retention time
of the chromium species or peak shape a 5 mg L1mixed species
standard was prepared in 0.5 mM, 0.6 mM and 0.7 mM EDTA
solutions. Each solution was adjusted to pH 8 using 10% v/v
ammonia solution, and le to stand at room temperature for
1 hour prior to analysis.
5. Storage stability of EBC samples. Two solutions of
0.5 mM EDTA were prepared and adjusted to pH 7.6 and pH 8
using 10% v/v ammonia solution. Two equal volumes of “blank”
EBC were spiked with 5 mg L1 Cr(III) and 5 mg L1 Cr(VI). Each of
Fig. 2 Flow chart showing optimisation stages of the method development.
Fig. 3 Chromatograms of 5 mg L1 single standards of Cr(VI) and Cr(III) analysed using an ESI OneFAST system coupled to a Dionex AG7 anion
exchange column and ICP-MS using a nitric acid and ammonia mixed mobile phase. (A1–A4) Chromatograms of Cr(III). (B1–B4) Chromatograms
of Cr(VI). (A1 & B1) Chromium species stored at laboratory room temperature (22 C). (A2 & B2) Chromium species stored at fridge temperature
(4 C). (A3 & B3) Chromium species stored at freezer temperature (20 C) for 24 hour. (A4) Baseline of chromatogram (A2) showing Cr(III)
intermediate compound. (B4) Baseline of chromatogram (B3) showing the unknown chromium intermediate compound.
Fig. 4 Chromatograms of a 5 mg L1 Cr(III) standard prepared in 0.5
mM EDTA analysed using an ESI OneFAST system coupled to a Dionex
AG7 anion exchange column and ICP-MS using a nitric acid and
ammonia mixed mobile phase. (A) Analysed immediately after prepa-
ration. (B) Analysed after being left to stand for 1 hour.
This journal is © The Royal Society of Chemistry 2016 J. Anal. At. Spectrom., 2016, 31, 924–933 | 927
Paper JAAS
O
p
en
 A
cc
es
s 
A
rt
ic
le
. 
P
u
b
li
sh
ed
 o
n
 0
8
 F
eb
ru
ar
y
 2
0
1
6
. 
D
o
w
n
lo
ad
ed
 o
n
 2
4
/0
1
/2
0
1
7
 1
4
:0
3
:5
7
. 
 T
h
is
 a
rt
ic
le
 i
s 
li
ce
n
se
d
 u
n
d
er
 a
 C
re
at
iv
e 
C
o
m
m
o
n
s 
A
tt
ri
b
u
ti
o
n
-N
o
n
C
o
m
m
er
ci
al
 3
.0
 U
n
p
o
rt
ed
 L
ic
en
ce
.
View Article Online
Fig. 5 Chromatograms showing the eﬀect of pH of the EDTA solution to successfully complex and stabilise Cr(III), analysed using an ESI OneFAST
system coupled to a Dionex AG7 anion exchange column and ICP-MS using a nitric acid and ammonia mixed mobile phase.
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the two spiked concentrations of EBC and a “blank” unspiked
EBC sample were aliquoted in triplicate for four sets of samples,
and then each diluted 10 fold with the pH 7.6 solution of
0.5 mM EDTA. Four further sets of these three samples were
prepared and diluted 10 fold with the pH 8 solution of 0.5 mM
EDTA. All samples were capped and le to stand at room
temperature for 1 hour. One of the four sets of samples of each
pH were analysed by mLC-ICP-MS. The remaining sets were
stored in the fridge (4 C), and analysed at 1 week, 4 weeks and
6 weeks.
6. Optimised method. Separation of Cr(III) and Cr(VI) was
achieved using a Dionex AG7 column and an isocratic ow of
ammonia solution and nitric acid mobile phase. The mobile
phase was prepared daily in ultrapure deionised water, by
adding 4% v/v ammonia solution and 3.2% v/v ultrapure nitric
acid. The pH was adjusted to between pH 1.8–2 using the
ammonia solution. The ow rate of both the mobile phase and
sample injection onto the column is controlled by the ICP-MS
peristaltic pump at a constant 1 mL min1. The sample is
injected onto the column for 30 seconds and overall sample
acquisition time is 230 seconds.
The optimised method incorporates a derivatisation step,
with a 10 fold dilution of the EDTA solution (at a concentration
of 0.5 mM adjusted to pH 8 with 10% v/v ammonia solution)
with the EBC sample. From the 1000 mg L1 single standard
stock solutions of Cr(III) and Cr(VI) 100 mg L1 single and
mixed species working solutions were prepared daily. Using the
100 mg L1 mixed species working solution, calibration stan-
dards of 0.01, 0.02, 0.05, 0.1, 0.5, 1, 2 and 5 mg L1were prepared
in the 0.5 mM EDTA solution using a 10 fold dilution to 50 mL.
Blank and spiked EBC samples were diluted 10 fold with the
EDTA solution to 1.5 mL. The original 1 in 1000 preparation of
the prociency testing material to validate the method was
subsequently diluted 10 fold to 50 mL with the EDTA solution.
All samples including standards were le to stand at room
temperature for a minimum of 1 hour prior to analysis by
mLC-ICP-MS.
Results & discussion
Method development
Following initial work with the AG7 ion exchange column, the
simultaneous separation of Cr(III) and Cr(VI) was achieved in
spiked aqueous samples using an isocratic ow of 4% v/v
ammonia solution and 3.2% v/v ultrapure nitric acid, with pH
adjustment to between pH 1.8–2 using the ammonia solution.
1. Standards made in water. A spiked aqueous standard
was stored at various temperatures for 24 hours prior to analysis
Fig. 6 Chromatograms showing the eﬀect of pH of the EDTA solution on Cr(VI) analysed using an ESI OneFAST system coupled to a Dionex AG7
anion exchange column and ICP-MS using a nitric acid and ammonia mixed mobile phase.
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to determine stability. The results (see Fig. 3) show that Cr(VI)
was stable when stored at both room temperature and refrig-
erated, but species instability and conversion of Cr(VI) to an
unknown intermediate chromium species (chromatograms B3
and B4 of Fig. 3) with the same retention time as the Cr(III)
intermediate was observed when stored frozen at 20 C.
Instability of Cr(III) was observed in all storage conditions (see
Fig. 3). The pH of water standards is neutral, so it is possible
that the unknown Cr(III) intermediate observed in chromato-
grams (A3) and (A4) of Fig. 3 is a result of the incomplete
hydrolysis or dissociation of the trivalent chromium compound
Cr(H2O)6
3+ to Cr(OH)2+, Cr(OH)2
+ or Cr(OH)3. Publications
concerned with the determination of trace elements in EBC,
specify that samples of EBC were frozen at 80 C aer collec-
tion.20,21,24,25,46 Initial observations of freezing a spiked aqueous
standard of chromium Cr(III) and Cr(VI) at 80 C showed the
same pattern of conversion to intermediate species as the
aqueous standard stored at20 C for 24 hours. If Cr(VI) cannot
be successfully stored frozen, chromium speciation samples
would need to be stored under refrigeration. Cr(III) cannot be
successfully stored at any temperature so the complexation with
EDTA is needed for stability.
2. Derivatisation by complexation of Cr(III) with EDTA. The
rst thing to note is that by complexing Cr(III) with EDTA the
elution order of the two chromium species changes. EDTA does
not form a complex with Cr(VI). Without complexation, Cr(III)
elutes aer Cr(VI) with a retention time of approximately 4.5
minutes. Cr(III) in solution exists in the form of a cationic
hydroxy complex and is retained on the sulfonated region of the
column whilst the Cr(VI) ions are retained on the alkyl quater-
nary ammonium region. However aer complexation the
EDTA–Cr(III) complex elutes rst with a retention time of just
over 1 minute in the nal optimised method, indicating the
anionic EDTA–Cr(III) ions are no longer retained by the column.
The chromatograms in Fig. 4 show that the complexation
reaction of Cr(III) with the EDTA solution was not instantaneous
but achieved near full complexation aer one hour at room
temperature prior to analysis. In many of the studies published
where EDTA complexation was used to stabilise or change the
charge of Cr(III), concentrations lower than 0.5 mM EDTA were
used and heat was also used for the derivatisation reaction to
occur. Both Suzuki & Serita41 and Byrdy et al.39 heated the
samples in a heat block for 1 hour at 50 C; Gurleyuk & Wall-
schlager40 heated their samples for 1 hour at 70 C and Leist
et al.47 heated for 1.5 hours at 70 C. This approach would not be
practical aer the collection of EBC samples from workers at
a place of work, and samples may not be delivered to the
laboratory for 24 hours, meaning immediate heating of samples
aer collection in a heat block is not a viable option. However,
Wolf et al.27 found that the complexation reaction was fully
achieved with 0.5 mM of EDTA when the samples were le to
stand at room temperature for 30 minutes prior to analysis;
having adjusted the pH of the EDTA solution to pH 7.6. The pH
of the EDTA solution used in this study without any adjustment
was pH 5, which may explain why the complexation reaction
shown in chromatogram B of Fig. 4 was not 100% eﬀective.
3. Eﬀect of pH on the EDTA–Cr(III) complex and Cr(VI).
Having undertaken the experiment outlined in Section 2 of the
method development – Derivatisation by complexation of Cr(III)
with EDTA, it was necessary to determine the eﬀect of pH on the
ability of EDTA to successfully complex Cr(III). It can be seen in
Fig. 5 that EDTA at pH 4, 5 and 7 did not fully complex and
Fig. 7 Chromatograms of two Cr(VI) spiked EBC samples, stored at fridge temperature (4 C) for 6 weeks prior to analysis using an ESI OneFAST
system coupled to a Dionex AG7 anion exchange column and ICP-MS using a nitric acid and ammonia mixed mobile phase. (A) EDTA pH 7.6. (B)
EDTA pH 8.
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stabilise Cr(III), meaning the elution of Cr(III) resulted in two
peaks, whereas EDTA at pH 7.6, 8 and 9 show full complexation
of Cr(III). The retention time of the EDTA–Cr(III) complex is the
same throughout the pH range, however pH does aﬀect the
eﬃciency of complexation. The pH of the EDTA solution in the
study reported by Wolf et al.27 is within a range of pH 7.2–7.6.
Single standards of 5 mg L1 Cr(VI) were prepared in the three
pH solutions of EDTA that achieved full complexation of Cr(III);
pH 7.6, 8 and 9. Fig. 6 shows that pH 7.6 and 8 had no eﬀect on
Cr(VI); however peak splitting was observed at pH 9.
4. Concentration of EDTA. As pH is an important factor in
the complexation of EDTA with Cr(III), it was necessary to
determine if the increased concentration of EDTA was also an
important factor. As both pH 7.6 and pH 8 have both shown to
be a suitable pH for the EDTA solution, pH 8 was selected for the
pH of the three diﬀerent concentrations of EDTA solutions. The
varying concentrations of 0.5, 0.6 and 0.7 mM EDTA solution at
pH 8 made no diﬀerence to the retention, sensitivity or peak
shape of either chromium species (data not shown).
5. Storage stability of EBC samples. Having developed the
chromium speciation method, storage stability studies of Cr(III)
and Cr(VI) in EBC samples were undertaken. Analysis of EBC
spiked with single standards of Cr(III) and Cr(VI) at a concentra-
tion of 5 mg L1 diluted 1 in 10 with a 0.5 mM EDTA solution of
either pH 7.6 or pH 8 showed that the EBC EDTA–Cr(III) complex
was stable with no sign of deterioration or species conversion
for the entire 6 week period at both pH values. The Cr(VI) sample
was also stable for the 6 week storage period when the Cr(VI)
Fig. 8 Linear calibration curves of 0–5 mg L1 for both EDTA–Cr(III) and Cr(VI) using an ESI OneFAST system coupled to a Dionex AG7 anion
exchange column and ICP-MS using a nitric acid and ammoniamixedmobile phase. (A) Blank EBC sample. (B) A 2 mg L1 spiked blank EBC sample
with EDTA–Cr(III) and Cr(VI). (C) Commercially available proﬁciency testing material for Cr(VI) in drinking water.
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spiked EBC samples were diluted with the pH 8 solution of
EDTA. However the Cr(VI) spiked EBC samples that had been
diluted with the pH 7.6 EDTA solution showed signs of insta-
bility aer only 1 week of storage. At pH 7.6 the Cr(VI) spiked
EBC sample began to show a peak at the retention time of
EDTA–Cr(III) and this had increased in size when analysed at 4
weeks and again at 6 weeks showing a 6% recovery of EDTA–
Cr(III) in an EBC Cr(VI) only sample whereas the pH 8 solution
showed no EDTA–Cr(III) at 6 weeks (see Fig. 7). The pH of
undiluted EBC was seen to range from pH 6–6.5 and, although
the prepared EBC was diluted 1 in 10 with the EDTA solution
adjusted to pH 7.6, the nal pH of the dilution would be less
than pH 7.6. Wolf et al.27 determined that when the pH of their
EDTA/TBAOH solution was less than pH 7.4 more than 10% of
their Cr(VI) samples were present as HCrO4
 and when it
dropped to between pH 6 and pH 7 their Cr(VI) sample existed as
HCrO4
2. Either the EBC Cr(VI) sample here is slowly reducing
to Cr(III) in the neutral to acidic EDTA solution during storage or
it is slowly converting to a diﬀerent compound of Cr(VI) which
has the same retention time as EDTA–Cr(III). It is neither
appropriate nor practical to measure the pH of each person's
EBC sample and adjust accordingly when work place moni-
toring, so an EDTA solution at pH 8 was chosen to compensate
for any reduction in pH as a result of the EBC.
6. Optimised method. The chromatogram in Fig. 8 shows
that this optimised method achieves full separation of EDTA–
Cr(III) and Cr(VI) in 3 minutes (180 000 ms). The calibration
range used in this study was 0–5 mg L1 for both species of
chromium. The limit of detection (LOD) was calculated as three
times the standard deviation of the blank; this was 0.006 mg L1
and 0.002 mg L1 for Cr(III) and Cr(VI) respectively. The limit of
quantication (LOQ) was calculated as 10 times the mean
background equivalent concentration (BEC); this was 0.040 mg L1
and 0.013 mg L1 for Cr(III) and Cr(VI) respectively.
The “blank” EBC spiked at a concentration of 5 mg L1,
analysed on four separate occasions over the 6 week storage
period, gave an average recovery of 91%  0.13 for Cr(III) and
95%  0.02 for Cr(VI). The prociency testing material when
prepared 1 in 1000 for this study has a target value of 2.81 mg L1
and an acceptance range of 2.28–3.28 mg L1. The PTM sample
was analysed three times and gave an average within range
result of 2.65  0.03 mg L1 for Cr(VI).
Calibration standards, samples and quality control material
are diluted 10 fold with 0.5 mM EDTA solution adjusted to pH 8
with 10% v/v ammonia solution. These samples are le to stand
a minimum of 1 hour prior to analysis mLC-ICP-MS, and can be
stored refrigerated for up to 6 weeks.
The use of ICP-MS can result in spectroscopic interferences,
e.g.with polyatomic interferences 40Ar12C+ and 36Ar16O+ on 52Cr.
However the optimised use of the collision cell will avoid most
of these interferences. It is also possible that the sample matrix
could create additional interferences given that element such as
C, O and Cl are abundant in biological samples. The main
contributor to a potential high background signal intensity on
52Cr due to 40Ar12C+. Having injected a weak butanol solution
with and without the EBC matrix, no peak or increase in back-
ground signal intensity was observed. The main chlorine based
interference on 52Cr would be the 35Cl16O1H+. To investigate the
impact of a chloride interference on the chromium species
a weak solution of HCl was injected onto the column. Prior to
complexing Cr(III) with EDTA, Cl eluted before Cr(VI) and Cr(III).
However, aer complexing Cr(III) with EDTA and altering the
retention time, when a weak solution of HCl is injected onto
the column or added to ‘blank’ EBC, Cl and EDTA–Cr(III) elute at
the same time. However, unlike a urine sample, the chloride
content in EBC is negligible, as can be seen in the blank EBC in
Fig. 8a. Furthermore the recovery of the spiked sample for Cr(III)
in the stability study was 91% so no over recovery from an
interference is evident. To conrm the absence of a chloride
interference, two EBC samples were collected from ve volun-
teers who were not occupationally exposed to chromium. There
was no signicant peaks obtained at Cr(III) in fact both EDTA–
Cr(III) and Cr(VI) were less than the LOQ for all 10 EBC samples
analysed.
Conclusion
The method described in this study is a robust and sensitive
method for the simultaneous determination of Cr(III) and Cr(VI)
in an EBC sample. This speciation method has been validated
with spiked samples of blank EBC and a commercially available
drinking water prociency testing material sample for Cr(VI). It
has been demonstrated that water samples and EBC samples
containing Cr(III) and Cr(VI) can be stored in the fridge (4 C)
for up to 6 weeks when they have been diluted 10 fold with the
EDTA solution, and that EBC samples must not be frozen aer
collection if the integrity of Cr(VI) is to bemaintained. This study
has developed a practical approach to collecting EBC samples in
the workplace from workers who are potentially occupationally
exposed to hexavalent chromium and that the integrity of the
chromium species will be intact prior to analysis by mLC-ICP-
MS. The next stage of this study will be to undertake site visits to
collect EBC samples from chromium workers and apply the
methods developed here to these ‘real’ samples.
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a b s t r a c t
The analytical method outlined in this feasibility study has been used to show that trivalent chromium
(Cr(III)) and hexavalent chromium (Cr(VI)) can be detected and measured in exhaled breath condensate
(EBC) samples. EBC samples and urine sampleswere collected froma cohort of 58workers occupationally
exposed to hexavalent chromium compounds and 22 unexposed volunteers (control group). Levels of
Cr(III) and Cr(VI) were determined in EBC samples and total chromium levels were determined in urine
samples. Pre and post working week samples for both EBC and urine were collected in tandem. Total
chromium in urine samples was analysed by inductively coupled plasma mass spectrometry (ICP-MS).
Analysis of Cr(III) and Cr(VI) in EBC samples used a hyphenated micro liquid chromatography (LC)
system coupled to an ICP-MS. Separation was achieved using an anion exchange micro-sized column.
The results showed that the occupationally exposed workers had signiﬁcantly higher levels of Cr(III) and
Cr(VI) in their EBC samples than the control group, aswell as higher levels of total chromium in their urine
samples. However, for the exposed workers no signiﬁcant difference was found between pre and post
workingweek EBC samples for either Cr(III) or Cr(VI). This study has established that Cr(III) and Cr(VI) can
simultaneously be detected andmeasured in ‘real’ EBC samples andwill help in understanding inhalation
exposure.
Crown Copyright © 2016 Published by Elsevier GmbH. This is an open access article under the Open
Government License (OGL) (http://www.nationalarchives.gov.uk/doc/open-government-licence/
version/3/).
1. Introduction
In Great Britain (GB), many activities/occupations can involve
the use of chemicals considered hazardous to worker health. It
is important that exposure to chemicals which are classiﬁed as
carcinogens, mutagens and sensitisers be reduced to as low as
reasonably practicable as stated in legislation (Health & Safety
Executive (HSE), 2013a). Biological monitoring (the measurement
of a chemical or its breakdown products in a biological sample) is
Abbreviations: EBC, exhaled breath condensate; Cr(III), trivalent chromium;
Cr(VI), hexavalent chromium; ICP-MS, inductively coupled plasmamass spectrome-
try; LC, micro liquid chromatography; COSHH, control of substances hazardous to
health; ATSDR, agency for toxic substances and disease registry; IARC, international
agency for research on cancer; HSE, Health & Safety Executive; RBC, red blood cells;
HSL, Health and Safety Laboratory; BMGV, biological monitoring guidance value.
∗ Corresponding author at: Health & Safety Executive, Harpur Hill, Buxton SK17
9JN, UK.
E-mail address: Liz.leese@hsl.gsi.gov.uk (E. Leese).
one approach for assessing occupational exposure to a chemical in
the workplace.
Hexavalent chromium (Cr(VI)), which includes chromates,
dichromates and chromic acid is one such chemical that is clas-
siﬁed as both a sensitising agent and a carcinogen (Agency for
toxic substances and disease registry (ATSDR), 2012; International
agency for research on cancer (IARC), 2016)). Exposure to Cr(VI)
compounds in the workplace can be through inhalation directly
into the lungs from breathing in dust, fumes or mists; dermal
absorption through the skin by contact with chromium solutions
or solids; or by ingestion as a result of hand to mouth contamina-
tion from handling food, smoking or biting nails when hands are
contaminatedwith chromium dust or solutions. Exposure to Cr(VI)
compounds can cause respiratory irritations such as nosebleeds,
ulcers and holes in the nasal septum, inﬂammatory respiratory
problems, skin irritation and rashes from allergic dermatitis, upset
stomachs, kidney and liver damage along with lung and nasal can-
cer (ATSDR, 2012; HSE, 2013b; Rakhunde et al., 2012). The types
of industry and commercial processes where occupational expo-
http://dx.doi.org/10.1016/j.ijheh.2016.12.003
1438-4639/Crown Copyright © 2016 Published by Elsevier GmbH. This is an open access article under the Open Government License (OGL) (http://www.nationalarchives.
gov.uk/doc/open-government-licence/version/3/).
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sure to Cr(VI) compounds might occur are chromate production,
productionof chromatepigments anddyes, electroplating and ano-
dising, the production of stainless steel and other chromium alloys,
the cutting, ﬁnishing andwelding of chromium alloys and stainless
steel, leather tanning and the production and spraying of paints
used in the aeronautic and maritime industries (Genovese et al.,
2015; HSE, 2013b; Rakhunde et al., 2012).
Exposure to Cr(VI) compounds leads to accumulation in vari-
ous tissues such as the lungs, liver and kidneys (Genovese et al.,
2015), with glutathione and ascorbate being responsible for reduc-
tion of Cr(VI) to trivalent chromium (Cr(III)) within cells with the
aid of cysteine (De Flora et al., 1989; Paustenbach et al., 2003).
Cr(III) is an essential element as it is needed for the regulation and
metabolism of glucose, sugars and fats (Genovese et al., 2015) and
thus is considered non-toxic. This difference in toxicity between
the two chromium species is largely related to their permeability
into cells. Although Cr(III) is more reactive than Cr(VI) (e.g. bind-
ing to DNA), Cr(III) is unable to permeate cell membranes, Cr(VI)
however is easily taken up by cells; where it undergoes sequen-
tial reduction from Cr(V) to Cr(IV) and ﬁnally Cr(III) (De Flora et al.,
1989; Hoet, 2005). Although exposure to Cr(VI) can be measured
in red blood cells (RBC) determined as Cr(III), reduction of Cr(VI)
to Cr(III) primarily occurs in plasma, reducing the uptake of Cr(VI)
into RBC (Hoet, 2005). For the purposes of biological monitoring
for exposure assessment, a urine sample iswidely accepted, largely
due to it being less invasive and easier to collect than a blood sam-
ple. All detectable chromium in a urine sample will be in the form
of Cr(III) (De Flora, 2000) and although this is not an ideal approach
to Cr(VI) exposure assessment, it is a practical one andwidely used.
A background unexposed reference range of <2.9mol/mol crea-
tinine (Morton et al., 2014) has been established by HSE’s, Health
and Safety Laboratory, and a Biological Monitoring Guidance Value
(BMGV) of 10mol/mol creatinine has been determined, based on
a Health & Safety Executive (HSE) study where the 90th percentile
was adopted from workplaces deemed to have good control (HSE,
2011). Urinary chromium levels can reﬂect both past and recent
exposure, with daily accumulation through the working week of
the occupationally exposed (Hoet, 2005). Studies have suggested
the excretion of chromium in urine after exposure by inhalation
as a two or three stage process (Hoet, 2005; Petersen et al., 2000),
witheliminationhalf-livesof 7h, 15–30days and3–5years (ATSDR,
2012; Hoet, 2005).
The main route of exposure to hexavalent chromium is by
inhalation (De Flora, 2000; Hoet, 2005) so a suitable biologi-
cal matrix to represent exposure by inhalation to hexavalent
chromium compounds might be exhaled breath condensate (EBC).
After an inhalation exposure of chromium into the lungs, it is
partially removed by mucociliary clearance, but some is known
to remain (Hoet, 2005). The exact bioavailability of respirable
chromium is not known, however animal studies have shown that
53–85% of respirable Cr(VI) is cleared from the lungs by absorption
into the blood stream or by mucociliary clearance in comparison
to only 5–30% of respirable Cr(III), with the rest remaining in the
lungs (ATSDR, 2012). The collection and measurement of EBC is a
promising technique primarily due to its non-invasiveness and the
lack of interfering solutes found in other biological matrices. EBC
is the collection of condensate from cooled exhaled breath during
regular tidal breathing. This collected exhaled air contains mostly
water vapour but also droplets of ﬂuid from the respiratory tract
(Corradi and Mutti, 2005), meaning EBCmeasurements will reﬂect
markers and molecules found in the mouth, tracheobronchial sys-
tem and the alveoli (Kharitonov and Barnes, 2001). EBC is reported
to contain both volatile substances in the gaseous phase alongwith
low volatile and non-volatile substances in the form of droplets
originating from the epithelial lining ﬂuid, as aerosol particles
in EBC (Rosias, 2012). The non-volatile substances will include
salts, proteins, lipids and environmental and/or occupational
contaminants (Corradi and Mutti, 2005; Goldoni et al., 2013;
Kharitonov and Barnes, 2001).
There are only a small number of studies concerning the rela-
tionship between EBC measurements and occupational exposure,
where detectable levels of metals in EBC have been reported such
as; for cobalt and tungsten (Broding et al., 2009; Goldoni et al.,
2004), beryllium (Hulo et al., 2016), manganese (Hulo et al., 2014),
lead (Felix et al., 2015) and iron, nickel, aluminium and chromium
(Caglieri et al., 2006; Goldoni et al., 2010; Goldoni et al., 2006; Gube
et al., 2010; Hoffmeyer et al., 2011). To date there are only two
published studies where Cr(VI) was measured in EBC samples of
workers (Goldoni et al., 2010; Goldoni et al., 2006), however both
used a method combining solvent extraction with complexation
with diphenylcarbazide and measurement performed by atomic
absorption spectrometry. There are no publications measuring
Cr(VI) by inductively coupled plasma – mass spectrometry (ICP-
MS) and there are no publications reporting the measurement of
Cr(III) in EBC samples of workers or background populations.
Wehavepreviouslyvalidatedandpublishedournovel analytical
methodology inwhich the two chromiumspecieswere determined
in EBC samples (Leese et al., 2016). The objective of this feasibility
study was to determine if both Cr(III) and Cr(VI) could be detected
and measured in ‘real’ EBC samples. Having collected samples the
aimwas to determine whether there was a difference between the
levels of Cr(III) and Cr(VI) found in EBC samples between a control
group not occupationally exposed to chromium compounds and
an occupational group who are potentially occupationally exposed
to Cr(VI) compounds by inhalation. In addition, any difference in
chromium EBC levels would be investigated between pre and post
working week samples from the occupationally exposed volun-
teers.
2. Experimental
2.1. Study group
The occupationally exposed group (n=58) consisted of 53males
and 5 females, all were over the age of 18 years, with a mean age
of 45 years. Individuals volunteered in response to an email sent to
companies who had previously sent urine samples to the Health
& Safety Laboratory for chromium analysis as part of a biologi-
calmonitoring program. The occupationally exposedworkerswere
categorised into three types ofworkers and termedCr(VI)Workers,
Non-Cr(VI) Workers and Other Workers;
Cr(VI) Workers– Individualswhoworkdirectlywith chromium
compounds (e.g. Cr(VI) platers, jiggers and blenders).
Non-Cr(VI) Workers – Individuals who did not work directly
with chromium compounds, but worked alongside colleagues
working directly with chromium (e.g. nickel, silver or copper elec-
troplaters, maintenance).
Other Workers – Individualswhowork neitherwith chromium
nor alongside chromium workers (e.g. inspectors, administration
staff, and managers).
Table 1 shows all the types of occupations detailed by the occu-
pationally exposed workers and in which of the three worker
categories they were placed in this study.
The volunteers in the control group (n=22) consisted of 16
males and 6 females, who were not occupationally exposed to
Cr(VI) compounds. All were over the age of 18 years, with a mean
age of 39 years. Individuals volunteered in response to an email
request outlining the study, sent to staff at the Health & Safety
Laboratory.
The studywas approved by the NHS Research Ethics Committee
London – Camden & Islington, REC number 14/LO/1273. All partici-
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Table 1
Types of occupational or workplace role listed on the questionnaire by all individual
volunteers potentially exposed to occupational Cr(VI) compounds.
Cr(VI) Workers
Chrome electroplater
Grinder
Plasma cutter
Blenders (chemical production of powders, liquids or solids)
Anodiser
Jigger
Passivater
Polisher
Non-Cr(VI) Workers (not working directly with chromium)
General area duties
Silver electroplating
Nickel electroplater & electroless-plater
Copper plater
Zinc plater
Tin plater
Lab analyst
Other Workers
Production Team Leader
Inspector
Manager
Ofﬁce worker
Supervisor
pating volunteers gave informed consent, and were provided with
a participant information sheet. Volunteer information was col-
lected via a questionnaire. Information collected included: gender,
age and smoking status, and for the occupationally exposed group
only; tasks and duties undertaken since providing the pre working
week sample. Because this is a feasibility study only, information
on length of employment status and instances of work related ill
health were not obtained.
For the occupationally exposed workers, workplace site visits
were conducted by the authors to collect both a urine and EBC
sample from each volunteer on a Monday morning at the start of
shift (pre working week) and again on a Thursday afternoon (post
working week).
For the control group, urine samples and EBC samples were col-
lected onsite at the Health and Safety Laboratory. Urine and EBC
samples were collected from each control volunteer at the begin-
ning of the week and again at the end of the working week as was
done for the occupationally exposed group.
2.2. Instrumentation
All sample analysis was undertaken using inductively coupled
plasma – mass spectrometry (ICP-MS). Both total chromium in
urine and chromium species Cr(III) and Cr(VI) in EBC samples were
determined using an XSERIES 2 ICP-MS (Thermo Fisher Scientiﬁc,
Hemel Hempstead, UK)monitoring 52Cr. For bothmethods the ICP-
MS was operated in collision cell (CCT) mode using 7% hydrogen in
helium, RF power 1400W, using Ni Xt skimmer and sample cones.
The ICP-MS conditions were optimised daily.
2.2.1. EBC samples – chromium speciation
Speciation analysiswas performed using a hyphenatedLC sys-
tem with the XSERIES2 ICP-MS. The separation of Cr(III) and Cr(VI)
was achieved using a 5 cm anion exchange column, (Dionex AG7
4mm×50mm i.d., 10m, Thermo Fisher Scientiﬁc, Hemel Hemp-
stead, UK). The delivery of both sample and mobile phase onto the
column was accomplished using an ESI OneFAST system (Elemen-
tal Scientiﬁc, Warrington, UK), with the ICP-MS peristaltic pump
controlling a constant ﬂow rate of 1mL/min, with a six port switch-
ing value and 500L sample loop. The operating conditions of the
LC-ICP-MS were: nebuliser gas ﬂow rate 0.86–0.96 L/min using a
PFA-ST nebuliser (Elemental Scientiﬁc, Warrington, UK), collision
gas ﬂow rate 3.4–3.7mL/min, dwell time of 100ms for 52Cr. The
speciﬁc conditions of the LC-ICP-MS method used in this study
and the optimised conditions for the collection, stability and anal-
ysis of Cr(III) andCr(VI) in EBChave been reported elsewhere (Leese
et al., 2016).
2.2.2. Urine samples – total chromium
Analysis was performed on the XSERIES2 ICP-MS using a
Burgener Miramist (Burgener Research Inc., Ontario, Canada)
nebuliser. Operating conditions were: nebuliser gas ﬂow rate
0.81–0.96 L/min, collision gas ﬂow rate 3.5mL/min, dwell times
were 100ms for 52Cr and 20ms for 72Ge (internal standard), with
100 sweeps per replicate and three replicates per sample.
2.3. Reagents
Potassium dichromate (K2Cr2O7) (analytical grade),
chromium(III) chloride (CrCl3)(laboratory grade) and EDTA
(diaminoethanetetracetic acid) were obtained from Fisher Sci-
entiﬁc (Loughborough, UK). SpA ammonia solution (NH3) and
UpA Nitric Acid were obtained from Romil (Cambridge, UK). BDH
ICP-MS single standards of 1000mg/L chromium and germanium
were obtained from VWR International (Lutterworth, UK).
All solutions were prepared fresh each day of analysis using
ultrapure deionised water (18.2Mhmcm) from a Millipore sys-
tem (Merck Millipore, Billerica, MA, USA).
2.4. Sample collection
All urine samples were collected in 25mL urine collection bot-
tles (Sterilin Ltd, Newport, UK). EBC samples were collected using
a TURBO-DECCS (Transportable Unit for Research on Biomarkers
Obtained fromDisposable Exhaled Condensate Collection Systems)
by ItalChill (Parma, Italy). The TURBO-DECCS technique is as previ-
ouslydescribed (Leese et al., 2016). Immediately after the collection
of each EBC sample an aliquot of EBC was diluted 10 fold with the
0.5mM EDTA (pH was adjusted to pH 8 using 10% v/v aqueous
ammonia solution) solution onsite by the authors. Urine and EBC
sampleswere returned to the laboratory on the day of collection by
the authors. Urine samples had creatinine content analysed upon
arrival by the Jaffe alkaline picratemethod (Cocker et al., 2011) on a
Pentra 400 spectrophotometer (Horiba UK Ltd, Northampton, UK).
Creatinine (a breakdown product of creatine phosphate in muscle,
which is usually produced at a constant rate by the body) allows
a urine sample to be normalised for hydration. Both urine sam-
ples and EBC samples were refrigerated at between 2 and 8 ◦C until
analysis.
2.5. Sample preparation and analysis
2.5.1. EBC samples – chromium speciation
A single mobile phase was prepared in water by adding 4%
v/v ammonia solution and 3.2% v/v ultrapure nitric acid pH was
adjusted to between pH 1.8–2 using the ammonia solution.
Exhaledbreath condensate sampleswere allowed to reach room
temperature andmixed on a roller mixer before analysis. The sam-
pleswere analysed in duplicate. For the calibration standards, stock
solutions of 1000mg/L of Cr(III) and Cr(VI) were prepared in water.
Using these 1000mg/L stock solutions a 100g/L mixed species
working solutionwas prepared inwater. Using the 100g/Lmixed
species working solution, standards of 0.01, 0.02, 0.05, 0.1, 0.5, 1
and 2g/L were prepared in the 0.5mM EDTA solution, giving a
linear calibration range up to 20g/L. Samples above the linear cal-
ibration range were diluted further with the 0.5mM EDTA solution
where necessary
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Acommercially availableproﬁciency testingmaterial (PTM)was
obtained from Sigma Aldrich (Dorset, UK) for Cr(VI) in drinking
water (sample 1045/PE1453, Lot LRAA1427). This PTM was within
date with a certiﬁed range. Whilst the manufacturer’s instructions
suggest the PTM is diluted 100 fold in water, for the purpose of
this study the PTM was diluted 1000 fold in water to more accu-
rately reﬂect the levels of total chromiumandCr(VI) in EBC samples
previously reported (Caglieri et al., 2006; Goldoni et al., 2010).
It was also necessary to collect a large volume of EBC from a vol-
unteer not occupationally exposed to Cr(VI) to create an EBC blank
sample and spike to use as an in-house quality control material.
Three equal volumes of “blank” EBC were spiked to create three
in-house controls: 2g/L Cr(III), 2g/L Cr(VI) and a mixed 2g/L
Cr(III) and Cr(VI) EBC sample.
Both the 1000 fold dilution of the PTM and the 2g/L in-house
spiked EBC samples were diluted 10 fold with 0.5mM EDTA solu-
tion for analysis and refrigerated at between 2 and 8 ◦C for up to 6
weeks between analyses, as per the storage stability study under-
taken by Leese et al. (2016). The PTM and the spiked EBC samples
were analysed at the beginning and the end of the analytical run as
well as every 10 samples.
2.5.2. Urine samples – total chromium
For total chromium analysis, a single standard stock solution of
1mg/L chromiumwas prepared inwater from the 1000mg/L single
standard. Using the 1mg/L stock solution, standards of 0.5, 2.5, 5,
10 and 20g/L were prepared in water, giving a linear calibration
up to 80g/L.
Urine samples were allowed to reach room temperature and
mixed on a roller mixer before analysis. Samples were diluted 20
fold and calibration standards 5 fold with a 1% v/v nitric acid solu-
tioncontaining10g/LGe internal standard, following theHealth&
Safety Laboratory UKAS accredited method for total chromium in
urine. The certiﬁed reference materials (CRMs) were Lyphocheck
urine metals control Level 1 (Lot 69161 & 69171) (Bio-RAD Lab-
oratories, Hemel Hempstead, UK) and Clinchek urine control for
trace elements Level 2 (Lot 122 & 432) (Recipe, Munich, Germany)
and were analysed like the urine samples at the beginning and the
end of each analytical run and after every 20 samples. In addition,
a 2g/L standard was analysed at the beginning and end of each
analytical run as well as every 10 samples to monitor drift within
the analysis.
3. Results
3.1. Analytical method & validation
3.1.1. EBC samples – chromium speciation
The method described in this study is a sensitive and robust
method for the determination of Cr(III) and Cr(VI) in EBC sam-
ples. The chromatograms in Fig. 1 show that this novel speciation
methodcan reproducibly separateCr(III) andCr(VI) inbothaqueous
standards and an EBC matrix within 2min 20 s (200,000ms).
Based upon the results of twenty two analyses of the determi-
nation of chromium species in EBC samples, the limit of detection
(LOD) and limit of quantiﬁcation (LOQ) have been established for
both Cr(III) and Cr(VI). The LOD were calculated as three times the
standard deviation of themean of the blank; thesewere 0.007g/L
and 0.002g/L for Cr(III) and Cr(VI) respectively. The LOQ were
calculated as ten times the background equivalent concentration
(BEC); these were 0.067g/L and 0.008g/L for Cr(III) and Cr(VI)
respectively. The results of the three in-house spiked EBC sam-
ples shown in Table 2 gave an average spiked recovery of 105%
for the EBC sample spiked only with 2g/L Cr(III); 98% for the EBC
sample spiked only with 2g/L Cr(VI), along with 99% and 95% for
the EBC sample spiked with both 2g/L Cr(III) and Cr(VI) respec-
tively. In each analysis the PTM for Cr(VI) inwater gave consistently
accurate results which were all within the acceptance range. As
shown in Table 2, no conversion of chromium specieswas observed
during analysis with the Cr(III) concentrations less than the LOQ
when measuring the PTM and EBC in-house sample spiked only
with 2g/L Cr(VI) (no Cr(III) should be present). The Cr(VI) con-
centration was also less than the LOQ when measuring the EBC
in-house sample spiked only with 2g/L Cr(III) (no Cr(VI) present).
3.1.2. Urine samples – total chromium
The determination of total chromium in urine is an established
UKAS accredited method at the Health and Safety Laboratory. The
LOD is 1nmol/L (0.05g/L) (uncorrected for creatinine). Both urine
CRMs, Biorad Level 1 and Clinchek level 2 are certiﬁed for total
chromium in urine; all gave good results within the target range,
this is shown in Table 2.
3.2. Study results
Of the 22 volunteers (16 males, 6 females) in the control group
only 1 (male) was a smoker, the remaining 21 volunteers were
non-smokers. Of the 58 volunteers (53 males, 5 females) in the
occupationally exposed worker group, 33 were non-smokers (3
female, 29male) and 25were smokers (1 female, 24male). Of these
58 workers, 35 were classiﬁed as Cr(VI) Workers, 12 as Non-Cr(VI)
Workers and 11 as Other Workers. Of the 35 Cr(VI) Workers only 1
volunteer was female, similarly of the 12 Non-Cr(VI) Workers only
1 volunteerwas female. Of the 11OtherWorkers 3 volunteerswere
female and 8 were male.
The EBC results for controls and workers are shown in Fig. 2
and presented in Table 3. The results for the EBC analysis from the
control group showed that 84% and 91% were below the LOQ for
Cr(III) and Cr(VI) respectively, compared with only 5% and 3% for
the occupationally exposed workers.
Fig. 2 and Table 3 show that the median values for Cr(III) in
EBC from the control group are below the LOQ. Furthermore all
Cr(III) found in EBC results from a Non-Cr(VI) worker or Other
Worker were above the LOQ. The median concentration of Cr(III)
in EBC samples for both pre and post working week of all 58 occu-
pationally exposed workers is very similar, with a median value
of 0.59g/L for pre working week and 0.54g/L for post working
week. The Cr(VI) Workers also showed similar median concentra-
tions of Cr(III) in EBC of 0.58g/L and 0.51g/L for pre and post
working week samples respectively. The Other Workers had the
highestmedianconcentrationsofCr(III) inEBCof0.70and0.66g/L
for pre and post working week samples. The Non-Cr(VI) Workers
gave the lowest median concentrations of pre and post working
week samples for Cr(III) in EBC of 0.38 and 0.54g/L respectively.
The maximum Cr(III) concentration measured was 11.02g/L and
was fromapostworkingweek EBC sample of a Cr(VI)Worker, com-
pared to themaximumCr(III) in EBC from aNon-Cr(VI)Worker and
an Other Worker both resulting from a pre working week sample,
of 9.1g/L and 2.97g/L respectively.
Fig. 2 and Table 3 show that the median values for Cr(VI) in EBC
from the control group are below the LOQ. As with Cr(III), there
were no Cr(VI) in EBC results from a Non-Cr(VI) worker or Other
Worker less than the LOQ. The results of Cr(VI) in EBC samples for
all 58 occupationally exposed workers showed a median concen-
tration increase from 0.58 to 0.72g/L of pre to post workingweek
samples. An increase in Cr(VI) EBC levels was observed between
thepre andpostworking samples for bothmedian (0.72–0.91g/L)
and 90th percentile concentrations (2.81–4.56g/L) for the Cr(VI)
Workers. This trend was also observed in the Non-Cr(VI) Workers
to a lesser extentwith a preworkingweekmedian concentration of
0.29g/L increasing to a post working weekmedian concentration
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Fig. 1. Chromatograms showing full separation of EDTA-Cr(III) and Cr(VI) using an ESI OneFAST system coupled to a Dionex AG7 anion exchange column and ICP-MS using a
nitric acid and ammonia mixed mobile phase. (A) Overlay of the individual standard calibration chromatograms of 0–2g/L calibration. (B) An in-house spiked EBC sample
2g/L mixed Cr(III) and Cr(VI). (C) An EBC sample from an occupationally exposed volunteer.
of0.44g/L.A two-fold increase from0.31g/L (preworkingweek)
to 0.62g/L (post working week) was observed in the median EBC
of the OtherWorkers. The OtherWorkers showed a higher median
and 90th percentile for both the pre and post working week Cr(VI)
in EBC samples than the Non-Cr(VI) Workers, but not the Cr(VI)
Workers. The maximum Cr(VI) concentration in EBC of 27.3g/L
was from the same Cr(VI)Worker’s post workingweek EBC sample
that contained the highest Cr(III) concentration in EBC. Similarly to
Cr(III) in EBC the highest level of Cr(VI) in both Non-Cr(VI)Workers
and Other Workers was from a pre working week sample, of 8.31
and 2.59g/L respectively.
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Table 2
Results obtained for the two species of chromium in the in house spiked EBC samples and the PTM samples and the urinary chromium CRM.
In-house spiked EBC (2g/L)
Cr(III) (n =58) (% recovery)
In-house spiked EBC (2g/L)
Cr(VI) (n =56) (% recovery)
In-house spiked EBC (2g/L) Cr(III)
& Cr(VI) mix (n=58) (% recovery)
PTM LRAA1427 (n=57)
Target range 2.28–3.28
Cr(III) EBC 2.09±0.3 (105%) <LOQ 1.98±0.26 (99%) <LOQ
Cr(VI) EBC <LOQ 1.95±0.16 (98%) 1.90±0.26 (95%) 2.63±0.17
Biorad Level 1–69161 (n=14)
Target range 0.359–0.995g/L
Biorad Level 1–69171 (n=35)
Target range 0.575–2.53g/L
Clinchek Level 2–122 (n=18)
Target range 16.2–24.4g/L
Clinchek Level 2–432 (n=31)
Target range 15.9–23.8g/L
Urinary total
chromium
0.82±0.09 0.90±0.16 18.9±1.20 18.6±0.75
All of the urinary total chromium results for the occupationally
exposed workers were above the limit of quantiﬁcation. As shown
in Fig. 3 all the urine samples from the control group were below
the HSL background unexposed reference range of <2.9mol/mol
creatinine.
Analysis of the urine samples from the occupationally exposed
workers showed; that 53% were below the background unex-
posed reference range, 31% were above the HSL UK background
unexposed reference range but below the BMGV of 10mol/mol
creatininewhilst 16% exceeded the BMGV. As shown in Table 3, the
median values for all 58 workers of the occupationally exposed
group showed a moderate increase in total chromium in urine
from 1.9 to 3.3mol/mol creatinine for pre to post working week
samples. However, the 90th percentile values showed over a 4-
fold increase from 3.1 to 13.7mol/mol creatinine for pre to post
working week samples. The increase of the median and 90th per-
centile from the pre working week samples to the post working
samples was also observed for all three categories of worker, with
a signiﬁcant increase observed in the 90th percentile for both
Cr(VI) Workers and Non-Cr(VI) Workers from pre to post work-
ing week samples. The highest urinary total chromium value was
found in a post working week sample of a Non-Cr(VI) Worker,
being 37.1mol/mol creatinine, compared to maximum value of
6.0mol/mol creatinine for an Other Worker. The highest urinary
total chromium value for both pre and post working week from a
Cr(VI) worker was 29.4 and 34.1mol/mol creatinine respectively
and came fromthe samevolunteer.However this volunteerwasnot
responsible for the highest Cr(III) and Cr(VI) levels found in EBC.
3.3. Statistical results
General statistical analysis was performed using Prism Graph-
pad Version 6 for Windows. Due to the skewness and distribution
fromnormality of the data, all the datawas log transformed. The log
of the data is normally distributed enabling parametric statistical
analysis. Results below the LOQ were replaced with half the LOQ.
Paired t-tests showed there was a signiﬁcant difference for total
chromium levels in urine betweenpre andpostworkingweek sam-
ples for all the occupationally exposedworkers (p =0.03). However
there was no signiﬁcant difference between pre and post working
week EBC samples for Cr(III) (p =0.63) or Cr(VI) (p=0.13). Unpaired
t-tests found there was a strong signiﬁcant difference between
workers and controls for total chromium in urine (p <0.0001), as
well as Cr(III) in EBC samples (p <0.0001) and Cr(VI) in EBC samples
(p <0.0001). As demonstrated in Fig. 4, no correlation was found
when comparing post working week levels of total chromium in
urine with Cr(III) in EBC (r2 =0.02, p =0.35), or post working week
levels of total chromium in urine samples with the sum of Cr(III)
and Cr(VI) in EBC samples (r2 =0.04, p =0.12). However, a weak
moderate correlation was observedwhen comparing post working
week levels of total chromium in urine with Cr(VI) in EBC samples
(r2 =0.11, p =0.01).
Statistical analysis was not performed for gender differences
because of the small proportion (9%) of females forming the occu-
pationally exposed group in this study. Therewas also no statistical
signiﬁcant difference observed between smokers and non-smokers
or between workers who wore facemasks/respiratory protective
equipment (RPE) and those who did not.
4. Discussion
Reported here are the determined chromium speciation results
of Cr(III) and Cr(VI) concentrations in EBC and total chromium
concentrations in urine from pre and post working week samples
collected from 58 occupationally exposed workers and 22 controls
not occupationally exposed to chromium.
The LOD and LOQ reported in this novel chromium speciation
study are very low, thus making this a suitable method for the
Table 3
Statistical summary of the mean, median and 90th percentile concentrations of pre working week (Pre W-Wk) and post working week (Post W-Wk) samples for Cr(III) and
Cr(VI) in EBC in g/L and total chromium in urine in mol/mol creatinine for both controls and workers.
Cr(III) in EBC g/L Cr(VI) in EBC g/L Total Cr in Urine mol/mol creatinine
Pre W-Wk Post W-Wk Pre W-Wk Post W-Wk Pre W-Wk Post W-Wk
All Workers:
n =58
Median
P90
Range
0.59
2.43
0.19–9.1
0.54
4.21
0.14–11.03
0.58
2.01
0.04–9.69
0.72
2.45
0.01–27.3
1.9
3.1
0.5–29.4
3.3
13.7
0.6–37.1
Cr(VI) Workers:
n =35
Median
P90
Range
0.58
2.15
<LOQ-3.38
0.51
2.98
<LOQ-11.02
0.72
2.81
<LOQ-9.69
0.91
4.56
<LOQ-27.3
3.4
14.8
0.6–29.4
4.7
20.4
1.1–34.1
Non Cr(VI)
Workers
n=12
Median
P90
Range
0.38
0.86
0.19–9.1
0.54
1.41
0.20–4.56
0.29
0.76
0.04–8.31
0.44
1.71
0.06–2.45
1.5
3.7
0.6–8.6
2.1
23.7
0.6–37.1
Other Workers
n=11
Median
P90
Range
0.70
2.2
0.27–2.97
0.66
2.05
0.14–2.21
0.31
2.01
0.03–2.59
0.62
1.84
0.01–2.20
1.2
1.6
0.5–5.1
1.5
2.7
0.8–6.0
Controls
n =22
Median
P90
Range
<LOQ
0.09
<LOQ–0.27
<LOQ
0.09
<LOQ–4.97
<LOQ
0.01
<LOQ–0.07
<LOQ
<LOQ
<LOQ-0.12
0.4
0.6
<LOQ-1.3
0.4
1.1
<LOQ-1.4
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Fig. 2. Scatter plots with median concentrations (g/L) from pre working week
(Pre W-Wk) to post working week (Post W-Wk) samples for (A) Cr(III) in EBC and
(B) Cr(VI) in EBC for both occupationally exposed volunteers and the unexposed
control group.
Fig. 3. Scatter plot showing the results of total chromium inurine (mol/mol creati-
nine) for both theoccupationally exposedworkers and the control group for bothpre
working week (Pre W-Wk) and post working week (Post W-Wk) samples. Showing
results in comparison to the background unexposed reference range and the BMGV.
Fig. 4. Correlations of log transformed data between post working week total
chromium in urine and; (A) Cr(III), (B)Cr(VI) and (C) the sum of Cr(III) and Cr(VI)
in post working week EBC samples.
analysis of EBC where median concentration of Cr(III) and Cr(VI)
were found to be less than 2g/L. No other studies have published
actual Cr(III) results in EBC samples, only Cr(VI) and total chromium
so there are no LOD/LOQ values to compare against. The Cr(VI)
LOD and LOQ reported here is lower than other reported stud-
ies (Goldoni et al., 2010; Goldoni et al., 2006). However, the LOD
and LOQ reported in this study are achieved using ICP-MS whilst
the LOD of 0.2g/L reported by Goldoni et al. (2010, 2006) uses
electrothermal atomic absorption spectrometry (ETAAS). Other
publications reporting chromium in EBC were for total chromium
only and the LODs reported were a limiting factor in their results
(Gube et al., 2010; Hoffmeyer et al., 2011).
The background unexposed reference range established by the
Health and Safety Laboratory, for total chromium in urine is
<2.9mol/mol creatinine (Mortonet al., 2014). For theurinary total
chromium results for exposed workers, 47% exceeded this value,
indicating that nearly half of the urine samples provided by the
58 workers showed some occupational exposure to Cr(VI) com-
pounds. Furthermore, 16% were above the BMGV of 10mol/mol
creatinine, indicating that 19 urine samples provided by the 58
workers showed signiﬁcant exposure to Cr(VI) compounds. This
exposure demonstrates that the occupationally exposed workers
who took part in this study were a suitable cohort to success-
fully meet the objective of this study and determine if Cr(III) and
Cr(VI) could be detected and measured in real EBC samples. As
shown in Table 3, the 90th percentile of urinary total chromium
for both Other Workers and the control group are within the back-
ground unexposed reference range, whereas the Cr(VI) Workers
and Non-Cr(VI) Workers is twice the BMGV of 10mol/mol creati-
nine, indicating a strong association with chromium occupational
exposure and urinary chromiummeasurements.
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It is important to note that the study outlined here was a pilot
feasibility study to ascertain if bothCr(III) andCr(VI) couldbedeter-
mined in EBC samples from workers occupationally exposed to
Cr(VI) compounds by inhalation. Consequently, no environmental
monitoring suchasairmonitoring, surfacewipesorhandwipesam-
pling was performed, nor was information taken regarding length
of time since last potential exposure or length of time and levels of
potential exposure fromanyof the occupationally exposedworkers
prior to providing a EBC or urine sample.
The statistical analysis found a lack of correlation between lev-
els of total chromium in urine with Cr(III) in EBC and levels of
total chromium in urine with the sum of Cr(VI) and Cr(III) in
EBC, however a low moderate correlation was found between lev-
els of total chromium in urine with Cr(VI) in EBC. This lack of
correlation is in agreement with other studies where no correla-
tion was found between total chromium in urine with Cr(VI) in
EBC (Goldoni et al., 2006) or with total chromium in urine com-
pared with total chromium in EBC (Caglieri et al., 2006; Goldoni
et al., 2010). However, this may be expected considering urinary
chromiumlevelswill reﬂect all three routesof exposure (inhalation,
dermal and ingestion); whereas EBC samples will reﬂect mainly
inhalation exposure with some contribution from what is present
in the mouth but not exposure by dermal absorption or ingestion.
Interestingly, Goldoni et al. (2010) found there was a signiﬁcant
correlation between total chromium in post shift EBC samples and
RBC samples only. This is not always the case, as better correlation
of urine with EBC samples has been observed for other elements
(Goldoni et al., 2004).
Whilst there is a lack of statistical signiﬁcance between the pre
andpostworkingweek samples for bothCr(III) andCr(VI) in EBC, all
the levels were higher than the controls. The data showed that 48%
of the occupationally exposed group showedan increase of the con-
centrations of Cr(III) in EBC from the pre to postworkweek sample,
and 59% showed an increase of the concentrations of Cr(VI) in EBC
from the pre to post working week sample. However, chromium
in lungs has shown to accumulate upon repeat inhalation (Hoet,
2005), something that is likely to happen in an occupational set-
ting. In addition, reduction of Cr(VI) to Cr(III) by glutathione was
found to be much slower than ascorbate leading to a longer res-
idence of chromium in lungs (Petersen et al., 2000), meaning the
higher levels of chromium in pre working week EBC samples may
be the result of high exposure the previous week. It must also be
noted that although both urine and EBC samples collected on the
Monday morning were considered pre working week, the workers
had already entered the work place. Although workers had been
instructed not to start ofﬁcial work that could result in inhalation
exposure (e.g. grindingor electroplating), theyhad startedprework
preparation, meaning some exposure may have already occurred
from chromium levels in the air of the workplace or from prepa-
ration procedures. This lack of correlation may also be related to
the combination of a high proportion of low g/L values for a sam-
ple size of only 58 occupationally exposed workers. In addition,
the lack of information regarding exposure of the workers prior
to providing the post working week EBC sample will be a con-
tributing factor. No statistically signiﬁcant difference was found
between smokers and non-smokers for Cr(III) or Cr(VI) in EBC or
total chromium in urine. Nor was there a statistical signiﬁcant dif-
ference found between those individuals that wore any type of
facemask/respiratory protective equipment (RPE) and those that
did not. However, this outcome is not unexpected when tandem
environmental analysis has not been performed and little informa-
tion is known on length of time since last exposure or length of
time the worker has experienced Cr(VI) exposure or the levels of
exposure. This uncertainty, along with the fact these comparisons
would reduce the dataset substantially, make it difﬁcult to com-
pare these more speciﬁc data groups and extrapolate any type of
signiﬁcance that would be statistically robust to investigate as to
whether wearing RPE or smoker status affected observed levels of
Cr(III) or Cr(VI) in EBC samples.
A similar study by Goldoni et al. (2006), determined Cr(VI)
in EBC samples from 10 chromium electroplaters; they looked
at overnight chromium decrease with EBC samples taken post
shift and again the following morning pre shift (15h since expo-
sure). A decrease in Cr(VI) levels from overnight post to pre shift
was observed, with concentrations of Cr(VI) found in EBC sam-
ples ranging from 0.1–2.9g/L for the post shift EBC samples and
0.1–2.1g/L for the pre shift EBC samples. However only 10 work-
ers were sampled and seven of the 20 EBC samples collected were
found to be below the LOD. The concentrations of Cr(VI) in EBC
reportedhere in the current studywerehigher,with overall (n =58)
concentrations of Cr(VI) inworkers ranging from0.04–9.69g/L for
the pre shift EBC samples and 0.01–27.35g/L for the post shift EBC
samples. A later study by Goldoni et al. (2010) reported a similar
study method but with tandem urine, red blood cell and plasma
sampling alongside the EBC sample collection. The median values
reported in this later study compare well with the results reported
here in this study. For example, median total chromium in urine
levels increased from4 to 6mol/mol creatinine in Goldoni’s study
compared to a median increase of 1.9–3.3mol/mol creatinine for
all workers and 3.4–4.7mol/mol creatinine for Cr(VI) Workers
reported here in this study. Additionally, in Goldoni’s studymedian
values for Cr(VI) in EBC samples increased from0.3 to 1.0g/L com-
pared to median values increasing from 0.58 to 0.72g/L for all
workers and 0.72–0.91g/L for Cr(VI) Workers reported here in
this study. The studies by Goldoni et al. (2006, 2010) in addition
to the work reported here indicate the need for a comprehensive
EBC collection protocol to better understand dwell, half-life and
excretion rates of chromium in EBC.
Also of interest is the two fold increase of 0.31g/L (preworking
week) to 0.62g/L (post working week) median levels of Cr(VI) in
EBC for the Other Workers. Although the median values are not
higher than the Cr(VI) Workers, they are higher than the median
values of the Non-Cr(VI) Workers, indicating inhalation exposure
is not limited solely to workers operating directly in areas of the
workplace where chromium processes occur. Chromium exposure
of OtherWorkers is more evident when themedian values for both
Cr(III) and Cr(VI) in EBC are compared against the control group
values, which were all below the LOQ, however there were only
11 volunteers in the Other Workers group. No other studies have
determined chromium EBC measurements in this type of worker
cohort for comparison.
In recent literature, there is reference to the need for a marker
in EBC samples to standardise for dilution (Kuban and Foret, 2013;
Rosias, 2012), in the same way creatinine is utilised to correct for
concentration of urine. It is suggested that the droplets of ﬂuid from
the respiratory tract can be diluted by the water vapour found in
EBC and will vary amongst individuals (Rosias, 2012). At present,
there is no consensus on a suitable and accurate biomarker to cor-
rect for dilution, as smoking status, inﬂammatory conditions such
as asthma or the inhaled contaminant itself have affected their use-
fulness in biomarkers studies (Dodig andCepelak, 2013;Hoffmeyer
et al., 2015). However Rosias (2012) and Reinhold and Knobloch
(2010) have suggested EBC results be expressed per volume of
EBC collected. Unfortunately, in this study neither approach was
explored. However, it is something that must be taken into consid-
eration in future EBC studies.
To enable the future of EBC as a biomarker for occupational
exposure to chromium species there needs to be an understanding
of the dwell time of chromium species detectable in an EBC sample
after exposure has ceased. In addition to a better understanding
of the relationship between levels of exposure and EBC measure-
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ments is essential. The latter could be achieved with correlation to
air measurements.
Previously known CRMs for either Cr(III) and/or Cr(VI) by NIST
and IRMM have either been discontinued or withdrawn. For the
future success of chromium speciation in EBC it is important that
CRMs in either water or EBC are made available. In addition, the
future of EBC as a biological matrix will rely on CRMs for other
trace elements.
5. Conclusion
This is the ﬁrst study to report the detection and measurement
of Cr(III) and Cr(VI) in ‘real’ exhaled breath condensate (EBC) sam-
ples of volunteers. The analyticalmethod outlined in this feasibility
study has shown that both Cr(III) and Cr(VI) can be simultaneously
detected andmeasured in EBC samples from a cohort of volunteers
whoareoccupationally exposed toCr(VI) compoundsby inhalation.
The occupationally exposed workers showed signiﬁcantly higher
levels of both Cr(III) and Cr(VI) than in the control group. However
no statistically signiﬁcant difference was found between pre and
postworkingweek samples for Cr(III) and Cr(VI) in EBC of the occu-
pationally exposed workers. The speciation method demonstrates
high sensitivitywith low limits of detection and quantiﬁcation. The
next stage of this studywill be to undertake site visits to performair
monitoring in tandemwith EBC sample collection to further under-
standand correlate the relationshipbetween levels of exposure and
EBC results for chromium.
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Abstract
Biological monitoring (BM) is a useful way of determining overall exposures to chemical substances; 
however, in the case of respirable crystalline silica (RCS), this has not been analytically feasible in 
conventional biological matrices. The aim of this study was to investigate the utility of exhaled breath 
condensate (EBC) as a potential biological matrix in which to determine exposure to RCS. A small 
pilot study was undertaken collecting EBC from six quarry workers and six occupationally unex-
posed persons; the samples were analysed using both single particle inductively coupled plasma 
mass spectrometry (spICP-MS) and transmission electron microscopy (TEM). The results showed 
that EBC obtained from the occupationally unexposed persons exhibited low background levels of 
dissolved silica whilst silica particles of various sizes were present in samples from quarry workers. 
This is the irst study to report EBC as a potential biological matrix that allows differentiation of RCS 
concentrations between samples from workers and occupationally unexposed controls. The results 
shown here conirm the presence of RCS in EBC by both spICP-MS and TEM. However, there are dif-
icult analytical challenges still to be overcome before this can be used as a BM method to determine 
workplace exposure, these are currently being investigated.
Keywords:  exhaled breath condensate; respirable crystalline silica; single particle ICP-MS; TEM and quarry workers
Introduction
The hazards and health outcomes of exposure to respirable 
crystalline silica (RCS) have been well reported. RCS has 
been classiied as a carcinogen when inhaled in its quartz 
or cristobalite forms by NIOSH (The National Institute for 
Occupational Safety and Health, 2016), the US National 
Toxicology Program (National Toxicology Program 2014), 
and IARC (Group1; IARC 2016). Occupational exposure 
to RCS induces distinctive lung toxicity in the form of sili-
cosis (a ibrotic pneumoconiosis), which is characterized 
by pulmonary oedema, interstitial inlammation, ibrotic 
granuloma, and silicotic nodules (Kawasaki 2015).
Biological effect markers of exposure, such as 
elevated levels of inflammatory cytokines, have been 
Annals of Work Exposures and Health, 2017, Vol. 61, No. 7 903
reported as result of exposure to RCS (Kawasaki 2015). 
The use of biological monitoring (BM) allows the assess-
ment of all routes of exposure and can subsequently help 
control and reduce exposures to a wide range of chemi-
cals. This is not the case with silica, until now the pos-
sibility of a direct BM marker of exposure has eluded 
researchers. This is as a consequence of the lack of solu-
bility and analytical sensitivity of silica and silicon using 
spectroscopic methods (resulting from interferences and 
inherent elevated background levels). Therefore, it has 
not been possible to use common BM matrices because 
of the relatively high concentrations of silicon in samples 
such as urine (Roberts and Williams, 1990; Kobayahsi 
et al., 1995; Widner et al., 1998) making it dificult to 
differentiate between workers with potential exposures 
and unexposed persons. Furthermore, measuring total 
silicon would not be a direct measurement of RCS, and 
if an inhalation exposure had occurred it is not known 
whether or not a urine sample would appropriately 
relect this exposure.
Recent developments in instrumental sensitivity and 
software now offer the potential to measure individual 
particles of known elemental status. Techniques such as 
single particle inductively coupled plasma mass spec-
trometry (spICP-MS) can measure to low concentrations 
of individual silica particles (as silicon at m/z 28) with-
out the need for aggressive sample digestion (Laborda 
et al., 2014). In combination with direct particle-sizing 
instrumentation such as electron microscopy, this offers 
a comprehensive analytical approach to help identify 
and quantify the presence of RCS in a suitable biological 
matrix. Whilst the measurement of silica nanoparticles 
has been achieved previously using an array of analyti-
cal techniques such as asymmetric field flow fraction-
ation, multi-angle light scattering as well as transmission 
electron microscopy (TEM), spICP-MS, and ICP-MS/
MS (Aureli et al., 2015; Barahona et al., 2015; Bartczak 
et al., 2015); there are no reports of RCS being analysed 
in biological samples in this way.
Exhaled breath condensate (EBC) may be an appro-
priate ‘biological matrix’ for biomonitoring purposes for 
RCS in workplace exposures where silica particles are 
being inhaled. An EBC sample is composed of mostly 
water vapour and droplets of epithelial lung lining luid 
from the bronchial and alveolar regions of the lungs 
(Hoffmeyer et al., 2011).
The novel work presented here investigates the mea-
surement of RCS in EBC samples from a small cohort 
of sandstone quarry workers and occupationally unex-
posed controls (laboratory workers) with analysis by 
spICP-MS and TEM with energy dispersive X-ray spec-
troscopy (EDX).
Method
Sample collection
The study group consisted of six workers from a sand-
stone quarry in North Yorkshire, England, and six con-
trol volunteers from the Health and Safety Executive’s 
Health and Safety Laboratory who were not occupation-
ally exposed. All participating volunteers gave informed 
consent in accordance with HSG 167 (HSE, 1997).
EBC samples were collected using a TURBO-DECCS 
(Transportable Unit for Research on Biomarkers Obtained 
from Disposable Exhaled Condensate Collection Systems) 
by ItalChill (Parma, Italy). The TURBO-DECCS technique 
is as previously described (Leese et al., 2016). The collec-
tion of EBC is by regular, calm tidal breathing through the 
mouth via a disposable mouthpiece for 15 minutes. The 
exhaled air produced passes into a temperature-controlled 
chamber where the EBC is cooled and collected as a liq-
uid condensate on the surface of a collection tube. EBC 
samples from both the quarry workers and the control 
group were frozen at −20°C immediately after collection 
and stored at −80°C at the laboratory until analysed. The 
collection of EBC results in very small sample volumes, 
usually <1 ml. Therefore, not all EBC samples could be 
analysed by both spICP-MS and TEM analysis.
A commercially available Health and Safety Labora-
tory RCS certiied reference material (CRM) (89% cer-
tified crystallinity) HSL A9950 (Respirable α-Quartz 
powder) was analysed by all methods. This was prepared 
with ultra-pure deionized water and diluted to various 
concentrations depending on the analytical technique.
Analysis
spICP-MS
Analysis was performed on an ICAP Q ICP-MS (Thermo 
Scientiic, Hemel Hempstead, UK) using kinetic energy 
discrimination (KED) mode with helium as the collision 
cell gas. The analytical method and sample prepara-
tion was performed as outlined in RIKILT’s spICP-MS 
 procedure (RIKILT Wageningen UR, https://www.
wur.nl/en/show/Single-Particle-Calculation-tool.htm, 
accessed 17 November 2016). Dwell times were 3 ms for 
both 197Au and 28Si; sample acquisition was for 60 s. The 
nebulisation eficiency was calculated at 6.5% by deter-
mining the sample low rate (0.24 ml/min) using a 30 
nm gold nanoparticle reference material (NIST 8012). 
All EBC samples were diluted 10-fold with ultra-pure 
deionized water. The time-resolved data for both the 
gold and silicon analyses were exported into the RIKILT 
single particle calculation tool (RIKILT Wageningen UR, 
https://www.wur.nl/en/show/Single-Particle-Calculation-
tool.htm, accessed 17 November 2016).
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Transmission electron microscopy
Analysis was performed using a Tecnai G2 Spirit 
120 kV TEM (FEI, Cambridge, UK), with attached 
X-MAX energy dispersive spectroscopy (EDX) system
(Oxford Instruments, Abingdon, UK). For each sample,
20 µl was dropped onto an ultrathin carbon-coated
200-mesh nickel grid (Agar Scientific, Stansted, UK)
and air dried. Electron micrographs were captured at
×30 000 plate magniication (approximately ×300 000
including magniication by the camera). Particles were
analysed by EDX for elemental composition and an
electron diffraction (ED) pattern obtained to conirm
crystallinity
Results and Discussion
As shown in Fig. 1, there was an obvious difference 
between the spICP-MS time scans for the control EBC 
sample and the quarry worker EBC sample, whilst the 
time scan of the RCS CRM appeared visibly similar to 
the quarry worker EBC sample.
Exporting the ICP-MS data into the RIKILT 
spreadsheet showed that it was possible to determine 
the number of silica particles in control EBC, worker 
EBC, and RCS CRM samples. Using this approach 
over a concentration range of 1–100 µg/l of the RCS 
CRM, the number of particles showed an incremen-
tal increase, from 2 to 245 particles. Results showed 
a signiicant difference between the number of parti-
cles detected in control EBC samples compared with 
worker samples. The number of particles detected in 
workers’ EBC ranged from 11 to 354 whilst the con-
trol samples showed between 0 and 8 particles. The 
EBC sample from the quarry worker cited in Fig. 1 
contained 354 particles with particles ranging in size 
from ~300 to 1200 nm.
There are limitations of the spICP-MS approach for 
RCS determinations and this impact upon the accurate 
quantitative reporting of particle size. Firstly, there are 
no commercially available certiied standard or refer-
ence materials of size-characterized crystalline silica 
particles to fully validate the spICP-MS method. Sec-
Figure 1. Time scan of silica particles as 28Si in EBC samples from (A) occupationally unexposed control (B) quarry worker (C) 
RCS CRM ~50 µg/l (HSL A9950 (Respirable α-Quartz powder), when measured by spICP-MS in KED mode. Note that the single par-
ticle peaks are detected randomly throughout the 1-minute sample acquisition and so the scans will not be replicated.
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ondly, the RIKILT calculations (RIKILT Wageningen 
UR, https://www.wur.nl/en/show/Single-Particle-Calcu-
lation-tool.htm, accessed 17 November 2016) assume 
spherical particles, but RCS is neither spherical nor a 
consistent shape and so all references to particle size 
using this approach at this point only give a qualitative 
value. Finally, the current limit of size detection using 
single quadruple ICP-MS is estimated to be around 
300 nm.
TEM was able to confirm the presence of RCS in 
EBC from the quarry workers in all four post-shift sam-
ples analysed. No RCS was observed by TEM in EBC 
samples from the control samples.
Using TEM, analysis of an EBC sample from the 
quarry worker with the most particles detected by 
spICP-MS exhibited 10 crystalline silica particles rang-
ing in diameter from 100 nm to 9000 nm (one is shown 
in Fig. 2). One particle was observed approximately 
every 5–10 grid openings inspected.
It is important to note that not all the silicon contain-
ing particles observed with TEM were crystalline silica 
(SiO
2
). Using EDX, it was possible to identify some par-
Figure 2. (a) TEM micrograph of a RCS particle observed in an EBC sample from a quarry worker (same sample as seen in Fig. 1), 
conirmed as silica by EDX (b).
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ticles as aluminium silicates. This information is helpful 
in identifying the composition of the ‘baseline’ observed 
with spICP-MS, i.e. the contribution of other silicates as 
well as amorphous silica. Another contributing factor 
is likely to be from the quartz background of the ICP-
MS sample introduction system, residual contamination/
impurities of all solutions including standards and of the 
argon gas used in the plasma.
Conclusion
This work demonstrates that it is possible to detect crys-
talline silica particles in EBC of quarry workers. How-
ever, as the collection of EBC only produces a small 
volume of sample we need to be able to acquire a lot 
of information eficiently. At this stage, the analysis and 
characterisation of the silica particles still require further 
method development. There are several analytical chal-
lenges to overcome; speciically that when using spICP-
MS, the particles are easily detected but not sized; and 
with the current TEM methodology, a large sample area 
must be searched to provide high analytical sensitiv-
ity. Future developments of these methods will include 
sample pre-concentration methods for the TEM and the 
use of a shorter dwell time in spICP-MS. The removal 
of interferences using ICP-MS/MS may also offer further 
analytical improvements. It may also be worth consid-
ering calculations using particle mass instead of size, or 
determining the hydrodynamic radius of RCS particles 
in solution.
The potential of EBC as a matrix for determining 
exposure to RCS has been realized. It is now likely that 
future EBC measurements will be able to show actual 
worker exposures and assist with the improvement of 
workplace controls.
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This discussion will examine and review the work outlined in Chapters 2 and 3 for 
arsenic speciation, Chapters 4 and 5 for chromium speciation in EBC and Chapter 6 for 
single particle analysis of silica. 
7.1 Arsenic Speciation 
Since the development of the arsenic speciation methodology using an Elemental 
Scientific oneFAST system coupled to an ICP-MS with a Dionex AG7 anion exchange 
column, as outlined in Chapter 2 of this thesis, it has become one of the Health & 
“afetǇ LaďoƌatoƌǇ͛s ;H“LͿ ƌoutiŶe assaǇs. It has ďeeŶ featuƌed as aŶ ͞aŶalǇtiĐal seƌǀiĐe͟ 
since 2012 and, to date, HSL have analysed over 2500 urine samples for customers 
around both the UK and the world, generating approximately £24K of annual revenue. 
With biological monitoring as the focus, the majority of customers are industry based, 
with samples routinely sent from semi-conductors workers, glass manufacture 
workers, infrared lens manufacture workers, miners, quarry workers and waste 
treatment, disposal and recycling industry workers. However, being the only 
laboratory in England to offer arsenic speciation as an analytical service has led to 
numerous samples being received from the NHS Trace Element Supra-Regional Assay 
Service (SAS) Laboratories, of which several are located around the UK. As with most 
commercial laboratories, the NHS laboratories lack the instrument capacity, time 
and/or expertise for a dedicated routine speciation service. Urine samples which are 
flagged as having an elevated total arsenic content during multi-elemental screening 
are sent to the HSL for arsenic speciation. One sample received from the SAS 
laboratory at Glasgow Royal Infirmary was from a hospital patient who suspected they 
had been poisoned with arsenic, which unfortunately resulted in being fatal for the 
patient. Speciation analysis indicated high concentrations of inorganic arsenic and 
methylated metabolites, in addition to a very large unexpected peak in the data. The 
investigation outlined in Chapter 3 identified this peak as thio-DMA. This resulted in a 
co-authored publication with Andy Duncan (the then, Glasgow SAS Trace Element 
Director) as a homicidal arsenic poisoning case study, which can be found in Appendix 
A.  
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The work described in Chapter 2 demonstrates a fast, reliable and reproducible arsenic 
speciation method to fully separate five arsenic species (As
3+
, As
5+
, MMA, DMA and AB) 
in urine in under 6 minutes.
243
 It highlights the need for speciation analysis due to 
different foodstuffs elevating methylated arsenic species in the urine of a population 
not occupationally exposed. The study reported that people who had consumed fish 
within the previous seven days had urinary DMA concentrations twice as high as those 
who had not eaten fish, which is in direct agreement with another UK study containing 
a non-occupationally exposed control group.
157
 It was also demonstrated that urinary 
MMA concentrations were twice as high for those who had consumed fish over those 
who had not, with red wine being a significant contributor to elevated urinary AB 
concentrations. The study also established for the first time in the UK the valuable 95
th
 
percentile background unexposed reference ranges for each of the five species of 
arsenic, which is now incorporated into all customer reports of samples analysed as 
part of the HSLs analytical service. Table 12 outlines the 95
th
 percentile of the five 
arsenic species obtained in Chapter 2 of this thesis in both µg/g of creatinine and 
uncorrected for creatinine (µg/L), (the results have been converted from µmol/mol 
creatinine to µg/g creatinine for comparison purposes). In addition, values reported in 
several recent worldwide occupationally unexposed population studies in both 
uncorrected for creatinine (µg/L) and µg/g creatinine where available are included. It 
highlights the different urinary arsenic species of a range of populations and 
communities due to dietary variations.  The 95
th
 percentile of urinary inorganic arsenic 
concentrations are relatively low in the UK,
243
 Germany,
244
 U.S.
211
 and Spain,
245
 
compared against the 95
th
 percentile of urinary inorganic arsenic concentrations for a 
Korean community living within the U.S., which was 10.8 µg/g of creatinine.
158
 Only the 
75
th
 percentile was reported for Japanese urinary As
3+
 concentrations, which  was 5.8 
µg/g of creatinine.
246
 The 95
th
 percentile would be even higher. In contrast, urinary 
DMA and AB concentrations were vastly different amongst the different populations, 
with the Spanish population study showing the highest 95
th
 percentile urinary DMA 
concentration of 1153.9 µg/g.
245
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Table 12 The 95th and 75th percentiles of different arsenic species reported 
in population studies around the World.(P% denotes the percentile of the 
population)
 µg/g creatinine corrected P% As
3+
 As
5+
 MMA DMA AB Ref 
UK (Chapter 2 of this thesis) 95 0.66 0.23 2.04 10.7 115.7 
243 
Germany 95 0.65 1.1 2.3 15.8 23.3 
244 
U.S. 95 1.62 <LOD 1.61 12.7 38.7 
211 
Canada 95 - <LOD 1.7 20 44 
247 
Spain 95 - - - 286.3 1153.9 
245 
U.S. Korean Community 95 10.8 6.0 77.0 - 
158 
Japan 75 5.8 1.1 4.0 47.9 88.5 
246 
UK Bangladeshi Community 75 0.81 0.88 25.3 - 
248 
µg/L uncorrected for 
creatinine 
P% As
3+
 As
5+
 MMA DMA AB Ref 
UK (Chapter 2 of this thesis) 95 0.54 0.23 2.37 12.68 126.7 
243 
Germany 95 0.49 0.53 1.6 9.1 22.7 
244 
U.S. 95 1.19 <LOD 1.53 11.8 30.5 
211 
Canada 95 - <LOD 1.5 16 56 
247 
Spain 95 <LOD <LOD 1.8 31.9 312.8 
245 
U.S. Korean Community 95 9.7 6.5 62.2 - 
158 
Japan 75 8.9 1.1 5.5 65.9 131.8 
246 
The results for each population study in Table 12 highlight the incidence of increased 
methylated metabolites from dietary sources and the need for speciation analysis. It 
also highlights the need for a comprehensive study into the arsenic species found in 
different foods. As different countries in the world (in particular the UK) become more 
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diverse in terms of the population itself, in addition to the importation and availability 
of worldwide foods, there is a clear need in understanding background unexposed 
populations when trying to interpret urinary occupational exposure. In addition, the 
incidence of different arsenic species to the five traditional species of biological 
monitoring, such as the presence of arsenolipids, arsenosugars and alternative DMA 
and MMA analogues, will likely increase.  A very recent publication by Carioni et al
249
 
built on the published study outlined in Chapter 2.
243
 They developed the method 
further to include the arsenic species AC and TMAO, reducing separation time to five 
minutes. Unfortunately, they were unable to separate TMAO from AB and reported 
this as a combined value. Additionally, due to possible co-elution of As
3+
 with either 
DMA or AC, urine samples were treated with hydrogen peroxide (H2O2) to oxidise all 
As
3+
 to As
5+
 and subsequently they reported a combined inorganic arsenic result. 
However, this method would not be suitable for urine samples containing possible 
thioarsenicals, as adding H2O2 to convert As
3+
 to As
5+
 would also oxidise any 
thioarsenicals in the urine samples to their oxoarsenical pairs. In the case of thio-DMA, 
oxidation would result in an increased urinary DMA concentration with no knowledge 
that the thio-DMA was present.   
The analysis of so many samples at the HSL sourced from different industries, 
population groups and locations around the globe has led to the detection of 
unexpected arsenic peaks within several urine samples. The focus of Chapter 3 in this 
thesis is to investigate two unexpected arsenic peaks found in various urine samples. 
One peak has been identified as thio-DMA, however the second remains unknown. 
Nevertheless, the work has established that it is not thio-DMA, DMAA, thio-DMAA, 
DMAE, thio-DMAE, AC or TMAO. Speciation analysis has shown that the unidentified 
peak is not related to inorganic occupational exposure and so must be related to 
environmental exposure, most likely from a dietary source.  The primary difficulty with 
this type of analytical investigation is the lack of commercially available standards 
(other than inorganic arsenic, DMA
5+
, MMA
5+
, AB, AC and TMAO) to aid identification 
and quantification of arsenic compounds. This also applies to certified reference 
materials (CRM) with ClinChek® Controls 8931 (Recipe, Germany)  providing two 
urinary levels for AB, DMA, MMA and As
5+
 only, NIST 3669 (Gaithersburg, U.S.) 
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providing an urinary elevated arsenic level for AB, DMA, MMA, As
5+
 and As
3+
, in 
addition to NIST 2669 also including urinary levels for TMAO and AC. There are no 
commercially available calibration quality standard materials or urinary CRM for other 
methylated metabolites, including DMA analogues such as thio-DMA in addition to 
arsenosugars. To enable further identification of arsenic species and continued 
research in the field, this lack of availability needs to be addressed. It is highly likely 
that thio-DMA and other DMA analogues will be routinely observed in urine samples 
and as such will need to be accurately measured and become part of a routine 
biological monitoring speciation method.  
A greater understanding of the variety of arsenic species in food also needs to be 
developed. For biological monitoring, it would be useful to primarily target different 
food stuffs as possible sources of dietary exposure when explaining and interpreting 
speciation results to customers. However, it is also necessary in the broader field to 
help characterise sources of exposure in diet for risk assessment and toxicological 
purposes. Figure 16 tries to simplify the routes of exposure and the currently known 
expected or possible metabolites from inorganic arsenic, arsenolipid, arsenosugar and 
arsenobetaine exposure. The range of these expected metabolites is likely to expand 
as further research continues and analytical technology carries on improving. For 
example, a study by Molin et al250 reported the urinary excretion of seventeen 
different arsenic compounds (six of which were thioarsenicals) in a volunteer study 
after identical ingestions of blue mussels, but with vastly different inter-individual 
excretionary patterns. This highlights the possibility of an extensive number of arsenic 
compounds found in urine. 
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Figure 16 Sources of different categories of arsenic exposure and the 
resulting metabolites. Red compounds indicate the major metabolite from 
each source of exposure 
It is important to note that, to date, inorganic arsenic exposure by either dermal 
absorption or inhalation has yet to be directly linked to the DMA analogues such as 
thio-DMA and has only been directly related to dietary inorganic exposure including 
drinking inorganic arsenic contaminated water. A reason for this may be that the 
137 
 
formation of DMA analogues, especially thioarsenicals is reliant on conditions unique 
to the stomach or gut. The in vitro formation of thioarsenicals from gut flora has been 
demonstrated in rats
251
 and mice,
252,253
 directly linking the importance of ingestion 
with the production of thio-DMA and other DMA analogues. However, the production 
of thio-DMA was demonstrated in RBC
156,254
 and most recently in human liver cells,
146
 
indicating the gut may not be the sole site of thioarsenical formation.  It is also 
interesting to note that DMA
5+ 
is the major urinary metabolite for all arsenic 
compounds, which can be metabolised by humans.  
Recent in vitro findings have determined that some organic arsenic compounds and 
their metabolites are cytotoxic,
142,145
 with other organic compounds, such as DMAA 
and DMAE in addition to their thio pairs, being neither cytotoxic or genotoxic.
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Though cytotoxic, some toxicity studies have determined that the cellular toxic modes 
of action differ from those of arsenite.
145,150 AƌseŶite͛s Đellulaƌ toǆiĐ ŵode of aĐtioŶ is 
genotoxic related, due to multiple DNA lesions and strand breakages.
145
 The variability 
in toxicity amongst the organic arsenic metabolites suggests that further toxicological 
investigations are required. It is acknowledged by the scientific community that there 
is a knowledge gap in understanding exposures, the transformation of species as well 
as the toxicokinetics and metabolic pathways of arsenic species in humans, and the 
individual variability of organic arsenic excretion.
130,135,255
  
Future work at the HSL will be to identify the unexpected arsenic compound known as 
peak 2, in the work reported in Chapter 3. This could involve the commencement of 
human dosing volunteer studies, to ingest known foods identified in the literature 
which have resulted in the metabolism and excretion of alternative arsenic compounds 
to those currently measured at the HSL and those investigated in Chapter 3 of this 
thesis. Food items already selected from the literature include cod liver oil, mussels 
and seaweed sources. This will help to identify dietary sources commercially available 
in the UK that might result in unexpected arsenic peaks in future biological monitoring 
urinary samples. In addition, this tactic may also result in an unexpected peak at the 
same retention time as peak 2 which will produce fresh urine samples for further 
identification purposes but also help narrow down the identity of the arsenic 
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compound if it has been previously metabolised and excreted in a specific ingestion 
study.  
7.2 Chromium Speciation 
The work described in Chapter 4 and Chapter 5 of this thesis, demonstrates a method 
to simultaneously detect and measure both trivalent (Cr(III)) and hexavalent (Cr(VI)) 
chromium in EBC samples. Chapter 4 outlines the development of the analytical 
method, including a storage stability study of spiked solutions of Cr(III) and Cr(VI) in 
EBC. Chapter 5 describes a feasibility study to determine whether Cr(III) and Cr(VI) can 
ďe deteĐted iŶ ͚ƌeal͛ EBC saŵples fƌoŵ ǁoƌkeƌs, using the method developed in 
Chapter 4. The feasibility study demonstrated for the first time that it was possible to 
measure and detect both species of chromium in occupationally exposed workers, 
with workers showing significantly higher levels of both Cr(III) and Cr(VI) in their EBC 
samples compared to the control group, in addition to higher urinary total chromium 
levels. Site visits consisted of collecting both pre and post working week urine and EBC 
samples. However, despite differences in urine samples, no significant difference was 
found between pre and post working week EBC samples. The work outlined in Chapter 
5 was one of the top 30 most downloaded articles published in the Journal of 
Analytical Atomic Spectrometry (JAAS) in 2016 and has been included in the JAAS 2016 
Most Accessed Articles Collection.    
Little is known about the mechanisms or EBC in terms of its effectiveness for exposure 
assessment and so using EBC as a matrix for biological monitoring raises numerous 
questions that cannot as yet be fully answered. Exact inhalation deposition rates of 
inhaled elemental particles/fumes/vapour and mucociliary clearance abilities from the 
lungs are undefined. Therefore, how much an individual inhales of hexavalent 
chromium for example in comparison to how much is then exhaled and measured in 
an EBC sample remains inconclusive. Further work at the HSL will involve site visits to 
companies with workers occupationally exposed to Cr(VI) by inhalation to repeat EBC 
sampling in tandem with personal air measurements. This will enable the investigation 
of whether there is a correlation of Cr(VI) air levels with levels exhaled in EBC samples. 
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IŶ additioŶ, it is also uŶkŶoǁŶ ǁhetheƌ the Cƌ;IIIͿ ŵeasuƌed iŶ the ǁoƌkeƌ͛s EBC 
samples was from reduction of Cr(VI) in the lungs or whether some contribution is 
from inhaled Cr(III) as a result of reduction from Cr(VI) in the environment of the 
workplace. The measurement of both Cr(III) and Cr(VI) from personal air samplers may 
help to answer this question. Other valid questions include: 
 what are EBC measurements representative of, the previous five minutes of 
exposure, five weeks or five years?   how long can Cr(VI) be measured in an EBC sample after exposure has ceased?  
These questions will be valid in the study of silica in EBC samples also, arising from the 
work outlined in Chapter 6. 
As previously stated, the feasibility study in Chapter 5 found no significant difference in 
EBC Cr(VI) levels between pre and post working week samples. However, this is not the 
case for other studies. A study by Goldoni et al,
65
 determining Cr(VI) only in EBC 
samples of 10 chrome platers, determined Cr(VI) in EBC samples of 9 of the 10 workers 
and 4 of those 9 workers had lower levels of Cr(VI) 15 hours after exposure. An earlier 
study by the same research group also investigated biomarkers of oxidative stress 
(hydrogen peroxide (H2O2) and malondialdehyde (MDA)) in addition to Cr(VI) levels in 
EBC.
66
 EBC samples were taken pre and post shift on a Friday and again on the 
following Monday morning. An increase in both Cr(VI) and the biomarkers was 
observed between the Friday pre and post shift samples, with detectable but lower 
levels also observed in the Monday morning EBC sample. Levels of Cr(VI) were shown 
to correlate with both EBC H2O2 and EBC MDA levels.
66
  
Hexavalent chromium is an elemental species of occupational concern to HSE. Chrome 
plating is a large and widespread industry within the UK, that both the HSE and the HSL 
have a good professional relationship with, including its professional trade association 
(Surface Engineering Association). This is mostly due to large scale HSE surveys 
conducted within the industry over the previous 10 years resulting in collaborative 
guidance documents and reports.
256-261
 Correlation between Cr(VI) air measurements 
and total chromium urinary measurements are already defined, in addition to 
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guidance values available from both the U.S. and Germany. This wealth of knowledge 
of occupational exposure is not known for many other elements, especially crystalline 
silica exposure. This information, in addition to employers and employees already used 
to volunteering in HSL studies, makes Cr(VI) an ideal element to begin the 
investigations into the potential of EBC as a new biological matrix for biological 
monitoring. Although differences are bound to be observed between different 
compounds and elements, the knowledge gained can be applied to future EBC 
measurements. This project has the potential to provide further information and 
evidence of exposure than that previously available and should in time help with 
controlling exposure. 
7.3 Single Particle Analysis 
The technique of spICP-MS is still in its infancy, with experts in ICP-MS analysis, particle 
and nanoparticle technology, ICP-MS instrument manufacture and software 
development all learning together regarding this extremely promising application. 
There are numerous techniques for measuring single particles or nanoparticles, as 
listed in Table 13. All have analytical limitations, which has resulted in no technique 
being the standout choice for single particle analysis. Degueldre and Favarger in 
2003
233
 presented the feasibility of ICP-MS to measure single particles. This has paved 
the way in recent years for ICP-MS to begin establishing itself as having the potential to 
accurately provide particle size, particle number concentration and size distribution in 
varied liquid matrices at concentrations relevant to environmental or biological 
systems. It is the only technique that both quantitatively counts particles and 
determines the chemical composition of the material.
262
 However, there is still a long 
way to go if spICP-MS is to establish itself as a preferred analytical technique for single 
particle or nanoparticle analysis. 
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Table 13 A comparison of abilities and limitations of different analytical techniques to measure particles and nanoparticles
262-270
 
Technique Strengths / Benefits Limitations Used to size, characterise or image 
spICP-MS 
 Particle size determination  Particle size distribution  Particle number concentration  Mass Concentration  Elemental composition determination  Minimal sample preparation required 
 Cannot determine shape  Measurement based upon spherical 
particles  Not capable of multi-element analysis  Calibration is based on a mathematical 
assumption  A developing technique in single 
particle analysis 
 
 Metal or metal oxide based particles 
Dynamic Light Scattering 
(DLS) 
 Fast and simple analysis time  Uses small sample volumes 
 Poor method sensitivity  Cannot distinguish elemental 
composition  Not quantitative 
 
 Proteins  Nanotechnology particles  Metal particles 
Transmission electron 
microscopy 
(TEM) 
Scanning electron microscopy 
(SEM) 
 Particle shape determination  Particle size determination  Ability to resolve agglomerates and 
aggregates  Can determine elemental composition 
only when combined with EDX* 
 Unsuited to high throughput  High particle count required  Poor method sensitivity  Not quantitative  Sample preparation can induce 
agglomeration 
 
 Asbestos and fibres counting  Material characterisation  Study of crystals and metals  Detection of flaws, fractures & 
damage in micro sized objects  Particles  Virus & bacteria imaging 
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Technique Strengths / Benefits Limitations Used to size, characterise or image 
 Cell biology  Cancer cell imaging 
Nanoparticle Tracking 
Analysis 
(NTA) 
Particle tracking analysis 
(PTA) 
 Particle size distribution  Particle size determination  Particle number concentration  Minimal sample preparation required 
 Cannot distinguish elemental 
composition  Struggles with sizes >500 nm  Measurement based upon spherical 
particles  Light emitted from large particles will 
overlay that of smaller particles  Unable to distinguish between 
particles of small size differences 
 Proteins  Virus characterisation  Nanotechnology particles  Metal particles  Cell composition 
Resistive Pulse Sensing (RPS) 
Scanning Ion Occlusion 
spectroscopy (SIOS) 
 Particle size determination  Particle size distribution  High throughput 
 Not suitable for particles suspended in 
water or organic solvents  Not suited for metal particles 
 Proteins  Virus characterisation  Nanotechnology particles  Characterisation of drug delivery 
particles  Cell composition 
Differential Centrifugal 
Sedimentation 
(DCS) 
 Particle size determination  Particle size distribution  Suitable for complex matrices  Suited to particle sizes of 5 - >1000 nm 
 Particles must be more dense that the 
liquid they are suspended in  Low density particles either cannot be 
analysed or involve a long analysis 
time. 
 Proteins  Virus characterisation  Nanotechnology particles  Metal particles 
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Technique Strengths / Benefits Limitations Used to size, characterise or image 
 Can separate particles of very small 
size differences 
 Cell composition 
Particle Induced X-ray 
Emission 
(PIXE) 
 No sample preparation needed  No restriction to the size of particle it 
can measure 
 Sensitivity in the mg/L range  Cannot provide quantitative size 
distribution and particle size   A developing technique in single 
particle analysis 
 Elemental particles 
*EDX – Energy Dispersive X-ray analysis 
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Degueldre and Favarger
233
 demonstrated that the ion cloud produced by a single 
particle in the plasma of an ICP could be detected and measured by the MS. The 
intensity of the signal produced related to the size of the particle and the frequency of 
these sigŶals, oƌ ͚flashes͛ as theǇ teƌŵed theŵ, ƌelated to the ĐoŶĐeŶtƌatioŶ of 
particles in the solution. As outline in section 1.6.3.2 of this thesis, the ICP-MS is 
operated in time resolved analysis (TRA) mode, with a low flow rate and a much 
reduced data acquisition time (dwell time) of a few milliseconds. However, as spICP-
MS is a new application, the ICP-MS in TRA mode will produce a time scan of peaks 
over the acquired time representing the signals or flashes only. The software can 
produce nothing else with this huge amount of raw data, meaning data manipulation 
has to be conducted offline, after exportation into a suitable software package (such as 
excel) where numerous, lengthy equations and calculations are semi-manually 
generated to determine the frequency of particles, particle diameter, size distributions 
and subsequently mass concentration.  
From 2003, a series of papers by Degueldre et al
233,271-274
 outlined several theoretical 
equations required to measure colloids in solution and in 2011, Laborda et al
236
 also 
presented the potential of spICP-MS with several theoretical equations and 
calculations. However, these papers are somewhat lacking in the explanation of the 
spICP-MS terms used and how data is generated to perform the equations to enable 
manipulation of the raw data. Fortunately, Pace et al
238
 developed a practical guide on 
the fundamentals, including an explanation of terms and outlined the steps needed to 
generate the data to be inputted into the equations and calculations required to 
quantitatively count and size particles. For the ease of everyone in the ICP-MS 
scientific community, the RIKILT research institute, working from within Wageningen 
University in the Netherlands, developed a spICP-MS procedure
275
 and a spreadsheet 
single particle calculation tool
276
 for all within the field to use. The spreadsheet is an 
Excel based document, into which the raw data generated by the ICP-MS for sample 
analysis is imported. It calculates the larger and more complicated theoretical 
equations to give you a particle frequency, particle mass concentration and particle 
size, in addition to a graphical particle size distribution. However, a number of factors 
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need to be known and inserted into the spreadsheet such as particle density, an ionic 
calibration intensity in cps/(ug/L), nebulisation efficiency and background threshold. 
The promising work outlined in Chapter 6, measuring respirable crystalline silica (RCS) 
by spICP-MS was performed using the RIKILT single particle calculation tool.  
The basic principal of spICP-MS is to acquire not more than one particle arriving at the 
deteĐtoƌ iŶ oŶe dǁell tiŵe. This is Đalled the ͚siŶgle paƌtiĐle ƌule͛. A dǁell tiŵe of 
approximately 3 ms is common with an acquisition time of 60 s. Therefore, a maximum 
of 20 000 particles can be detected per minute, with the detection of a particle known 
as a particle event. However, this can result in what is termed a multiple event, where 
more than one particle is detected at a time. Therefore, a dilution of the particle 
suspension is required to satisfy the single particle rule and reduce the occurrence of a 
multiple event. Ideally, RIKILT states there should not be more than 2000 particle 
events per minute. The background threshold relates to the continuous background 
baseline signal that a particle has to generate a large enough pulse/peak to be 
detectable from. A blank sample is run following the same 3 ms dwell time and 60 s 
acquisition time; the background threshold is then calculated as five times the 
standard deviation of the blank plus the mean. When a blank is analysed, no more 
than 10 particle events should be above this calculated background threshold.    
The nebulisation efficiency is calculated using Equation 1, where; ܰ� = nebulisation 
efficiency, ݍ௣  = particle events (number of particles detected above the base line in a 
minute), �௣ = Particle number concentration and � = Sample flow rate. 
 
Equation 1 
   ܰ� = ௤���� × ͳͲͲ 
However, the particle event (ݍ௣) and particle number concentration (�௣) can only be 
calculated using a particle sized CRM. Currently only two commercially available gold 
nanoparticle CRMs are available, with the 60 nm (NIST 8013) and 30nm (NIST 8012) 
being suitable for this application. The CRM is diluted low enough to allow less than 
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2000 particle events in a minute above the background threshold and Equations 2 and 
3 below are used to determine particle number concentration (�௣): 
Equation 2     Equation 3 ܯ௣ =  ��36 × ݌    �௣ = ���� 
Where;     Where; ܯ௣ = particle mass (g)    �௣ = particle number concentration (mL) � = particle size (cm)     �� = mass concentration (g/mL) ݌ = density (g/mL)     ܯ௣ = particle mass (g)  
 
For example, the RIKILT procedure suggests a concentration of 50 ng/L for any CRM as 
a starting point for these calculations to determine less than 2000 particle events per 
minute (in this work using the iCAP Q ICP-MS at HSL, 25 ng/L is a preferable 
concentration). When performing Equation 2, using the 30 nm NIST 8012 reference 
material, and remembering to adjust to the correct units (e.g. 30 nm to cm), the Mp is 
2.7x10
-16 
g. Inserting the acquired ܯ௣ value and other data into Equation 3, adjusting 
to the correct units (e.g. 25 ng/L to g/mL), the �௣ is 88 273 mL. Including the number of 
particle events counted above the background all the information needed for Equation 
1 has been acquired. An ionic gold calibration is performed and the ICP-MS response to 
the ion standard of the element in cps/(µg/L) is obtained and inserted into the 
spreadsheet. When analysing particles of which a sized particle CRM is not available, 
the procedure outlined above is still followed. However, an ionic calibration of the 
element to be analysed is also performed with the ICP-MS response in cps/(µg/L) and 
its density being incorporated into the RIKILT spreadsheet, in addition to those of gold. 
Figure 17 shows the table included in the RIKILT calculation tool; the orange boxes 
indicate the information that the user must know and insert to enable the spreadsheet 
to perform the calculations. Using these calculations the RIKILT calculation tool has 
measured the 25 ng/L 30 nm gold CRM as 23 ng/L and 29 nm (shown in the yellow box) 
and the graphical particle size distribution is displayed below. Figure 18 shows the 
section of the RIKILT table for samples that the particle mass and diameter are not 
known. The sample demonstrated in Figure 18 is of an HSL in-house RCS reference 
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material at an approximate concentration of 50 µg/L. The orange boxes indicate the 
information that the user must know and insert to enable the spreadsheet to perform 
the calculations as the element of interest is now silica rather than gold. The 
spreadsheet has calculated that the 132 particles of silica have been detected with an 
average particle size of 401 nm.  
 
Figure 17 A section of the RIKILT calculation tool spreadsheet showing the 
known criteria and result of the calculated nebulisation efficiency using a 
gold ionic calibration and 30 nm gold NIST CRM. 
INSTRUMENT SETTINGS AND CALIBRATION DATA
Instrument settings:
ICPMS sample inlet flow 0.240 ml/min
ICPMS dwell time 3 ms
Determination of nebulization efficiency:
elemental composition of standard particle Au
element density 19.3 g/ml
standard particle mass concentration 24 ng/l
standard particle diameter 30 nm
calculated standard particle mass 0.27 fg
limit for particle det. 5824 cps 
detected number of particles 1384 #/min
calculated transport efficiency 0.065
Determination of ion response target element:
Elemental composition op target particle Au
ICPMS response to ion standard of target 68767 cps/(µg/L)
Check results
Concentration (particle numer) 8.8E+07 particles/L
Concentration (mass) 23 ng/L
Particle size 29 nm
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Figure 18 A section of the RIKILT calculation tool spreadsheet showing the 
known criteria and result from an RCS in-house (A9950) reference material 
approximately 50 µg/L 
7.3.1 Advancements in Single Particle Analysis 
Advances in ICP-MS technology since beginning this investigation to measure single 
particles of silica in EBC samples have been the introduction of ICP-MS single particle 
software. In 2015, Thermo Scientific launched an optional single particle software 
plugin as an upgrade available to purchase for the iCAPQ ICP-MS, called npQuant. The 
INSTRUMENT SETTINGS AND CALIBRATION DATA
Instrument settings:
ICPMS sample flow 0.21 ml/min
ICPMS dwell time 3 ms
Properties of target particle:
elemental composition of target particle Si
molar mass particle/molar mass analyte 2.139
particle density 2.634 g/ml
Calibration data:
transport efficiency 0.032
ICPMS response ion standard 248 cps/(µg/L)
limit for particle detection 18571 cps 
number of particles detected 132
Results
Concentration (particle numer) 2.0E+07 particles/L
Concentration (mass) 2844 ng/L
Particle size 401 nm
other ICP-MS manufacturers also each have their own single particle software for their 
instruments. All of these software packages and the associated calculations are based 
on the RIKILT procedure and spreadsheet, with each being able to calculate the 
nebulisation efficiency. However, for npQuant, manual calculations of ܯ௣ and �௣ using 
Equations 2 and 3, are still required by the user.  
Another advancement has been the introduction of a triple quadrupole (QQQ) ICP-MS 
by Agilent Technologies (Cheadle, UK). The QQQ ICP-MS adds an MS/MS mode for 
interference removal. It consists of two quadrupole mass filters with the 
collision/reaction cell quadrupole situated in between. This allows for two options of 
analysis using the two mass filters. The first option is mass shift analysis, where the 
mass of the element of interest is applied to the first mass filter quadrupole and the 
second mass filter quadrupole is the sum of the mass plus the mass of the reaction cell 
gas, which enables the elimination of polyatomic interferences. The second option, 
which is employed for silica analysis, is on-mass selection analysis, where both mass 
filter quadrupoles are set to m/z 28, as shown in Figure 19.   
Technologies, Inc. 
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Figure 19 A QQQ ICP-MS/MS consisting of two mass filters and a 
collision/reaction cell situated in between, demonstrating its efficiency at 
removing nearly all polyatomic interferences, by applying m/z 28 to both 
mass filters. © Agilent Technologies, Inc. 2017. Image kindly supplied by Agilent 
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As demonstrated in Figure 19, the polyatomic interferences (
14
N2
+
 and 
12
C
16
O
+)
 and 
28
Si 
ions pass through the first mass filter set at m/z 28 and subsequently enter the 
collision/reaction cell. The cell employs hydrogen as a reaction gas to react with the 
interfering ions to form larger polyatomic ions (N2H
+ 
and COH
+
) which are now 
discarded as they pass through the second mass filter also set to m/z 28, only allowing 
28
Si ions to pass to the detector.  
The QQQ ICP-MS has greatly enhanced sensitivity and has a reduced limit of detection 
(LOD) compared to single quadrupole ICP-MS. This ability to further reduce polyatomic 
interferences allows for a lower background threshold when analysing silica particles 
which in turn enables smaller particle sizes to be measured. In Chapter 6 of this thesis, 
the particle size LOD for crystalline silica is estimated to be approximately 300 nm 
(depending on daily sensitivity and the background signal of m/z 28). Other studies 
have reported a particle size LOD for colloidal silica particles of 200 nm,
235
 300 nm,
277
 
403 nm
278
 and 572 nm,
279
 whilst studies using a QQQ ICP-MS have reported particle 
size LODs for colloidal silica down to 20 nm.
280-282
 In addition the second generation 
QQQ ICP-MS from Agilent Technologies incorporates a re-engineered argon gas flow 
path, which helps to further reduce background contamination of silicon and sulphur. 
It also has a more powerful and faster detector, allowing a dwell time as low as 0.1 
ms
262
 (the first generation Agilent Technologies QQQ ICP-MS and all single quadrupole 
ICP-MS detectors only allow a dwell time as low as 3 ms). Thermo Scientific unveiled 
their first QQQ ICP-MS in February 2017 at the European Winter Conference on Plasma 
Spectrochemistry. 
Further applications include the hyphenation of spICP-MS with front-end separation 
techniques such as flow-field flow fractionation (A4F)
283
 or hydrodynamic 
chromatography (HDC).
283
 
The use of different reaction/collision cell gases is an alternative option to increasing 
sensitivity and reducing background noise. The iCAP Q ICP-MS at the HSL uses helium 
gas as the standard Thermo Scientific recommended cell gas. Other studies have 
reported using helium,
277
 7% hydrogen in helium
279
 and ammonia,
278,284
 however 
hydrogen also seems to be very efficient.
285
 In addition, the use of non-quartz based 
151 
 
glassware for the torch, spray chamber and injector of the sample introduction setup 
in the form of pfa (perfluoroalkoxy), ceramic, platinum and sapphire have all been 
reported to help reduce the silicon background.
282,284
 All of these aspects and 
alternative approaches will need further research at HSL to help improve and develop 
a RCS spICP-MS method. 
7.3.2 Current spICP-MS Limitations 
Although the development of single particle analysis is extremely exciting, it still has a 
number of limitations that are currently holding back progress, as well as reducing the 
accuracy and precision of the data obtained. 
The primary limitation is the lack of sized particle CRMs. At present, the main option to 
calculate the nebulisation efficiency is by using gold particles. This nebulisation 
efficiency value is crucial, as it is used to calculate particle frequency, particle mass 
concentration and particle size distribution. This means that the nebulisation efficiency 
of a gold particle is used to calculate the particle frequency, mass and distribution of 
other elemental particles. However, it cannot be assumed that the nebulisation 
efficiency of gold particles would match those of zinc, RCS or titanium particles, for 
example. 
Another limitation is the reliance on the spICP-MS software to calibrate using an ionic 
standard rather than calibrating using the single particles themselves. A calibration of 
one single particle size at different mass concentrations could be used; however, it has 
not been investigated whether using one single particle size would be accurate when 
measuring particles across the nm size range. Several calibrations of different sized 
particles could be employed, for example three separate calibrations of a small, 
medium and large sized particle dependent on the expected particle sizes in the 
samples to be analysed, of which an average could be taken. Again, this is yet to be 
investigated. However, it is known that the signal intensity of different sized particles 
at the same mass concentration is not linear. As previously stated, the intensity of the 
signal produced by a single particle is related to its size, however it is also proportional 
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to the cube of the particle diameter. So for example, the intensity signal produced by 
the 30 nm NIST gold CRM is not half that of the 60 nm NIST gold CRM but 1/8 and, if a 
15 nm NIST gold CRM existed, it would produce an intensity signal 1/64 that of the 60 
nm NIST gold CRM. Therefore, a calibration of different particle sizes would need to 
consider this.  
Regarding RCS, the greatest limitation is the shape of the actual RCS particles. The 
calculations used to determine particle size for spICP-MS in addition to other 
techniques such as particle/nano tracking analysis are all based on the assumption that 
the particles are spherical. The TEM micrographs obtained at HSL of two different RCS 
particles shown in Figure 20 demonstrate that not only are RCS particles non-spherical 
but they are irregular. The two RCS silica particles, identified and sized by TEM, are 5 
µm (5000 nm) and 0.5 µm (500 nm) and were observed in the EBC sample of a quarry 
worker taking part in the work outlined in Chapter 6 of this thesis. However the fact 
that there is currently no biological monitoring available to assess occupational 
exposure to RCS and using spICP-MS can easily and quickly detect and count the 
frequency of RCS particles in an EBC sample far outweighs the fact that the particle 
sizing is likely to be inaccurate. 
 
Figure 20 Micrographs of two different respirable crystalline silica particles, 
demonstrating the irregularity in shape using a Tecnai G2 Spirit 120kV TEM 
with attached X-MAX energy dispersive spectroscopy system. 
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As spICP-MS applications grow in popularity and more varied sample types are 
investigated, the measurement of multiple particle sizes in a single sample is going to 
be challenging. An individual, occupationally exposed to RCS, will inhale all sizes of 
crystalline silica across the respirable size range. However, as demonstrated in Figure 
18, the results are expressed as an average particle size and mass. A strength of the 
iCAP Q spICP-MS software is that it provides a choice, to build a method to either 
calculate all the particles as an average or to measure individual sizes of particles. In 
the software a minimum and maximum threshold is inserted which specifies the 
minimum and maximum peak height of the intensity signals. Therefore, different sets 
of minimum and maximum thresholds can be inserted to correspond to the different 
intensity signal peak heights from different nm sizes of particles. This is easily 
performed with two distinct sized particles such as the 30 nm and 60 nm gold NIST 
CRMs. However, it is considerably more challenging with an EBC sample, which may 
contain many different sized particles across the nm size range, where particles can 
vary in size from 100 nm up to 1000 nm.  
Instrument cleanliness and contamination has also proven to be a limitation at the HSL 
for the analysis of silica and gold particles. The iCAP Q ICP-MS is no longer used for 
sample analysis outside of this work here if the reagents needed for the application 
contain high concentrations of gold or silica, in addition to the samples themselves (for 
example, elemental quantification of air monitoring samples on glass fibre filters) to 
maintain the low background threshold required for spICP-MS analysis.   
7.4 Silica Particles  
The reporting of spICP-MS results for RCS particles will need thoughtful consideration, 
for example, how to convert the particle frequency and the many sizes of crystalline 
silica into a result that is understandable and transferable to the entire community 
from spICP-MS users, occupational hygienists and GPs to finally the employers and 
employees. For crystalline silica to be classed as RCS it has to be less than 10 µm in size 
to enter the alveoli regions of the lungs where it is able to cause damage and induce 
lung diseases such as silicosis. Although the link between occupational exposure to RCS 
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and its related health effects is well documented very little is known about the effect 
of particle size and the development of disease.
286,287
 It is suggested that the surface 
chemistry of particles allows for increased reactivity within cells
288
 and so the smaller 
the particle the larger the surface area to volume ratio resulting in higher reactivity per 
gram of a chemical.
262
 However, as RCS particles are not spherical, a more irregular 
shaped particle may have a larger surface area to volume ratio than a smaller less 
irregular shaped particle.  An in vitro study looking at the uptake and biological activity 
of different sized colloidal silica particles in macrophage cells from mice found that 850 
nm particles appeared more biologically active than 150, 250 and 500 nm particles, 
however the smallest sized particles in the study of 150 nm had the greatest uptake.
289
 
Wiessner et al
290
 demonstrated that larger crystalline silica particles had a greater in 
vivo inflammatory response than smaller particles; the same was also demonstrated by 
Kajiwara et al.
291
 However, a more recent study involving crystalline silica particles as 
small as 300 nm found the smallest particles generated more mitochondrial reactive 
oxygen species than larger particles.
286
 It has also been suggested that smaller particles 
of less than 100 nm in size are more easily cleared from the lungs and into the 
circulatory system by mucociliary clearance, whereas the larger particles remain, 
causing persistent inflammation and cell death.
292
 With this in mind, a more simplistic 
approach may be to generate a result consisting only of the number of RCS particles 
detected in EBC in comparison to the 95
th
 percentile of RCS particles found in a 
background population. This could be increased from the frequency to also include the 
minimum and maximum size found, along with where the greatest percentage of 
particles was found within that range. Because of the irregularity in shape, the most 
obvious suggestion would be to no longer focus on trying to express RCS as a nm size, 
but to maybe present it as a density in the form of the particle mass per unit volume. 
As already stated, the occupational exposure assessment of crystalline silica using 
biological monitoring is not currently possible, though EBC is demonstrating the 
potential to resolve this problem. However, a small handful of studies have already 
emerged, investigating biomarkers of oxidative stress for the early diagnosis of silicosis 
and the primary effects of silica exposure. A study by Sauni et al
293
 found increased 
nitric oxide levels in the EBC of workers occupationally exposed for more than 20 years 
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to silica in comparison to an unexposed control group. The authors postulate that 
exposure to crystalline silica induces an inflammatory response prior to the formation 
of silicosis and that the measurement of nitric oxide could be used to identify 
individuals at risk of developing silicosis. Aldehydes are a known oxidation product 
used for the quantification of oxidative stress,
294
 with Sakhvidi et al investigating 
malondialdehyde (MDA) in tile and ceramic production workers employed for longer 
than 2 years compared with a control group; however no significant difference 
between EBC MDA concentrations was found between the two groups. The studies by 
Sauni et al
293
 and Sakhvidi et al
294
 both eliminated volunteers with pre-existing 
pulmonary conditions such as asthma and respiratory or lung diseases. In contrast, 
other studies have purposefully focused on silica exposed workers with occupational 
lung diseases. The first study to report markers of oxidative stress in EBC samples of 
silicosis patients was by Pelclova et al
48
 in 2007. The study compared oxidative stress 
biomarkers 8-isoprostane and four leukotrienes in silicosis patients with a control 
group. They reported elevated EBC levels of both 8-isoprostane and one leukotriene 
(D4) only in silicosis patients compared to controls.
48
 In 2011, Pelclova et al
51
 
compared levels of 8-isoprostane, in addition to aldehydes MDA and hydroxynonenal 
(HNE), in patients with varying degrees of asbestosis and silicosis against a control 
group. The study reported elevated levels of 8-isoprostane and HNE in EBC samples of 
both asbestosis and silicosis patients in comparison to the controls, but not for MDA.
51
  
Another study, comparing four different leukotrienes in EBC samples, in addition to the 
lung function of patients with varying degrees of asbestosis or silicosis, was published 
by the same research group the following year.
50
 Although lung function was 
significantly impaired in both silicosis and asbestosis patients the amount of EBC 
collected did not differ between the two groups or when compared against the control 
group.
50
 The study reported elevated levels of two leukotrienes (D4 and E4) in EBC 
samples of both sets of patients compared to the control group, along with elevated 
leukotrienes (C4 and cysteinyl) in EBC samples of asbestos patients only.
50
 Additionally, 
increased levels of leukotrienes correlated to the severity of asbestosis and a 
significant correlation was found between leukotriene concentration and total lung 
capacity of asbestosis patients. However, no correlation between leukotriene levels 
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and disease severity or lung function could be found for the silicosis patients.
50
 A 
similar study comparing asbestosis and silicosis patients reported a simultaneous 
method to analyse 8-isoprostane in addition to MDA and HNE.
47
 Unlike the Sakhvidi
294
 
and Pelclova
51
 studies, MDA levels in EBC were shown to be significantly elevated in 
comparison to the control group in addition to both HNE and 8-isoprostane.
47
 
However, in the Sakhvidi study the volunteers did not have silicosis.
294
   
The work outlined in Chapter 6 is the only study to report silica particles in EBC 
samples of occupationally exposed workers and controls. However, one other study 
has attempted to do the same. This very recent study, published online at the end of 
January 2017 by Sauvain et al,
295
 reports the particle number concentration and size 
distribution of particles (of unknown elemental composition) in EBC samples of 
workers exposed to soapstone or quartz dust using nano tracking analysis (NTA). 
However, unlike spICP-MS, NTA cannot determine the precise nature of the particles 
nor differentiate between elemental compositions of the different particles. Although 
environmental monitoring of personal air samplers confirmed the respirable dust 
fractions collected gravimetrically contained silica (confirmed by x-ray diffraction, but 
not specifying amorphous or crystalline silica), the SEM analysis of the EBC samples 
identified particles containing sodium, potassium, chlorine, sulphur, calcium, 
magnesium, aluminium, iron, titanium and silicon. Therefore, the particles counted 
and the particle size distributions produced would be inclusive of all these particles of 
different composition. However, it was reported that particle size variability was 
significantly higher in crystal quartz workers compared to soapstone workers and the 
control group, in addition to the number of particles detected also being significantly 
higher. The particle sizes found in all volunteer EBC samples, ranged from 45 nm up to 
290 nm using NTA. However, silica particles of approximately 1000 nm were confirmed 
by SEM analysis that were not detected by NTA, indicating that NTA may not be a 
suitable technique for RCS identification. 
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7.5 The Potential of other Elemental Single Particle Analysis 
The method of spICP-MS allows for the analysis of particle suspensions in a liquid 
sample, in particular metal and metalloid oxide particles. Although considerable 
progress has been made, this is still an emerging technique with the majority of 
publications involving the development and optimisation of the technique using 
commercially available particles as pristine particle test cases rather than the analysis 
of particles in authentic samples and applications. However, a small handful of studies 
is beginning to emerge consisting of authentic spICP-MS applications which include: an 
attempt to measure silver nanoparticles in blood samples of burns victims treated with 
silver nanoparticle dressings;
296
 the measurement of arsenic particles from 
environmental sample leachates from mine waste;
297
 detection of zinc oxide and 
cerium oxide nanoparticles in drinking water treatment facilities.
298
 
It may be possible that spICP-MS could be used to detect chromium particulate in EBC 
samples. For example, specifically for workers who potentially inhale aerosolised 
chromium particulates such as welders and grinders as opposed to chrome platers 
who inhale chromium vapour. However, exposure to soluble chromium and fumes 
creating an elevated background signal within the samples may be of concern for 
spICP-MS analysis.  
The measurement of various metal and metalloid particulates in biological samples by 
spICP-MS is a possible future development for spICP-MS.    
7.6 Conclusion 
The aims of this PhD study were to develop new analytical speciation methods and to 
evaluate exhaled breath condensate, for its potential as a new biological matrix for 
exposure assessment. This has been achieved to varying degrees with arsenic, 
chromium and silica. The developed arsenic speciation method is now utilised 
routinely at HSL and will continue to be so. For chromium, a speciation method has 
been developed and both Cr(III) and Cr(VI) have been detected in EBC samples of 
workers occupationally exposed to Cr(VI). Future work is planned to further 
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understand Cr(VI) inhalation exposures and its correlation to EBC measurements. For 
silica, the work is less developed, however the analytical technique shows promise. 
RCS particles in EBC samples of workers occupationally exposed to crystalline silica 
have been detected and the technique of spICP-MS will be explored further. 
The better understanding, detection and measurement of arsenic species in urine, 
chromium species in EBC and RCS particles in EBC should therefore mean reduction in 
worker exposure will be possible using the techniques developed. 
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Chapter 8.                                                                         
Publications, Oral Presentations and Poster 
Presentations. 
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8.1 Publications 
1. E. Leese, J.F. Staff, V.A. Carolan and J. Morton. Exhaled breath condensate: A novel 
matrix for biological monitoring to assess occupational exposure to respirable 
crystalline silica. Ann. Work. Exp. Health. (formerly Ann. Occup. Hyg.), 2017, 61(7): 
902 – 906. doi: 10.1093/annweh/wxx047. 
2. E. Leese, M. Clench, Morton, J. P.H.E. Gardiner and V.A. Carolan. The investigation 
of unexpected arsenic compounds observed in routine biological monitoring 
urinary speciation analysis. Toxics. 2017, 5(2): doi:10.3390/toxics5020012 
3. E. Leese, J. Morton, P.H.E. Gardiner and V.A. Carolan. The simultaneous detection 
of trivalent and hexavalent chromium in exhaled breath condensate: A feasibility 
study comparing workers and controls. Int. J. Hyg. Environ. Health., 2017, 220: 415-
423. 
4. E. Leese, J. Morton. P.H.E. Gardiner and V.A. Carolan. Development of a method for 
the simultaneous detection of Cr(III) and Cr(VI) in exhaled breath condensate 
samples using µLC-ICP-MS. J. Anal. At. Spectrom., 2016, 31(4): 924-933.  
5. E. Leese, J. Morton, E. Tan, P.H.E. Gardiner and V.A. Carolan. µLC-ICP-MS 
determination of unexposed UK urinary arsenic speciation reference values. J. 
Anal. Toxicol., 2014, 38(1): 24-30.  
8.2 Oral Presentations 
1. Supra-Regional Assay Service/Association of Clinical Biochemistry: Trace Elements 
Meeting, 20
th
 October 2016, York, UK. Exhaled breath condensate: A new biological 
matrix to measure and detect trivalent and hexavalent chromium in occupationally 
exposed workers. 
2. The 18
th
 Biennial National Atomic Spectroscopy Symposium, 4
th
-6
th
 July 2016, John 
Mooƌe͛s UŶiǀeƌsitǇ, Liǀeƌpool, UK. Eǆhaled ďƌeath ĐoŶdeŶsate: A Ŷeǁ ďiologiĐal 
matrix to measure and detect trivalent and hexavalent chromium in occupationally 
exposed workers. 
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3. Thermo UK ICP-MS User Meeting, 16
th
 June 2016, Jodrell Bank Discovery Centre, 
Manchester, UK. Exhaled breath condensate: Silica single particles and their effect 
on health. 
4. Surface Engineering Association Northern Finishers Meeting, 10
th
 May 2016. Leeds, 
UK. Exhaled breath condensate measurement of hexavalent and trivalent 
chromium in occupationally exposed workers. 
5. The 4
th
 UK and Ireland Exposure Science Meeting, 20
th
 April 2016, Health & Safety 
Laboratory, Buxton, UK. Exhaled breath condensate: A new biological matrix to 
measure and detect trivalent and hexavalent chromium in occupationally exposed 
workers.  
6. The Surface Engineering Association Annual Industry Conference, 16
th
 October 
2015, Stratford Upon Avon, UK. Exhaled breath condensate: A new biological 
matrix for hexavalent and trivalent chromium.  
7. HSE Workshop, 30
th
 July 2015, Health & Safety Laboratory, Buxton, UK. Exhaled 
breath condensate: A new biological matrix. 
8. Thermo Ion Chromatography and Trace Elements User Meeting, 15
th
 July 2014, 
Altrincham, UK. Arsenic and chromium speciation methods at the Health & Safety 
Laboratory.  
9. The 9
th
 International Symposium on Biological Monitoring, 9
th
-11
th
 September 
2014, Manchester, UK. Arsenic speciation in urine using µLC-ICP-MS for routine 
biological monitoring. 
10. Thermo Speciation Analysis Meeting, 17
th
 November 2011, Health & Safety 
Laboratory, Buxton, UK. Arsenic speciation by µLC-ICP-MS. 
8.3 Poster Presentations 
1. The 3
rd
 UK and Ireland Exposure Science Meeting, 24
th
 April 2015, London, UK. 
Investigation of arsenic peaks observed in urine from interesting forensic and 
occupational cases. 
2. The 3
rd
 UK and Ireland Exposure Science Meeting, 24
th
 April 2015, London, UK. 
Single particle ICP-MS of silica in exhaled breath condensate of UK workers.  
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3. The 3
rd
 UK and Ireland Exposure Science Meeting, 24
th
 April 2015, London, UK. 
Speciation of trivalent and hexavalent chromium by µLC-ICP-MS in exhaled breath 
condensate samples: initial results. 
4. European Winter Conference on Plasma Spectrochemistry, 22
nd
-25
th
 February 
2015, Munster, Germany. Investigation of arsenic peaks observed in urine from 
interesting forensic and occupational cases. 
5. European Winter Conference on Plasma Spectrochemistry, 22
nd
-25
th
 February 
2015, Munster, Germany. Single particle ICP-MS of silica in exhaled breath 
condensate of UK workers. 
6. European Winter Conference on Plasma Spectrochemistry, 22
nd
-25
th
 February 
2015, Munster, Germany. Speciation of trivalent and hexavalent chromium by µLC-
ICP-MS in exhaled breath condensate samples: initial results. 
7. The 17
th
 Biennial National Atomic Spectroscopy Symposium, 31
st
 August – 4th 
September 2014, Aberdeen University, Scotland. Investigation of arsenic peaks 
observed in urine from interesting forensic and occupational cases. 
8. The 17
th
 Biennial National Atomic Spectroscopy Symposium, 31
st
 August – 4th 
September 2014, Aberdeen University, Scotland. Speciation of trivalent and 
hexavalent chromium by µLC-ICP-MS in exhaled breath condensate samples: 
Method development. 
9. The Society of Occupational Medicine Annual Scientific Meeting. 2
nd
 July 2014. 
Establishing background levels for five arsenic species in urine sample in a UK 
population. 
10. The 2
nd
 UK and Ireland Exposure Science Meeting, 4
th
 March 2014, Manchester, 
UK. Establishing background levels for five arsenic species in urine sample in a UK 
population. 
11. European Winter Conference on Plasma Spectrochemistry, 10
th
-15
th
 February 
2013, Krakow, Poland. Arsenic speciation in urine using µLC-ICP-MS for routine 
biological monitoring.  
12. BMRC Christmas Poster Session, 16
th
 December 2011, Sheffield Hallam University, 
Sheffield, UK. Arsenic speciation in urine using µLC-ICP-MS for routine biological 
monitoring.  
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